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RÉSUMÉ 
 
 
La thérapie cellulaire est une avenue pleine de promesses pour la régénération myocardique, 
par le remplacement du tissu nécrosé, ou en prévenant l'apoptose du myocarde survivant, ou 
encore par l'amélioration de la néovascularisation. Les cellules souches de la moelle osseuse 
(CSMO) expriment des marqueurs cardiaques in vitro quand elles sont exposées à des 
inducteurs. Pour cette raison, elles ont été utilisées dans la thérapie cellulaire de l'infarctus au 
myocarde dans des études pre-cliniques et cliniques. Récemment, il a été soulevé de possibles 
effets bénéfiques de l'ocytocine (OT) lors d’infarctus. Ainsi, l’OT est un inducteur de 
différenciation cardiaque des cellules souches embryonnaires, et cette différenciation est 
véhiculée par la voie de signalisation du monoxyde d’azote (NO)-guanylyl cyclase soluble. 
Toutefois, des données pharmacocinétiques de l’OT lui attribue un profil non linéaire et 
celui-ci pourrait expliquer les effets pharmacodynamiques controversés, rapportés dans la 
lttérature. 
Les objectifs de ce programme doctoral étaient les suivants :  
1) Caractériser le profil pharmacocinétique de différents schémas posologiques d'OT chez le 
porc, en développant une modélisation pharmacocinétique / pharmacodynamique plus 
adaptée à intégrer les effets biologiques (rénaux, cardiovasculaires) observés.  
2) Isoler, différencier et trouver le temps optimal d’induction de la différenciation pour les 
CSMO porcines (CSMOp), sur la base de l'expression des facteurs de transcription et des 
protéines structurales cardiaques retrouvées aux différents passages. 
3) Induire et quantifier la différenciation cardiaque par l’OT sur les CSMOp.  
4) Vérifier le rôle du NO dans cette différenciation cardiaque sur les CSMOp. 
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Nous avons constaté que le profil pharmacocinétique de l’OT est mieux expliqué par le 
modèle connu comme target-mediated drug disposition (TMDD), parce que la durée du 
séjour de l’OT dans l’organisme dépend de sa capacité de liaison à son récepteur, ainsi que de 
son élimination (métabolisme). 
D'ailleurs, nous avons constaté que la différenciation cardiomyogénique des CSMOp médiée 
par l’OT devrait être induite pendant les premiers passages, parce que le nombre de passages 
modifie le profile phénotypique des CSMOp, ainsi que leur potentiel de différenciation.  
Nous avons observé que l’OT est un inducteur de la différenciation cardiomyogénique des 
CSMOp, parce que les cellules induites par l’OT expriment des marqueurs cardiaques, et 
l'expression de protéines cardiaques spécifiques a été plus abondante dans les cellules traitées 
à l’OT en comparaison aux  cellules traitées avec la 5-azacytidine, qui a été largement utilisée 
comme inducteur de différenciation cardiaque des cellules souches adultes. Aussi, l’OT a 
causé la prolifération des CMSOp. Finalement, nous avons observé que l'inhibition de la voie 
de signalisation du NO affecte de manière significative l'expression des protéines cardiaques 
spécifiques. 
 
En conclusion, ces études précisent un potentiel certain de l’OT dans le cadre de la thérapie 
cellulaire cardiomyogénique à base de cellules souches adultes, mais soulignent que son 
utilisation requerra de la prudence et un approfondissement des connaissances. 
  
 
Mots-clés: Ocytocine, cellules souches adultes, différenciation cardiomyogénique, monoxyde 
d’azote, porc, pharmacokinetic, pharmacodynamic 
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ABSTRACT 
 
Cell therapy has been suggested as a promising treatment for myocardial regeneration 
through cardiomyocyte replacement or by preventing apoptosis of surviving myocardium 
and/or improving neovascularisation. Bone marrow stem cells (BMSCs) express cardiac 
markers in vitro upon stimulation with different inducers. The BMSCs have been used as cell 
therapy after myocardial infarction (MI) in pre-clinical and clinical studies. Recent reports 
have uncovered the potential beneficial effects of oxytocin (OT) after MI. Particularly, OT is 
an inducer of cardiomyogenic differentiation of embryonic stem cells and this differentiation 
is mediated by the nitric oxide (NO)-soluble guanylyl cyclase pathway. However, some 
studies have shown that OT exhibits nonlinear pharmacokinetics and that this could explain 
the previously described controversial hemodynamic alterations.  
 
Therefore the objectives of the present work were to:  
 
1) Characterize the pharmacokinetic profile of different dosing regimens of OT in swine, by 
using a more suitable pharmacokinetic / pharmacodynamic modelization that could explain 
the time-course of cardiovascular and renal effects observed following OT administration.  
 
2) To isolate, differentiate and find the optimum time of porcine BMSC (pBMSC) 
differentiation based on the expression of cardiac related transcription factors and structural 
proteins expressed at different passages.  
 
3) To induce and quantify the OT-mediated cardiomyogenic differentiation of pBMSCs.  
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4) To document the role of the NO pathway in the OT-mediated cardiomyogenic 
differentiation of pBMSCs.  
 
We found that OT pharmacokinetics are better explained by target-mediated drug disposition 
(TMDD) kinetics, because the time-course of plasma OT concentration depends on the 
binding capacity to its receptor, as well as OT elimination (metabolism). 
 
Also, we found that OT-mediated cardiomyogenic differentiation of pBMSCs should be 
induced during the first passages, because passaging affects the phenotypic profile of 
pBMSCs, as well as the differentiation potential of pBMSCs. 
  
We observed that OT induces cardiomyogenic differentiation of pBMSCs, because OT-
induced cells expressed cardiac markers, and the expression of cardiac specific proteins was 
more abundant in OT-treated cells vs. 5-azacytidine-treated cells, which has been used widely 
as a cardiomyogenic differentiation inducer of adult stem cells. Moreover, OT improved 
proliferation of pBMSCs. Finally, we observed that the inhibition of the NO pathway 
significantly affects the expression of cardiac specific proteins. 
 
To conclude, these studies demonstrate some interesting potential in cardiomyogenic 
differentiation of adult stem cells for OT, but its precise role in cell therapy will need 
prudence and further investigations. 
 
Keywords: Oxytocin, adult stem cells, cardiomyogenic differentiation, nitric oxide, swine, 
pharmacokinetics, pharmacodynamics. 
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CHAPTER 1. INTRODUCTION 
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Cardiovascular diseases remain the leading cause of mortality and morbidity worldwide. 
Despite substantial improvements in acute management, survivors of myocardial infarction 
often progress to heart failure (Siu, Moore et al. 2007). Heart failure is a condition that can 
result from any structural or functional cardiac disorder. It is defined as the inability of the 
left ventricle to fill with and/or eject sufficient blood to meet the metabolic requirements of 
the body. It is undoubtedly an increasing common condition (Harris 1994).  
Despite major advances in treatment, the prognosis after a diagnosis of heart failure is poor 
and comparable to that of several forms of cancer. Even though, the rate of fatalities per case 
associated with heart failure has declined, the crude number of deaths attributed to the 
condition has increased, primarily because of increasing prevalence of the condition. Several 
epidemiological investigations have identified the main risk factors for heart failure, which 
are: increasing age, hypertension, coronary artery disease (CAD), diabetes, obesity, valvular 
heart disease, and the metabolic syndrome (Kenchaiah, Narula et al. 2004). 
The relative contribution of risk factors to the occurrence of heart failure in the community 
may be changing over time. The aging of the population, the better treatment of CAD, and 
the improved survival and ‘‘salvage’’ of patients with myocardial infarction (MI) with 
subsequent progression to pump failure are believed to be some factors contributing to the 
growing burden of heart failure. Heart failure is also predicted to increase in line with 
increased atrial fibrillation and diabetes among the elderly population. Nowadays, 
hypertension and CAD are the major modifiable risk factors for heart failure. Globally, CAD 
and arterial hypertension alone or in combination account for more than 90% of cases of 
heart failure (Lloyd-Jones, Evans et al. 2002; Ezekowitz and Kaul 2010).  
 
Although human cardiomyocytes are reported to proliferate and contribute to the increase in 
muscle mass of the myocardium after myocardial infarction (Beltrami, Urbanek et al. 2001), 
their capacity for regeneration, mitigation of the adverse effects of ventricular remodelling, 
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and contribution to cardiac function is limited. Among other factors, cardiac wall thinning 
and cardiac remodelling lead to a diminished capacity of the heart to pump blood effectively 
leading to eventual heart failure and ultimately death of the patient. Heart transplantation is 
currently the last resort for end stage heart failure, but is hampered by rejection and a severe 
shortage of donor organs. The main purpose of cell-based therapies as applied for the 
treatment of myocardial infarction is to prevent heart failure by either rescuing the host 
myocardium or regenerating cardiac cells (Christoforou and Gearhart 2007; Tao and Li 2007; 
Dimmeler and Zeiher 2009). 
In the past, a variety of cell types have been used experimentally, obtaining promising results, 
mainly by improving neovascularization, reducing infarct size, limiting wall thinning, and 
providing proangiogenic and antiapoptotic factors promoting tissue repair in a paracrine 
manner. By all these mechanisms cell therapy may curb the degeneration to heart failure (Tao 
and Li 2007).  
The cell types used previously include skeletal myoblasts, as a non-cardiac contracting cell, 
and foetal cardiomyocytes, but these approaches are also limited by cell availability or side 
effects, mainly due to a non-cardiac identity, as observed in the case of skeletal myoblasts. 
There is a special interest in the use of stem cells in cell-based therapies, because of their 
capacity of cell renewal, and differentiation potential. In vitro studies examined the ability of 
stem cells to differentiate into cardiomyocytes and then proceeded to investigate the 
functional characteristics of these cells. In vivo studies examined the capacity of stem cells to 
graft into the host myocardium and then assayed the functional recovery of the diseased 
heart.  
 
During the latest years, pre-clinical and clinical studies exploiting stem cells from different 
sources for transplantation in animal models and patients have reported favourable outcomes 
(Christoforou and Gearhart 2007; Tao and Li 2007; Dimmeler and Zeiher 2009).  
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 Unfortunately, full recovery has not been achieved yet, due to many variables that need to be 
considered. For instance, the optimal cell type, which in turn should generate contractile cells 
that integrate both functionally and structurally into the surrounding viable myocardium. 
These cells have to beat in a synchronized manner to avoid alterations in the electrical 
conduction and syncytial contraction of the heart, these cells should also be able to survive in 
the hostile environment into which they will be grafted (Tao and Li 2007; Dimmeler and 
Zeiher 2009). 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 2. LITERATURE REVIEW 
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2.1 Stem cells 
 
2.1.1 Definition and properties 
Stem cells are unspecialized cells, with the long-term capacity of symmetrical self-renewal. 
Differentiation is a process that involves undifferentiated or unspecialized cells progressing 
into specialized cells with restricted developmental potential. They can differentiate into 
specialized cells, including cardiomyocytes (Blau, Brazelton et al. 2001; Bishop, Buttery et 
al. 2002). The differentiation capacity of these specialized cells in vivo to form mature cell 
types ultimately depends on the state of commitment of the cell and both intrinsic factors and 
the extra-cellular environment (niche) (Perino, Yamanaka et al. 2008). 
The genetic and cellular mechanisms that initiate stem cell differentiation are poorly 
understood. Transplanted stem cells also undergo a “homing” process in which they are 
attracted to the site of injury (Hardy 1995). The exact homing mechanism and organ-specific 
differentiation signals for stem cells are not clearly understood but may be related to 
microenvironmental factors that are favourable to stem-cell growth and function, integrin and 
other adhesion molecules, homing receptors, ischemia, and increased expression of different 
paracrine factors and cytokines (Lee, Wolf et al. 2000; Caplice and Gersh 2003). 
 
2.1.2 Classification 
Stem cells have been classified based on their source of isolation, and by their differentiation 
potential into embryonic stem cells, adult stem cells and induced pluripotent stem cells. 
 
2.1.3 Embryonic stem cells (ESCs) 
Embryonic stem cells can be derived from the embryo at morulae stage, based on their 
differentiation potential, they are known as totipotent cells because they can give rise to 
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extraembryonic and embryonic tissues. Stem cells derived from the inner cell mass of the 
embryo at blastocyst stage are known as pluripotent cells. These pluripotent cells can 
differentiate into the three primary germ layers, endoderm, mesoderm, and ectoderm, 
meaning they have the potential to differentiate into all tissue specific cells of an embryo, and 
if the embryo is implanted in utero following tetraploid aggregation, an entire ES cell-derived 
embryo, excluding some extra-embryonic tissues, can be formed (Nagy, Gocza et al. 1990). 
Figure 1. Embryonic stem cells derived from embryos at morulae and blastocyst stage 
 
Source: http://www.stemcellresearchfoundation.org 
 
Embryonic stem cells can also be used for the generation of chimeric animals, in which the 
ES cell genotype can be passed through the germline (Illmensee and Mintz 1976). Another 
pluripotent cell type includes germ cells, progenitor cells of the germline, these cells are 
found in a specific part of the foetus called the gonadal ridge, germ cells can also give rise to 
cells from the three germ layers (Moreno-Ortiz, Esteban-Perez et al. 2009). 
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2.1.4 Adult stem cells   
Adult stem cells possess a more restricted developmental potential, giving rise to a subset of 
cells belonging to the same germ layer, they are generally considered to be multipotent to 
unipotent. They typically produce only cells of a closely related family (cells from the tissue 
or organ in which they reside), providing “new” cells in order to replenish damaged 
specialized cells in the adult (Wobus and Boheler 2005; Perino, Yamanaka et al. 2008). 
Figure 2. Adult stem cells derived from adult tissues 
 
Source: National institutes of health.  www.nih.gov 
Both embryonic and adult stem cells are capable of cell division in the undifferentiated state 
(self-renewal). Embryonic stem cells readily form tumours when implanted outside the 
blastocyst, adult stem cells (e.g., hematopoietic, mesenchymal, neuronal) may or may not 
form tumours, but both ES and adult stem cells are different to cancer stem cells (Perino, 
Yamanaka et al. 2008). 
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Noteworthy, cancer stem cells are oncogenic, have lost the ability to prevent uncontrolled 
proliferation or differentiation, and are therapeutically unviable, properties that make them 
different from normal stem cells (Maenhaut, Dumont et al. 2010). 
 
2.1.5 Cardiomyogenic potential of embryonic stem cells  
Embryonic stem cells are conducive to cell implantation therapy, mainly because they are 
pluripotent. These unique pluripotent cell lines can be propagated in the undifferentiated state 
in culture and coaxed to differentiate into cell derivatives of the three germ layers, including 
cardiomyocytes (Capi and Gepstein 2006; Tao and Li 2007).  
Doetschman and colleagues (Doetschman, Eistetter et al. 1985) made the initial observation 
that when ESCs are grown in suspension culture and under conditions favourable for 
differentiation (without feeder layer and cytokines that maintain an undifferentiated state, i.e. 
leukaemia inhibitory factor –LIF–), ESCs aggregated to form spherical structures called 
embryoid bodies (EBs). Stochastic differentiation within EBs resulted in the juxtaposition of 
different developmental fields, thereby mimicking induction cues that occurred during 
normal embryogenesis. As a consequence, cell lineages of endoderm, ectoderm, and 
mesoderm origin were observed to appear in differentiating EBs. Prominent 
cardiomyogenesis occurred during EB differentiation, as evidenced by the presence of well-
formed myofibers, as well as spontaneous contractile activity. Thus, differentiating ESCs 
might provide a surrogate source of donor cardiomyocytes for therapeutic cell transplantation 
(Rubart and Field 2006; Perino, Yamanaka et al. 2008). 
Studies with ESCs derived cardiomyocytes revealed that cardiomyogenic differentiation in 
EBs closely paralleled that observed for early stages of heart development in vitro 
(Doevendans, Kubalak et al. 2000), and that cardiomyocytes with the typical characteristics 
of the primitive heart tube and early chamber myocardium could be easily identified 
(Fijnvandraat, van Ginneken et al. 2003; Fijnvandraat, van Ginneken et al. 2003). The 
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temporal phenotypic changes in myofiber structure in ES-derived cardiomyocytes closely 
paralleled those observed in cardiomyocytes in vivo (Guan, Rohwedel et al. 1999). Similarly, 
ES-derived cardiomyocytes exhibited a temporal pattern of cell cycle withdrawal and 
multinucleation similar to that observed in vivo (Klug, Soonpaa et al. 1995). 
Electrophysiological studies revealed that cells with characteristics of atrial, ventricular, and 
sinus-nodal foetal cardiomyocytes were present following terminal differentiation of ESCs 
(Maltsev, Rohwedel et al. 1993), a result that was confirmed via molecular analyses (Miller-
Hance and Chien 1993). The developmental changes in the electrophysiological properties of 
ESCs derived cardiomyocytes from initial cardiomyoblast commitment (Kolossov, 
Fleischmann et al. 1998), through formation of three-dimensional, spontaneously contracting 
structures (Maltsev, Rohwedel et al. 1993; Banach, Halbach et al. 2003) have been well 
characterized. 
The reproducible differentiation observed in cultured EBs has been exploited not only to 
identify factors that could be able to enhance cardiomyogenic induction, but also it has been 
useful to identify transcription factors or signalling pathways important for cardiomyogenic 
differentiation. Examples of these transcription factors are: Nkx2.5, GATA-4 and Mef2, 
which also have been used as markers of differentiation. Some studies have implicated the 
signalling pathways of bone morphogenic proteins and Wnt family members in 
cardiomyogenic differentiation of ESCs (Winnier, Blessing et al. 1995; Czyz and Wobus 
2001; Behfar, Zingman et al. 2002; Kawai, Takahashi et al. 2004; Terami, Hidaka et al. 
2004). In addition, signalling through the fibroblast growth factor (Dell'Era, Ronca et al. 
2003; Kawai, Takahashi et al. 2004), insulin growth factor-II (Morali, Jouneau et al. 2000), 
Cripto (Parisi, D'Andrea et al. 2003), cardiotrophin (Sauer, Neukirchen et al. 2004), 
transforming growth factor beta (Behfar, Zingman et al. 2002), and dynorphin B (Ventura, 
Zinellu et al. 2003) pathways enhanced cardiomyogenesis during EB differentiation. 
Cardiomyogenic differentiation has being promoted also by indirect mechanisms, such as 
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LIF-regulated cardiomyogenesis in ESCs cultures via its effect on parietal endoderm 
differentiation (Bader, Al-Dubai et al. 2000). Thus, altering the relative content of other cell 
lineages subsequently provided cardiomyogenic inducing factors, that enhances the yield of 
cardiomyocytes. 
In addition to these defined factors, co-culture experiments revealed that precardiac 
endoderm contained factors capable of enhancing ESC cardiomyogenic differentiation 
(Rudy-Reil and Lough 2004). Other inducers used in enhancing ESC cardiomyogenic 
differentiation are some organic compounds such as dimethysulfoxide (DMSO) (Rudnicki, 
Jackowski et al. 1990), a novel butyric and retinoic acid linked ester of hyaluronan (Ventura, 
Maioli et al. 2004), and inorganic compounds including lithium (Schmidt, Guan et al. 2001), 
reactive oxygen species (Sauer, Neukirchen et al. 2004), and nitric oxide (NO) and its 
signalling components which apparently play a pivotal role during cardiomyogenesis (Bloch, 
Fleischmann et al. 1999), and enhance the differentiation of ESCs into cardiomyocytes 
(Kanno, Kim et al. 2004; Mujoo, Krumenacker et al. 2006). Also the neurohypophyseal 
hormones arginine vasopressin and oxytocin (OT) enhanced the ESC cardiomyogenic 
differentiation (Paquin, Danalache et al. 2002; Gassanov, Jankowski et al. 2007). 
Gene transfer experiments identified additional pathways that enhanced cardiomyogenic 
differentiation in ESCs. For example, overexpression of GATA-4 (Arceci, King et al. 1993; 
Grepin, Nemer et al. 1997), alpha-1,3-Fucosyltransferase (Sudou, Muramatsu et al. 1997), 
and TBX5 (Fijnvandraat, Lekanne Deprez et al. 2003) resulted in increased yields of 
cardiomyocytes in differentiating EB cultures.  
In summary, the reports described above identified many factors that could increase 
cardiomyocyte content in differentiating ESCs cultures. The information obtained from such 
studies can in turn be exploited to enhance the production of ESCs derived cardiomyocytes 
for clinical applications, or to discover signalling pathways that could be used to improve the 
differentiation of adult stem cells. 
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In spite of all the interesting qualities of ESCs, there are some ethical concerns about their 
use in cell therapy. The use of human ESCs in research requires the generation of human 
ESC lines. The lines currently used were mostly produced from fertilized oocytes that had 
undergone about 7-8 divisions. The major objection to the use of ESCs is that their 
generation is purported to involve an “act of killing”. The resulting controversy has delayed 
or stopped human ESCs research in some countries, and could affect the extent to which 
human ESCs derived therapies are developed and used (Robertson 2001).  
Many obstacles remain to be overcome before ESCs can be expected to undergo evaluation 
in clinical trials. Further, the multiple regulatory issues that surround the use of ESCs and 
their derivatives, including the difficulties this potentially raises with respect to federal 
funding, continue to heavily influence the research that is conducted with these cells. Despite 
this, steady progress continues to be made toward understanding the mechanisms/pathways 
that control ESCs. A particularly important issue is the potential of ESCs to induce teratoma 
formation when transplanted. This may be dependent on many factors, including the 
experimental model and the exact nature of the ESCs population that is administered 
(Gonzales and Pedrazzini 2009). Currently, the consensus view is that the administration of 
ESCs that are at least partially committed to a certain fate may considerably reduce the risk 
of teratoma formation (Kovacic, Harvey et al. 2007). 
Given the possible risk of graft rejection, the ethical and other concerns surrounding the use 
of human ESCs, a recent possible alternative for the possible graft rejection, could be the 
ESCs like induced pluripotent stem (iPS) cells initially derived from murine fibroblasts. The 
iPS cells have been created by the retroviral introduction of Oct3/4, Sox2, c-Myc, and Klf4, 
these factors have been related to pluripotency in ESCs (Kovacic, Harvey et al. 2007). The 
iPS could be considered a substitute in the evolution of the stem cell field and for cell-based 
therapies. Unfortunately, the high risk of teratoma formation remains. Furthermore, various 
safety concerns exist that must be resolved before iPS cell therapy becomes a reality. 
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Potential risks are related to the delivery of the endogenous factors, alterations in target cells, 
the cellular effects of the expression and reactivation of the factors that induce pluripotency, 
and safety issues related to the incorrect characterization and incomplete differentiation of the 
reprogrammed cells (Jalving and Schepers 2009). 
An interesting alternative to the controversial destruction of a human embryo and the possible 
teratoma formation, is the use of stem cells obtained from adult tissues (Dickens and Cook 
2007).  
Cell therapy with autologous stem cells from adults, i.e. bone marrow cells is completely 
justified ethically, except for the small numbers of patients with direct or indirect bone 
marrow disease (e.g. myeloma, leukaemic infiltration) in whom there would be lesions of 
mononuclear cells (Strauer, Brehm et al. 2008). 
The use of human autologous adult (bone marrow) stem cells is clinically justified and 
ethically unquestionable because no side-effects have been reported, especially with regard to 
teratocarcinoma. Moreover, in contrast to differentiation of embryonic stem cells 
immunosuppressive therapy is unnecessary. Thus, the therapeutical advantage clearly 
prevails, and clinical use has already been realized, at least in cell therapy for MI, obtaining 
promising results and no arrhythmogenic potential has been reported (Strauer, Brehm et al. 
2008). 
Further and intensified research using autologous human bone marrow stem cells is needed 
and is essential in order to promote stem cell therapy for the numerous cardiac diseases. 
Clinical use of autologous bone marrow mononuclear cells has no ethical problems. Therapy 
is performed with usual cardiac catheterization techniques (Strauer, Brehm et al. 2008).  
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2.1.6 Adult stem cells with cardiomyogenic potential 
Whereas ESCs clearly have the capacity to differentiate into a variety of cell types and give 
rise to all tissues, adult stem cells are more specified (more lineage committed) and the use of 
adult stem cells for cell therapy appears to be rather limited.  
The cardiomyogenic potential of adult stem cells is a continuous source of controversy, due 
to the diversity of experimental protocols, cell sources, the limited in vitro functional tests, 
and the difficulties in the follow up of transplanted cells in vivo. The follow up of the in vivo 
differentiation of adult stem cells represents a special challenge because of the presence of 
two types of artefacts, the transfer of cell labels used to track implanted cells to neighbouring 
cells (Burns, Ortiz-Gonzalez et al. 2006), and heterotypic cell fusion, which is a process 
whereby donor and host cells merge, resulting in a fused cell with the genetic information of 
both cells, including any genetic marker (Nygren, Jovinge et al. 2004; Reinecke, Minami et 
al. 2008). Both artefacts have been observed in vitro and in vivo, and complicate the 
demonstration of adult stem cell in vivo differentiation potential (Reinecke, Minami et al. 
2008). 
Demonstration of in vitro differentiation potential of adult stem cells also represents some 
challenges, for instance the demonstration of an unambiguous cardiac phenotype. The most 
common approach is to show the expression of one or more cardiac specific markers by 
immunocytochemistry (ICC), reverse transcriptase-polymerase chain reaction (RT-PCR) 
(Antonitsis, Ioannidou-Papagiannaki et al. 2007), and western blot (Genovese, Spadaccio et 
al. 2009). In reality, there are very few specific cardiac markers, and so this approach requires 
the judicious selection of multiple markers and appropriate controls.  Ideally, such 
phenotyping by cardiac markers is accompanied by functional assays (Rubart and Field 
2006), such as action potential recordings or fluorescent calcium (Ca2+) imaging (Yoon, Choi 
et al. 2008).  
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Even with all the difficulties listed above there are several reports showing the existence of 
adult stem cells with cardiomyogenic potential which reside mainly in the heart itself or in 
the bone marrow. 
 
2.1.6.1 Resident cardiac stem cells (CSCs) 
Several independent laboratories have reported the existence of CSCs, based on the presence 
of the receptor tyrosine kinase c-Kit (Beltrami, Barlucchi et al. 2003), stem cell antigen-1 
(Sca-1) (Oh, Bradfute et al. 2003), or the presence of side population (SP) cells that express 
multidrug resistance transporter genes and exclude Hoechst dye (Liang, Tan et al. 2010).  
Proponents of the stem cell theory of cardiac self-renewal postulate that these cells, isolated 
from cardiac tissues, easily differentiate into cardiomyocytes. Some reports have described 
these observations as experimental artefacts or cell fusion. Perhaps more importantly, 
opponents have suggested that some of the putative stem cell derivatives may arise from de-
differentiated adult cardiac myocytes, trans-determination or even trans-differentiation events 
and therefore these cells are not authentic or resident stem cells. The origin of 
cardiomyogenic stem cells is also open to debate, partly because hematopoietic stem cell 
markers such as c-Kit and Sca-1 are most prominent outside the heart, suggesting that they 
may originate elsewhere (Braun and Martire 2007). Although SP cells have been associated 
at least partially with hematopoietic stem cell (HSC) populations, others have shown that the 
HSCs were equally distributed in the non-SP population, suggesting that precaution should be 
taken with respect to the claim that SP cells represent a stem cell population (Goodell, Brose 
et al. 1996; Morita, Ema et al. 2006). 
 
2.1.6.2 The c-Kit positive cells 
Beltrami et al. first reported the discovery of a c-Kit+ population of resident stem cells that 
could be isolated from adult rat heart and expanded in vitro under limiting dilution conditions 
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(Beltrami, Urbanek et al. 2001). These relatively small cells were calculated to be present at 
only about 1 per 100 cardiomyocytes and were lineage negative (Lin−) for blood lineage 
surface markers [cluster differentiation (CD) CD34, CD45, CD20, CD45RO and CD8]. The 
c-Kit+ cells were also very heterogeneous, with less than 10% of the cells expressing Nkx2.5, 
GATA-4 and Mef2 cardiac transcription factors, and less than 0.5% of the cells expressing 
sarcomeric proteins. Under appropriate conditions, these cells could differentiate into 
cardiomyocytes (Beltrami, Urbanek et al. 2001). Based on the proof of cell division, using 
Ki-67 protein as a recognized marker strictly associated to cell proliferation, the authors also 
indicated that repair occurred independently of cell fusion. However, most of the derived 
cardiomyocytes appeared immature with either limited sarcomeric structures or the presence 
of stress fibers that are typical of fibroblasts or myofibroblasts (Urbanek, Quaini et al. 2003).  
 
2.1.6.3 The Sca-1 positive cells 
Sca-1 is one of the most recognized HSCs markers in mice, and an anti-Sca-1 antibody is 
routinely used to identify and isolate murine HSC from bone marrow. Oh et al. identified a 
small number of Sca-1+ cardiac cells that overlapped with a SP of cells from heart. The 
cardiac Sca-1+ cells lacked blood lineage surface markers (CD4, CD8, B220, Gr-1, Mac-1, 
and TER119), c-Kit, Flt-1, Flk-1, vascular endothelial-cadherin, von Willebrand factor, and 
HSC markers CD45 and CD34. Moreover, these cells expressed GATA-4, Mef2 transcription 
factors and Tef-1, but not Nkx2.5 or genes that encoded cardiac sarcomeric proteins. The 
Sca-1+ stem/progenitor cells did not spontaneously differentiate into cardiomyocytes, but 
following induction with 5-azacytidine, a DNA demethylating agent that causes pronounced 
epigenetic modifications, genes for Nkx2.5, α-myosin heavy chain (MHC), β-MHC, and the 
type 1A receptor for bone morphogenetic proteins (Bmpr1a) were induced, and contraction 
was observed. The cells were however mononucleated and fibroblast-like in structure (Oh, 
Bradfute et al. 2003).  
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On the other hand, Matsuura et al. reported that OT, but not 5-azacytidine, induces Sca-1+ 
cells from the adult murine heart to differentiate into functional, spontaneously beating, 
immature cardiomyocytes with Ca2+ transients typical to those found in heart cells (Matsuura, 
Nagai et al. 2004). The 5-azacytidine-treated cells however developed a fibroblast-like 
morphology and never spontaneously contracted. In this study, both treatments up-regulated 
cardiac transcription factors Nkx2.5, GATA-4, and MEF-2C and structural proteins for α- 
and β-MHC, myosin light chain (MLC)-2a, MLC-2v, and cardiac α-actin. The OT-treated 
cells that formed cardiomyocytes were few in number, but these cells had positive inotropic 
responses to isoproterenol via β1-adrenergic receptor signalling (Matsuura, Nagai et al. 2004). 
Given the apparently small number of cardiomyocytes generated in vitro from this induction, 
it seems that cardiomyogenesis is not a default pathway for these cells, and the potential to 
differentiate into true cardiac progenitors and cardiomyocytes requires further investigation 
(Matsuura, Nagai et al. 2004).  
 
2.1.6.4 Side population cells 
The ATP-binding cassette (ABC) transporter family contains 50 members that use the 
hydrolysis of ATP to pump toxins from cells. The ABC transporters encoding multidrug-
resistance genes (MDRs) also efflux the DNA binding dye Hoechst 33342, which allows for 
the easy identification and sorting of ABC transporter-positive and transporter-negative cells 
by flow cytometry. In most cases, cells positively expressing ABC transporters comprise a 
very small percentage of freshly isolated cells, which appear as a “side population” (SP) of 
cells relative to the majority of non-SP cells as observed using flow cytometry. The SP cells 
and especially the Abcg2-dependent SP cell populations, have been associated with 
stem/progenitor cells and with long-term self-renewal (Goodell, Brose et al. 1996). The ATP-
binding cassette, sub-family G, member 2, also known as Abcg2 gene is robustly expressed 
in the developing heart (Martin, Meeson et al. 2004). At later developmental stages and in the 
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adult heart, this transporter could also be used to identify a rare cell population, this SP 
phenotype comprising around 1% of all cells in the mouse heart and these cells did not 
express hematopoietic surface markers that was not enriched for the hematopoietic markers 
CD34, c-Kit, Sca-1, Flk-2, and Thy1 (Hierlihy, Seale et al. 2002). Further experiments, in 
which cardiac SP cells from adult green fluorescence protein (GFP) transgenic mice were 
isolated and co-cultured with cardiac main population cells from wild-type mice, showed that 
after 14 days, an unspecified fraction of the GFP positive SP-derived cells immunostained for 
the striated muscle marker α-actinin. The purified myocardial SP cells from GFP transgenic 
mice were capable of forming cardiomyocytes, but similarly to the c-Kit+ cells previously 
described, only did so under co-culture conditions with primary cardiomyocytes.  
 
2.1.6.5 Non-resident cardiomyogenic stem cells 
Many non-resident stem cell populations with cardiomyogenic potential have been described. 
Many clinical trials have shown the safety and therapeutic potential of bone marrow 
mononuclear cells after myocardial infarction (Strauer, Brehm et al. 2002; Lipinski, Biondi-
Zoccai et al. 2007; Arminan, Gandia et al. 2008). However, this population is very 
heterogeneous and is not enriched with stem or progenitor cells, therefore recent clinical 
trials using cellular cardiomyoplasty have focused on the potential of specific subpopulations, 
such as mesenchymal stem cells (MSCs), or HSCs.  
 
2.1.6.6 Hematopoietic stem cells  
Therapeutic applications of HSCs in patients with infarcted myocardium have resulted in 
very different results. Probably, this was due to differences in purification protocols, 
influencing the outcome of the therapies. Transplanted cells may have contained different 
contents of stem cells or maybe the selected cells were a heterogeneous population containing 
other cells with regenerative potential (paracrine effects). The latter is quite possible because 
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different CD surface antigens were used to purify the definitive stem cell populations. The 
HSCs are the most studied and well characterized population of stem cells. These cells 
display a unique set of markers (Murine: c-Kit+, Sca-1+, Lin−; Human: CD34+, Thy-1+, Lin−). 
Cells expressing these markers correspond to a resident stem cell population suitable for 
long-term replacement therapy. Some reports have shown that HSCs have the ability to 
promote myocardial regeneration; Orlic et al. mobilized HSCs from bone marrow to show 
that the “trans-differentiated cells” could repair the infarcted heart (Orlic, Kajstura et al. 
2001; Perino, Yamanaka et al. 2008). In a complementary study, they isolated HSCs from 
mice that constitutively expressed the GFP and used these cells to look for cardiac integration 
and repair (Orlic, Kajstura et al. 2001). After two weeks of myocardial infarction induction, 
the mice transplanted with the GFP-labelled HSCs presented improved function of the 
myocardium, and the newly formed myocardium contained GFP-labelled cells that occupied 
up to 68% of the infarcted portion of the ventricle. These labelled cells also expressed 
sarcomeric actins and myosins, troponin and several cardiac-associated transcription factors; 
however, the sarcomeric structures appeared disorganized. These results were further 
supported with a report by Rota et al. (2007) who showed that bone marrow cells engraft, 
survive, and grow within the spared myocardium after infarction (Rota, Kajstura et al. 2007). 
More specifically, they reported that locally delivered bone marrow cells generate new 
myocardium composed of integrated cardiomyocytes and coronary vessels, and that the 
cardiomyogenesis was independent of cell fusion, but dependent on close contact with 
resident cardiomyocytes (Rota, Kajstura et al. 2007). 
On the other hand, several reports have contradicted these findings. Murry et al. reported that 
the HSCs did not express cardiac specific genes, and that they could not detect any increase 
in cardiomyocytes in a murine model of MI region of the heart (Murry, Soonpaa et al. 2004). 
Also, Kawada et al. showed that mobilized murine HSCs expressing GFP do not differentiate 
into cardiomyocytes after myocardial infarction (Kawada, Fujita et al. 2004).  
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2.1.6.7 Mesenchymal stem cells 
Mesenchymal stem cells possess multipotent capabilities; they can proliferate in vitro and in 
vivo. These cells are able to induce angiogenesis, and to differentiate into cell types 
belonging to the mesodermal lineage, such as osteogenic, chondrogenic, adipogenic and 
myogenic cells. The MSCs have been first isolated from bone marrow (Pittenger, Mackay et 
al. 1999), which is the main source of MSCs. But they have also been isolated from other 
sources, like dental pulp (Pierdomenico, Bonsi et al. 2005), adipose tissue (Izadpanah, Trygg 
et al. 2006), umbilical cord blood (Wang, Seshareddy et al. 2009), chorionic villi of the 
placenta (Igura, Zhang et al. 2004), amniotic fluid (Tsai, Lee et al. 2004), and others. 
Although, MSCs obtained from different sources share the expression of certain genes, 
differences in self-renewal, proliferation, and differentiation have been reported to exist 
among these various sources of MSCs (Arminan, Gandia et al. 2008). 
Animal studies and early clinical studies suggest that therapeutically delivered MSCs can 
improve heart function after acute MI. More specifically, MSCs seemed to improve 
contractility, wall thickness and decrease necrosis (Nagaya, Fujii et al. 2004). It has been 
proposed that the observed therapeutic benefits are probably mediated through the release of 
a variety of signalling molecules, which may be anti-inflammatory, anti-apoptotic and 
angiogenic. 
The paracrine factors secreted by bone marrow mononuclear cells and endothelial progenitor 
cells are well characterized (de Macedo Braga, Lacchini et al. 2008). More recently, the gene 
expression profiles of cultured MSCs were determined by microarray. In particular, 
transcripts of IL-6, leukemia inhibitory factor (LIF) and vascular endothelial growth factor 
(VEGF) family members were found to be expressed in human MSCs. Also expressed are 
several mRNAs for matrix-mediating factors such as matrix metalloproteinase (MMP)-2, 
inhibitors such as tissue inhibitor of metalloproteinase-1, 2, and matricellular proteins 
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(thrombospondin-1 and tenascin C) were also highly expressed in human MSCs. The results 
of the microarray analysis demonstrated that cultured human MSCs expressed mRNAs for a 
variety of secreted factors that may be cardioprotective and reparative (Iso, Spees et al. 
2007). The anti-apoptotic role and broader spectrum of all the paracrine molecules produced 
by MSCs suggest that the release of these mediators could augment angiogenesis, reduce 
apoptosis and promote the recruitment of circulating progenitor stem cells into the injured 
tissue, leading to the favourable remodelling of the damaged heart (Kinnaird, Stabile et al. 
2004).  
Studies by Tang et al. have reported that the expression of basic fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), and stromal cell-derived factor (SCDF-1) 
is increased after MSCs in a rat model of MI. The FGF, is a mostly mitogenic protein, is 
produced by MSCs and stimulates sustained quiescence and proliferation in uncommitted and 
committed MSCs (Benavente, Sierralta et al. 2003), and it has been suggested that SCDF-1 
may have tissue protective and regenerative roles in solid tissues, this by activating the cell-
survival pathway mediated by protein kinase B  (Tang, Zhao et al. 2005; Saxena, Fish et al. 
2008). 
These data suggest that paracrine effects are responsible for the cardioprotection seen with 
MSC therapy cells in the bone marrow. 
 Some authors claim that there is only limited data suggesting cardiomyogenic differentiation 
of MSCs (Li, Guo et al. 2009). But apparently, MSCs have a wider differentiation potential 
than what it has been previously thought. Some reports have shown that MSCs can 
differentiate into vascular endothelial cells, and smooth muscle cells (Song, Lee et al. 2007), 
but more importantly, it has been shown that MSCs are able to differentiate into 
cardiomyocytes in vivo and in vitro. For instance, in vitro studies have shown that MSCs 
express some cardiac transcription factors and structural proteins when exposed to 5-
azacytidine, a DNA demethylating agent, which induces pronounced epigenetic changes. The 
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reputed formation of cardiomyocytes after 5-azacytidine exposure was based on the 
spontaneous contraction of cells in culture, action potentials similar to those found in foetal 
cardiomyocytes, the expression of sarcomeric proteins, and the expression of atrial natriuretic 
peptide (ANP) and brain natriuretic peptide (BNP). These peptides are expressed in cardiac 
muscle; but the sarcomeric proteins used as markers, skeletal α-actin and β-MHC, are 
associated with both cardiac and skeletal muscle cells. In addition, published images clearly 
showed multinucleated cells, which are most typical of skeletal muscle (Makino, Fukuda et 
al. 1999). These results suggest that the MSCs exposed to 5-azacytidine were not authentic 
cardiomyocytes, but probably a mixed population of muscle cells, due to the 
hypomethylation of regulatory genes caused by 5-azacytidine treatment. Therefore, it is very 
possible that 5-azacytidine differentiation induction is not cardiac specific (Bittira, Kuang et 
al. 2002). 
Differentiation of MSCs has also been achieved by co-culture with cardiomyocytes 
(Rangappa, Entwistle et al. 2003); these cells after co-culture with cardiomyocytes were 
positive for β-myosin heavy chain, cardiac troponin T, cardiac troponin I, cardiac α-actin, and 
desmin. They also exhibit Ca2+ transients, and several types of action potentials (Li, Yu et al. 
2008). Furthermore, it has been reported that even without stimulation, MSCs express certain 
cardiac markers, such as connexin-43, α-actinin, and GATA-4, but fail to express cardiac 
specific structural proteins (Bayes-Genis, Roura et al. 2005). The ability of MSCs to form 
cardiomyocytes is still in doubt and in almost all the cases in which cardiomyogenic 
differentiation has been reported, the cells had to go through a cultivation period that may 
have altered some basic properties. In vivo differentiation has also been reported, there are 
some studies stating that MSCs can differentiate into cardiomyocytes when injected into 
healthy murine heart (Toma, Pittenger et al. 2002). The MSCs however remain attractive as a 
vehicle for cell transplantation or for tissue engineering, because they can be obtained in 
relatively large numbers and are easily expanded in culture, in addition they can be obtained 
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from the bone marrow of the patient, eliminating the problems related with graft rejection. 
Therefore, MSCs remain a promising source for cell therapy in cardiac diseases.  
There are many factors influencing the capabilities of MSC differentiation, such as: culture 
medium, presence and concentration of undetermined growing factors in the foetal bovine 
serum (FBS), number of passages, as well as differentiation inducer(s) added to the medium. 
In fact, some reports have shown that MSCs have certain predisposition to differentiate into 
cardiomyocytes (Bayes-Genis, Roura et al. 2005) or have passage-restricted differentiation 
potential into cardiomyocyte-like cells depending on the time they have been in culture, with 
a very possible variation among species (Zhang, Li et al. 2005). Phenotype and gene 
expression are affected during culture (Vacanti, Kong et al. 2005). For these reasons, it is 
possible that full and effective cardiomyogenic differentiation of MSCs has not been 
achieved yet. 
 
2.2. Oxytocin (OT)  
2.2.1 Definition and structure 
The peptide hormone OT has many functions in the human body, including facilitating milk 
expulsion during lactation (Nishimori, Young et al. 1996), and mediating maternal behaviour 
(Young, Wang et al. 1998). However, OT is best known as a powerful uterotonic agent that 
stimulates uterine contractions during labour, for which it is frequently used to augment labor 
and to prevent postpartum haemorrhage (Wise and Clark 2008). Oxytocin was the first 
hormone to have its structure elucidated and the first to be chemically synthesized in a 
biologically active form (Du Vigneaud, Ressler et al. 1953). Oxytocin is a cyclic nonapeptide 
(single linear chain of nine amino acids), derived from large precursor proteins called pro-
peptides, which in turn are derived from even larger molecules known as pre-propeptides. 
The molecular formula of OT is C43H66N12012S2 and it has a molecular weight of 1,007 Da. It 
possesses a cyclical disulphide configuration being the ring shape essential to its biological 
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effect. There is a close homology between OT and vasopressin, the difference consisting only 
in two amino acids. The similarity in chemical structure explains several common properties 
which can become evident when OT is administered in high doses (Lippert, Mueck et al. 
2003).  
 
2.2.2 Oxytocin synthesis  
The synthesis of OT occurs in the neural cell bodies of the supraopticus nucleus (SON) and 
paraventricularis nucleus (PVN) of the hypothalamus. From this nuclei, it is transported into 
the neurohypophysis in the form of a precursor molecule, oxytocin-neurophysin, this 
complex passes down the axons of hypothalamic nuclei to be stored as a dimeric in dilated 
nerve terminals in the posterior lobe of the pituitary gland (neurohypophysis), from which it 
is released into the blood stream in a pulsatile form (al-Eknah and Homeida 1991; Lippert, 
Mueck et al. 2003).   
The inactive precursor protein is progressively hydrolyzed into smaller fragments (one of 
which is neurophysin I) via a series of enzymes. The last hydrolysis which releases the active 
oxytocin nonapeptide is catalyzed by peptidylglycine alpha-amidating monooxygenase 
(Sheldrick and Flint 1989).  
The release of the neurosecretory product from the terminals occurs mainly as a consequence 
of invasion of the terminal membranes by action potentials. The electrical activity of the 
neuron is thus the immediate determinant of secretory output (Bicknell 1985). 
 
2.2.3 Other sites of OT synthesis 
Recent studies have shown that OT is a hormone that can be synthesized at many sites and 
several physiological activities have been attributed to this peptide.  
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It was believed that both OT and arginine vasopressin were exclusively released from the 
neurohypophysis and synthesized only by hypothalamus, but it has been reported that OT can 
be founded in other tissues, such as corpus luteum, heart, and vasculature as described next. 
 
 
2.2.3.1 Heart 
Oxytocin may be involved in the regulation of blood volume because of its natriuretic 
properties and its relationship with the modulation of blood pressure secondary to the release 
of ANP. Based on this hypothesis, Jankowski et al. (Jankowski, Hajjar et al. 1998) carried 
out a study to determine whether OT was synthesized locally in the heart. They reported that, 
in fact, the heart is a site of OT synthesis and also of release. The presence of OT was 
detected by radioimmunoassay in the four chambers of the rat heart, and the transcription of 
OT gene was demonstrated by the amplification of rat heart cDNA using PCR technique. 
They have shown the presence of OT in the effluent of isolated rat heart perfusates and in the 
medium of cultured atrial myocytes, which confirms that OT is synthesized and released from 
the heart. It was shown that cardiac OT is structurally identical to, and therefore derived from 
the same gene as, the OT found primarily in the hypothalamus.   
The localization of OT in the heart was also determined by immunostaining, showing its 
presence in the atria and ventricles, the signal being stronger in the atria, the right atrium with 
the strongest signal. The immnunolocalization revealed the presence of OT in fibroblasts and 
atrial myocytes. These results suggested that OT present in the heart is rather constitutively 
secreted than stored because immunostaining did not reveal abundant OT tissue deposits, but 
faint staining was localized in small groups or single cells randomly distributed throughout 
the atrium; OT was found in the heart perfusate and indicating it is secreted from the heart, 
and the OT concentration was relatively high in the incubation medium of cultured atrial 
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myocytes and low within these cells, which suggests immediate secretion of OT by the cells 
after its synthesis and posttranslational processing (Jankowski, Hajjar et al. 1998).  
 
2.2.3.2 Vasculature 
Oxytocin has been identified in rat, sheep, and dog vessels by radioimmunoassay technique, 
but also OT transcripts containing the coding sequence of the OT gene using the RT-PCR 
have been found (Jankowski, Wang et al. 2000). 
In rats, the superior vena cava and the thoracic aorta were collected to determine the presence 
of OT in the homogenate of these vessels by radioimmunoassay with an antibody that 
recognizes specifically biologic active OT (Jankowski, Wang et al. 2000).  
The vessels of the rat and other species contain significant amounts of OT immunologically 
equivalent with synthetic OT. Levels of vascular OT (2–4 ng/mg protein) are comparable to 
those obtained in other peripheral tissues, such as the ovary (Ivell and Richter 1984) and 
thymus (Geenen, Legros et al. 1986), and are only 2- to 4-fold lower than the levels found in 
the hypothalamus (Jankowski, Wang et al. 2000).  
 
2.2.3.3 Ovary and uterus 
The synthesis of OT by the ovary of the human and sheep was demonstrated by 
radioimmunoassay and chromatography (Wathes and Swann 1982). Some years later it was 
found that OT is synthesized in the ovary of other species like cow (Wathes, Swann et al. 
1983), cynomolgus monkey (Khan-Dawood, Marut et al. 1984), goat (Homeida 1986), 
baboon (Khan-Dawood, Huang et al. 1988) and sow (Jarry, Einspanier et al. 1990). It has 
been shown that the corpus luteum of the sow only stores OT, because the synthesis of OT is 
carried out by the uterus (Hu, Ludwig et al. 2001), which is the major site of production of 
reproductive tract origin OT. This was also observed in the rat (Zingg, Rozen et al. 1995) and 
the mare (Behrendt-Adam, Adams et al. 1999).  
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2.2.4 Regulation of oxytocin production and secretion 
The human gene for OT-neurophysin I encoding the OT pre-propeptide is mapped to 
chromosome 20p13, and consists of three exons: the first exon encodes a translocator signal, 
the nonapeptide hormone, the tripeptide processing signal, and the first nine residues of 
neurophysin; the second exon encodes the central part of neurophysin (residues 10-76); and 
the third exon encodes the COOH-terminal region of neurophysin (residues 77-93/95)(Rao, 
Loffler et al. 1992). 
The OT pre-propeptide is subject to cleavage and other modifications as it is transported 
down the axon to terminals located in the posterior pituitary (Brownstein, Russell et al. 1980). 
The mature peptide products, OT and its carrier molecule neurophysin, are stored in the axon 
terminals until neural inputs elicit their release (Renaud and Bourque 1991). The main role of 
neurophysin, a small (93-95 residues) disulfide-rich protein, is related to the proper targeting, 
packaging, and storage of OT within the granules before release into the bloodstream. 
Oxytocin is found in high concentrations (>0.1 M) in the neurosecretory granules of the 
posterior pituitary complex in a 1:1 ratio with neurophysin. In such complexes, OT-
neurophysin dimers are the basic functional units as suggested by the crystal structure of the 
neurophysin-OT complex (Rose, Wu et al. 1996). The Cys-1 and Tyr-2 in the OT molecule 
are the principal neurophysin binding residues. In particular, the protonated α-amino group 
(Cys-1) in OT forms an essential contact site to neurophysin via electrostatic and multiple 
hydrogen bonding interactions. Due to its dependence on amino group protonation (pKa ~6.4), 
the binding strength between OT and neurophysin is much higher in an acidic compartment 
like the neurosecretory granules (pH ~5.5). Conversely, the dissociation of the complex is 
facilitated as the complex is released from the neurosecretory granules and enters the plasma 
(pH 7.4) (Gimpl and Fahrenholz 2001). 
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2.2.5 Central regulation of oxytocin production and secretion 
In the central nervous system, the OT gene is primarily expressed in magnocellular neurons 
in the hypothalamic PVN and SON. Action potentials in these neurosecretory cells trigger the 
release of OT from their axon terminals in the neurohypophysis (Poulain and Wakerley 
1982).  
In the PVN, two populations of OT-staining neurons have been identified: magnocellular 
neurons which end in the neurohypophysis and parvocellular neurons which end elsewhere in 
the central nervous system (CNS). The strength and frequency of electric stimulation 
received at the PVN and SON will determine the rate of OT secretion in the blood stream 
(Poulain and Wakerley 1982; Bicknell, Chapman et al. 1985).  
The OT concentrations present in the extracellular fluid of the SON have been reported to be 
>100- to 1,000-fold higher than the basal OT concentration in plasma, meaning more than 1-
10 nM. For example, milk ejection reflex, might release even higher local OT concentrations 
(Landgraf, Neumann et al. 1992). 
Plasma OT does not readily cross the blood-brain barrier, and there is no relationship 
between the release of OT into the blood by the neurohypophysis and the variations in OT 
concentrations in the cerebrospinal fluid (CSF). Peripheral stimulations such as suckling or 
vaginal dilation that elicit large increases in plasma OT may or may not change the 
concentration of OT in the CSF. As shown in rats, electrical stimulation of the 
neurohypophysis only evokes the release of OT into the blood, whereas stimulation of the 
PVN elicits a release of OT into the blood and into the CSF (Jones, Robinson et al. 1983). 
After hypophysectomy, OT disappears from the blood, whereas its concentration increases in 
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the CSF (Dogterom, Van Wimersma Greidanus et al. 1977). The OT in the CSF is probably 
derived from neurons that extend to the third ventricle, the limbic system, the brain stem, and 
the spinal cord. In the CSF, OT is normally present at concentrations of 10-50 pM, and its 
half-life is much longer (28 min) than in the blood (1-2 min) (Jones and Robinson 1982). In 
humans and in monkeys, a circadian rhythm in the OT concentrations in the CSF has been 
found with peak values at midday. Also it has been described that environmental lighting and 
circadian rhythms regulate levels of OT in the CSF in mice and rats (Forsling 2000; 
Devarajan and Rusak 2004; Devarajan, Marchant et al. 2005). Circadian rhythms have also 
been observed in plasma OT concentrations (Lindow, Newham et al. 1996; Morawska-
Barszczewska, Guzek et al. 1996; Devarajan and Rusak 2004). 
Therefore, at the OT plasma concentration level, OT secretion is produced in an intermittent 
manner without being ruled by a biologic rhythm, consequently OT secretion is dictated by 
peripheral stimuli (Brimble and Dyball 1977; Brimble, Dyball et al. 1978).  
It was thought that contrary to other hormones, OT secretion was not controlled by a 
feedback loop that allows the modulation of its production. And that because of this reason, it 
is possible to observe high plasma concentrations during certain physiologic situations; OT 
secretion occurs in a pulsatile manner during birth and lactation (Brimble, Dyball et al. 1978; 
Higuchi, Honda et al. 1985; Fuchs, Romero et al. 1991; Uvnas-Moberg and Eriksson 1996). 
More recently, an in vitro study reported that progressive increases from extremely low OT 
concentrations (0.1–10 fM) to high concentrations (0.1–10 nM) induced excitation and 
subsequent spike frequency reduction (i.e. a gradual reduction of the firing frequency) in 
OT neurons. These results suggest that the specific autoregulatory effects of OT, and perhaps 
other neuropeptides as well, are time and concentration dependent (Wang, Ponzio et al. 
2006).  
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On the other hand, it has been reported that during parturition, a receptor-mediated positive 
feedback action of OT on its own release within the SON, which seems to be involved in the 
progress of parturition without significantly affecting circulating OT levels. Oxytocin 
released within the SON might be important for the coordinated activation of OT neurons and 
for the synergistic central and peripheral OT effects involved in the regulation of parturition-
related events necessary for the survival of the newborn, including the onset of lactation 
(Neumann, Douglas et al. 1996). 
Pulsation frequencies reach their maximum during the last phase of birth (Fuchs, Romero et 
al. 1991). This type of secretion represents an advantage during a long labour procedure, by 
assuring an effective and rapid contractile activity from the uterus, that responds to OT 
stimuli (Crall and Mattison 1991). 
2.2.6 Other factors controlling oxytocin secretion  
Oxytocin is very similar in structure to vasopressin (AVP). Vasopressin is also synthesized 
and realized by mangnocellular neurosecretory neurons when action potentials arrive from 
the cell bodies in the SON and PVN (Leng, Brown et al. 1999). The major stimuli that excite 
these AVP neurons are an increase in extracellular osmolarity, generally a result of increased 
[Na+] (with Cl-), and decreased system blood volume and pressure (Leng, Brown et al. 2001; 
Bourque 2008). 
The AVP and OT amino acid sequences differ only in the 3 and 8 positions. Oxytocin 
secretion could also be stimulated by hyperosmolarity of extracellular fluid, at least in the rat 
(Leng, Brown et al. 2001)and it has peripheral natriuretic actions. These natriuretic actions 
involve direct effects in the kidney (Antunes-Rodrigues, de Castro et al. 2004) and actions in 
the right atrium to stimulate atrial natriuretic peptide (ANP) secretion (Haanwinckel, Elias et 
al. 1995). Release of OT is also stimulated by induced hypovolemia in a rat model (Stricker, 
Hosutt et al. 1987). 
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Moreover, OT is secreted postprandially (Haanwinckel, Elias et al. 1995), and may contribute 
to post-prandial ANP secretion (McCann, Gutkowska et al. 2003), and hence post-prandial 
natriuresis. 
Oxytocin is a more potent natriuretic hormone than AVP. These effects can be explained by a 
direct action of both peptides on specific receptors already shown to be present in the tubular 
cells of the kidney (Samson and Schell 1995). The different potencies of these hormones can 
be attributed to a relative affinity of OT for its own receptor or to its lower affinity for V2 and 
V1 AVP receptors.  
Also, some studies have suggested a synergistic effect of AVP and OT in the inner medullary 
collecting duct, where both peptides induce an increase in cAMP accumulation and 
natriuresis (Baek, Kwon et al. 1996; Evans 1996). Oxytocin binds to the AVP subtype V2 
receptor because of its structural similarity to AVP. The urinary sodium excretion induced by 
OT is completely blocked by pre-treatment with an OT receptor antagonist, but not affected 
by an AVP subtype V1 receptor antagonist (Stock, Granstrom et al. 1989).  
The central administration of OT decreases salt intake (Blackburn, Samson et al. 1993). The 
inhibitory role of OT in the control of sodium appetite has been supported by studies in OT 
knock-out mice that display an enhanced salt appetite compared with OT +/+ mice after water 
deprivation (Amico, Morris et al. 2001). 
In women, during pregnancy OT is involved in the maintenance of hypervolaemia. Salt 
appetite is increased in pregnancy (Atherton, Dark et al. 1982) and total circulating sodium is 
increased, although water retention reduces plasma [Na+] while increasing volume. In these 
circumstances a natriuretic response can be expected, through stimulation of ANP secretion 
by right atrial distension (Haanwinckel, Elias et al. 1995), but this kind of response is either 
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ineffective or suppressed in pregnancy. Indeed, circulating ANP levels decrease in late 
pregnancy (Nadel, Ballermann et al. 1988; Jansakul, King et al. 1989; McCann, Antunes-
Rodrigues et al. 2002). Reduced OT content in the atria in pregnancy, and reduced OTR 
mRNA expression near term (McCann, Antunes-Rodrigues et al. 2002) may contribute to this 
reduced ANP secretion. 
 
2.2.7 Oxytocin receptor: Classification and activation 
The physiological effects of OT are primarily mediated through a specific G protein-coupled 
receptor (GPCR), the OTR. The OTR preferentially couples to Gαq/11 proteins to activate 
phospholipase C (PLC) which hydrolyzes the membrane phospholipid phosphatidylinositol 
4,5-bisphosphate (PIP2) to form inositol 1,4,5-trisphosphate (IP3), which mobilizes Ca2+ 
from the sarcoplasmic reticulum, and diacylglycerol (DAG), which activates protein kinase 
C, resulting in the phosphorylation of several target proteins (Ku, Qian et al. 1995; Holda, 
Oberti et al. 1996; Willets, Brighton et al. 2009).  
Oxytocin causes a rapid increase in intracellular free Ca2+, activates mitogen-activated 
protein (MAP) kinase, and stimulates prostaglandin E2 synthesis by activating 
cyclooxygenase. In addition, an increase in Ca2+ bound calmodulin leads to the activation of 
kinase primarily responsible for the phosphorylation of MLC, regulating myometrial 
contractility (Nakamura, Itakuara et al. 2000; Gimpl and Fahrenholz 2001).  
The high-affinity receptor state requires both Mg2+ and cholesterol, which probably act as 
allosteric modulators (Gimpl and Fahrenholz 2001). 
The presence of OTR in several tissues and organs demonstrates that OT effects are not only 
restricted to the reproductive system (Nakamura, Itakuara et al. 2000). The OTR has been 
cloned from human (Nakamura, Itakuara et al. 2000), rat (Bale and Dorsa 1997)  and other 
species. It is highly conserved across the species and has been found in a variety of tissues, 
particularly in the uterus (Kimura, Tanizawa et al. 1992), but also in the mammary and 
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pituitary glands, brain (Adan, Van Leeuwen et al. 1995), kidney (Stoeckel and Freund-
Mercier 1989), thymus (Elands, Resink et al. 1988), ovary (Sernia, Gemmell et al. 1989), 
testis (Bathgate and Sernia 1994), heart (Jankowski, Hajjar et al. 1998) and blood vessels 
(Jankowski, Wang et al. 2000). 
The function and physiological regulation of the OT/OTR system is strongly steroid 
dependent, but the OTR modulators are not only present among hormones, they also include 
neurotransmitters and cytokines, like IL-1β and IL-6 which have inhibiting effects on OTR 
expression in myometrial cells. This observation was supported by the report of Rauk and 
Friebe-Hoffmann who found down regulation of OTR in cultured uterine myocytes treated 
with IL-1 for 24 hours (Rauk and Friebe-Hoffmann 2000; Bussolati and Cassoni 2001; 
Schmid, Wong et al. 2001).  
The regulation by gonadal and adrenal steroids is one of the most remarkable features of the 
OT system, but unfortunately this has not been clarified (Gimpl and Fahrenholz 2001). On 
the other hand, it has been demonstrated that the estrogens cause an improvement in the OT 
and OTR gene expression (Gimpl and Fahrenholz 2001; Richter, Kubler et al. 2004; Hong, 
Park et al. 2006). 
 
2.2.8 Oxytocin receptor 
2.2.8.1 Brain 
There is a high diversity of OTR distribution among the species (Gimpl and Fahrenholz 
2001). For example, the ventral subiculum in the hippocampus contains high densities of OT 
binding sites in the rat (Shapiro and Insel 1989), whereas in the guinea pig (Tribollet, 
Barberis et al. 1992), the hamster (Dubois-Dauphin, Pevet et al. 1992), and the marmorset 
(Schorscher-Petcu, Dupre et al. 2009), no OT binding sites were detected in this area. In 
monogamous vs. polygamous voles, OTR distribution was shown to reflect social 
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organization (Insel and Shapiro 1992). In human brains, dense OTR were visualized in the 
pars compacta of the substantia nigra unlike in several other species examined so far. Thus, 
in humans, nigrostriatal dopamine neurons could be a target for OT, and the OT system may 
be involved in motor and other basal ganglia-related functions. Strong OT binding intensity 
was also observed in the basal nucleus of Meynert, but OT binding sites were lacking in the 
hippocampus, amygdala, entorhinal cortex, and olfactory bulb of human brains (Loup, 
Tribollet et al. 1991).  
 
2.2.8.2 Kidney 
Studies performed in rats showed by autoradiographical analysis the existence and precise 
localization of OTR in the kidney. The distribution of OT binding sites experience some 
changes during postnatal development and this event was also observed in the rat brain during 
maturation (Schmidt, Jard et al. 1990).  
Specific OT binding sites have been first detected at embryonic day 17 in the renal cortex, 
while in the medulla OT binding sites were detected at embryonic day 19 when this region is 
experiencing its developmental phase. In the adult rat, OT binding sites were exclusively 
localized in the cortex, mainly concentrated in the macula densa. In the inner medulla, the OT 
binding sites were found on the loops of Henle of the juxtamedullary nephrons (Arpin-Bott, 
Waltisperger et al. 1997). 
It is important to underline that renal cortical OT-binding sites had a higher selectivity for OT 
vs. AVP compared with the medullar sites of binding for both hormones. It was therefore 
suggested that OT binding sites of the macula densa and Henle's loop could represent two 
subtypes of OTR. The specific profile of localization of the receptors suggests a role 
performed by OT in the regulation of tubuloglomerular feedback and solute transport (Arpin-
Bott, Waltisperger et al. 1997). 
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Gene expression of OT and OTR in the kidney is regulated by other hormones, such as 
steroids. It was shown that estrogens induced an increase of OTR gene expression in the 
outer medulla region and also in OTR at the macula densa and proximal tubule cells of 
ovariectomized female and adrenalectomized male rats. Since, it was probable that OTR may 
mediate estrogen-induced alterations in renal fluid dynamics, Ostrowski et al. (1995) realized 
a study in which they measured the OTR mRNA levels in kidneys of late-pregnant, peri-
parturient, and lactating rats. They found that OTR transcripts could not be detected in renal 
tissues of peri-parturient females, because, at this time, OTR mRNA levels were highest in 
uterus but also levels of estrogens were low, there is a stronger influence of progesterone 
instead (Ostrowski and Lolait 1995).  
However, OTR gene expression in macula densa cells gradually reappeared and again 
achieved control levels by day 20 post partum. It was observed that both the OTR mRNA 
levels, as well as, the OT binding capacity of rat renal extracts were significantly lower at 
term. Although in the rat kidney there was no indication for another than the uterine-type 
OTR gene expression, the mechanisms controlling the expression of OTR genes in uterus, 
pituitary gland, and kidney are obviously different (Breton, Pechoux et al. 1995).  
 
2.2.8.3 Heart and cardiovascular system  
The OTR transcripts and OT binding sites were shown to be present on atrial and ventricular 
sections as detected by in situ hybridization and autoradiograpy. Furthermore, the OTR gene 
is expressed in all chambers of the rat heart, and the analysis of the RT-PCR products 
indicated the presence of the uterine-type OTR in the heart. Although the OTR mRNA levels 
in the atria were found to be higher than in the ventricles, overall the OTR mRNA levels were 
calculated to be at least 10 times lower than the OTR mRNA level present in the uterus of a 
non-pregnant rat (Gutkowska, Jankowski et al. 1997). The OTR mRNA has been also found 
in vascular tissue. This was demonstrated by RT-PCR amplification (Jankowski, Wang et al. 
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2000). Additionally, it has been demonstrated that human vascular endothelial cells express 
OTR that are structurally identical to the uterine and mammary OTR (Thibonnier, Conarty et 
al. 1999).  
 
2.2.9 Oxytocin effects extern to the reproductive system 
The OT and OTR effects in the reproductive system are well known. But, the proofs of other 
sites of OT synthesis, out of the reproductive system, and the wide distribution of its 
receptors have shown that the OT system is much more complex. Therefore, OT is related 
with more physiological activities than previously thought. Recently, it has been shown that 
OT/OTR also participate in the regulation of different behavioural, neuro-mediated functions, 
including sexual and maternal behaviour, memory, food and drink intake, and modulation of 
anorexia, this activities have shown marked differences among the species (Gimpl and 
Fahrenholz 2001; Rotzinger, Lovejoy et al. 2009; Stein 2009; Andari, Duhamel et al. 2010; 
Gouin, Carter et al. 2010).  
 
2.2.10 Oxytocin renal effects 
One of the main targets of the neurohypophyseal hormones is the control of fluid and 
electrolytes excretion is the kidney. It has been documented that OT is involved in the 
management of water and electrolytes excretion. Renal effects of OT have been reported in 
rats, dogs and more recently in men (Andersen, Engstrom et al. 1992; Conrad, Gellai et al. 
1993; Forsling, Judah et al. 1994; Rasmussen, Simonsen et al. 2004). Though, these effects 
are variable depending on the target species, dose and administration regimen (bolus, 
infusion, pulsatile).  
The stimuli that promote OT release are the hypovolemia or hyperosmolarity. Oxytocin is a 
non-hypertensive natriuretic agent and it is involved in normal osmolar regulation, which is 
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presumably different from the volume regulatory components of Na+ homeostasis (Gimpl and 
Fahrenholz 2001; Mahia, Bernal et al. 2009). 
Some studies have been developed to elucidate the complex effects of OT in renal function. 
For example, the acute administration of physiological doses of synthetic OT in conscious 
rats produced a modest increase in glomerular filtration rate (GFR) and effective filtration 
fraction (Conrad, Gellai et al. 1993). 
It has been reported that OT has natriuretic effects in rats. Haanwinckel et al. (1995) showed 
that OT produce a release of ANP, which is a peptide hormone synthesized in the atria of the 
heart that also regulates Na+ and water excretion. The release of ANP was mediated by the 
interaction of OT with its receptors found in the right atrium, ANP release caused in 
consequence natriuresis and diuresis suggesting that the natriuresis and diuresis effects of OT 
are mediated by ANP release (Haanwinckel, Elias et al. 1995).  
In addition, it has been shown that OT has natriuretic effects by itself. Soares et al. (1999) 
found that the natriuretic effect of OT is caused by the activation of OTR and further 
production of NO in proximal tubule and macula densa cells, resulting in reduced fractional 
Na+ reabsorption (Soares, Coimbra et al. 1999). It was suggested that OT binding with its 
receptors on these nitrergic cells in the proximal tubules and macula densa leads to an 
increase of intracellular Ca2+ concentration, followed by Ca2+-calmodulin-induced 
stimulation of NO synthase (NOS) and subsequent activation of the soluble guanylate cyclase 
(sGC) by released NO. The consequent release of cyclic guanosine monophosphate (cGMP) 
could then mediate natriuresis and kaliuresis via closure of Na+ and K+ channels. In cortical 
collecting duct cells, it has been shown that the NO-inhibited Na+ transport is associated with 
increased cGMP content. Overall in rats, OT, as well as ANP, induces a concomitant 
reduction of both extracellular and intracellular fluid volume in states of increased body fluid 
volume (Soares, Coimbra et al. 1999).  
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Verbalis et al. (1991) found that OT produces natriuresis in rats at physiological plasma 
levels and that elevated plasma OT levels correlate with increased Na+ excretion (Verbalis, 
Mangione et al. 1991).  
In rats, the natriuresis is not only dose dependent. Sjoquist et al. (1999) found that the 
pulsatile increase in plasma OT did not produce natriuresis. When OT was administrated in 
bolus with 5 to 10 minutes intervals simulating the OT release in physiologic states, like 
during suckling, OT did not produce natriuresis. Although, when the same dose of OT was 
administrated by constant rate infusion (CRI), it produced natriuresis. So, it is possible that 
the receptors in mammary glands and uterus are sensitive to pulsatile secretion of OT and 
then the OTR mediating natriuresis require more continuous exposure (Sjoquist, Huang et al. 
1999). 
Similar effects have been described in the dog, in which OT had a natriuretic but not diuretic 
effect when administrated also as a one hour infusion (Andersen, Engstrom et al. 1992). In 
opposition with the effects reported in rats and dogs, Rasmussen et al. (2004) reported an 
anti-diuretic and anti-natriuretic effect in men and this effect has been also reported in non-
human primates (Wesley and Gilmore 1985; Rasmussen, Simonsen et al. 2004).  
Earlier reports mention that the natriuretic effect of OT might be species-specific or that it is 
only observed in lower animal species (Conrad, Gellai et al. 1993; Rasmussen, Simonsen et 
al. 2004), however, it is quite possible that the discrepancies found in the articles reporting 
the renal effects of OT are related with the differences in animal preparation methodology, 
doses and administration regimen. 
 
2.2.11 Oxytocin cardiovascular effects 
Oxytocin may modify blood pressure and heart rate (HR) by affecting CNS controls, or other 
organs such as the heart, blood vessels, and kidney, or by acting on other mediators like ANP 
and NO (Petersson 2002).  
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The cardiovascular effects of OT have been studied mainly in rats; in vivo studies reported 
that daily central administration of OT can cause different effects; intracerebroventricular 
daily injection during five days caused a long term decrease in mean arterial pressure (MAP) 
without affecting HR. This effect was present even at eight days after the last injection 
(Petersson, Alster et al. 1996); in another experiment, OT infusion into the dorsal vagal 
complex induced a sustained hypertension (Tian and Ingram 1997). Conversely, other authors 
have not found any change in MAP and HR when OT was administered by microinjection 
into the nucleus tractus solitarius (Vallejo, Carter et al. 1984). Oxytocinergic projections 
from the hypothalamus to the brain stem appear to be important for the baroreflex control of 
the HR (Higa, Mori et al. 2002).  
Peripheral administration of OT resulted in short lived increase (Costa, Pereira-Junior et al. 
2005; Bakos, Bobryshev et al. 2008) followed by a prolonged decrease (Petty, Lang et al. 
1985; Petersson, Lundeberg et al. 1999) in MAP. Oxytocin treatment also produced a 
reduction in HR and contractility (Costa, Pereira-Junior et al. 2005). In human studies, 
intravenous bolus injection of synthetic OT was found to be associated with hypotension 
(Thomas, Koh et al. 2007).  
The effects of OT, in the absence of central control mechanisms, have been also described in 
isolated heart of rats and dogs, finding that OT causes negative inotropic and chronotropic 
effects (Mukaddam-Daher, Yin et al. 2001; Costa, Pereira-Junior et al. 2005). Even though 
the exact mechanism of these effects have not been fully studied, apparently they are 
mediated by local release of ANP (Favaretto, Ballejo et al. 1997).  
As was mentioned before, the OT/OTR system is present in the heart and it seems that 
because OT was found stored only in small amounts, it is immediately secreted, which means 
that it may act locally producing ANP release. After blood volume expansion, ANP also 
plays a physiological role by causing a negative chronotropic and inotropic effect, and in 
consequence a decrease in cardiac output resulting in a reduction in the circulating blood 
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volume (Gutkowska, Jankowski et al. 2000). So, the physiologic mechanism that OT plays in 
the heart has been explained as follows, the blood volume expansion as a result of increased 
venous return to the heart would stretch the cardiomyocytes activating OT release. The OT 
locally released would promote the release of ANP that in turn acts on its receptors to 
activate particulate guanylyl cyclase and reduce intracellular Ca2+ release. The decrease in 
intracellular Ca2+ causes the negative inotropic and chronotropic effects, which in turn reduce 
cardiac output and in consequence the effective circulating blood volume (McCann, Antunes-
Rodrigues et al. 2002).  
Gutkowska et al. proposed that OT and ANP act in concert in the control of body fluid and in 
cardiovascular homeostasis (Gutkowska, Jankowski et al. 1997).  
In addition, OT was found to modulate the intrathoracic sympathetic ganglionic neurons 
regulating the canine heart (Armour and Klassen 1990). These authors showed that when OT 
was injected into right atrial ganglionated plexi, HR and atrial forces were reduced in 5 of 
10 dogs studied. However, no cardiac changes occurred when OT was injected into left atrial 
or ventricular ganglionated plexi. In this study, the connectivity with the CNS was found to be 
necessary to elicit consistent OT-induced responses. Although OT elicited neuronal and 
concomitant cardiovascular responses in most dogs when administered adjacent to 
spontaneously active intrinsic cardiac neurons, OT injection into the superior vena cava only 
evoked a slight systemic hypotension in two of seven dogs. 
In the vasculature, particularly in the endothelial cells (Thibonnier, Conarty et al. 1999), OTR 
activation leads to an increase in intracellular Ca2+, which is related with cell proliferation. It 
has been proposed that the OTR trophic properties may participate in the maintenance of the 
integrity of the vascular endothelial lining. This mitogenic action of OT involves several 
mediator including Ca2+ calmodulin kinase II and PKC.   
The presence of the OT/OTR system in the vasculature suggests that OT might also play a 
role in the regulation of vascular tone and therefore in blood pressure. Effects of OT on 
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vasculature are controversial. In vitro experimentations have shown that OT can cause both 
vasorelaxation and vasoconstriction (Katusic, Shepherd et al. 1986). Oxytocin vasodilatory 
effect was demonstrated using isolated canine basilar arteries; OT caused endothelium-
dependent vasorelaxation, which means that when endothelium was mechanically removed, 
the vasodilatory effect disappeared (Katusic, Shepherd et al. 1986). On the other hand, OT 
presented a potent vasoconstrictor effect in uterine arteries, when administrated at great 
doses; this vasoconstrictor effect was partially counteracted with the administration of an OT 
antagonist, suggesting the possible binding of OT with arginine vasopressin receptor V1a-
type (Chen, Shepherd et al. 1999; Loichot, Krieger et al. 2001).  
The controversial effects of OT on vasculature may be related with OTR expression in 
endothelial cells and vascular smooth muscle cells. Activation of OTR in endothelial cells 
produces a Ca2+-dependent vasodilatory response via stimulation of the NO/sGC pathway, 
consequently producing vasorelaxation (Thibonnier, Conarty et al. 1999). Whereas OTR 
activation in smooth muscle cells produces an increase in IP3 production and intracellular 
Ca2+ concentration, thus causing vasoconstriction (Yazawa, Hirasawa et al. 1996). Whether, 
the vasodilatory or vasoconstrictor effects of OT are mediated through its receptor is not clear 
because OTR and vasopressinergic V1 receptor are co-localized in endothelial and smooth 
muscle cells along the vasculature. It has been demonstrated that if OT is administrated at 
high doses, OT can bind to V1a receptors (Chen, Shepherd et al. 1999; Loichot, Krieger et al. 
2001; Miller, Davidge et al. 2002).  
 
2.2.12 Oxytocin cardio-protective effects 
It has been recently reported that perfusion with OT before ischemia can attenuate the extent 
of irreversible myocardial damage in an induced ischemia/reperfusion (I/R) in vitro model of 
MI in rats; this was demonstrated as a reduced size of infarction. Oxytocin also decreased or 
mitigated the post-ischemic cardiac stunning, which is a condition characterized by 
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prolonged mechanical dysfunction that persists after brief episodes of ischemia and 
reperfusion, without no histological signs of irreversible injury to cardiomyocytes (Pomblum, 
Korbmacher et al. 2010). Apparently the negative chronotropic but not inotropic action of OT 
appeared to be involved in the mediation of its protective effects (Ondrejcakova, Ravingerova 
et al. 2009).  
In a I/R rabbit model, postinfarct treatment with OT reduced MI size and improved left 
ventricle function and remodeling by activating OTR and prosurvival signals, and by exerting 
anti-fibrotic and angiogenic effects through activation of matrix metalloproteinase-1 (MMP-
1), endothelial NO synthase, and vascular endothelial growth factor (Kobayashi, Yasuda et 
al. 2009).  
Using a swine MI model, it was demonstrated that endogenous pre-MI OT levels and timing 
of administration post-MI are important criteria, if OT is intended to be used as a therapeutic 
strategy for ischemic heart disease. Pigs with low endogenous OT level receiving OT 
subcutaneous infusion (10 ng·kg−1·hr−1) starting 8 days post-MI, as well as pigs with high 
endogenous OT level receiving saline presented lower MI area measured by planimetry, and 
cardiac function was also less affected. Moreover, high endogenous OT level pigs receiving 
OT infusion had highly-affected cardiac function associated to bigger MI area, as well as 
down-regulation of myocardial OTR (Authier, Tanguay et al. 2010).  
Recently, Jankowski et al. (2010) examined the effect of OT infusion on cell apoptosis, 
expression of proliferating cell nuclear antigen (PCNA) and inflammation in the acute and 
subacute phases of rat MI model. Oxytocin infusion increased the number of cells expressing 
PCNA in the infarct zone, diminished cell apoptosis and fibrotic deposits in the remote 
myocardium. In OT treated rats, inflammatory response was reduced, since there was less 
infiltration of neutrophils, macrophages and T lymphocytes. Moreover, expression of 
proinflammatory cytokines, tumour necrosis factor-alpha and interleukin-6 was also reduced 
in OT-infused rats with promotion of transforming growth factor-beta. Oxytocin treatment 
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reduced expression of atrial and brain natriuretic peptides in the infarcted ventricle, as well as 
the concentration of both peptides in the circulation. These results indicated that continuous 
OT delivery reduces inflammation and apoptosis in infarcted and remote myocardium, thus 
improving function in the injured heart (Jankowski, Bissonauth et al. 2010). 
 
2.2.13 Oxytocin in cardiomyogenesis 
As mentioned before, heart is a site of OT synthesis and release, and OTR is also expressed 
in all the chambers of the heart. There are supporting data showing a potential role of 
OT/OTR system during cardiomyogenesis. Protein levels of OT and OTR are up-regulated in 
the developing rat heart at day 21 of gestation and postnatal days 1-4, when cardiomyocytes 
are at a stage of intense hyperplasia. Between postnatal days 1 and 66, OT decreased linearly 
in all the chambers of heart (Jankowski, Hajjar et al. 1998). The expression of OTR, which is 
eminent in postnatal cardiomyocytes, declined with age to low levels in adults.  
 
2.2.14 Oxytocin in cardiomyogenic differentiation of stem cells 
When cultures of embryonal carcinoma P19 cell line, often used for studying in vitro 
embryonic development, were supplemented with OT, there was an increased production of 
beating cell colonies, this increased production of beating cell colonies was completely 
inhibited when OT supplemented cells were exposed to an OT antagonist (Paquin, Danalache 
et al. 2002).  
Oxytocin also improved cardiomyogenic differentiation of embryonic and adult stem cells. 
Matsuura et al. (2004) reported the presence of Sca-1+ cells in adult hearts which presented 
some stem cell features. When treated with OT, Sca-1+ cells expressed genes of cardiac 
transcription factors and contractile proteins and showed sarcomeric structure and 
spontaneous beating. Isoproterenol treatment increased the beating rate, which was 
accompanied by intracellular Ca2+ transients. The cardiac Sca-1+ cells also expressed OTR 
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transcripts, and this expression was up-regulated upon OT treatment (Matsuura, Nagai et al. 
2004). Oxytocin appeared to be a more potent differentiation inducer of adult Sca-1+ cells 
than the widely used cardiomyogenic agent 5-azacytidine.  
The involvement of the OT/OTR system in cardiomyocyte differentiation was also confirmed 
by using murine ES cells, as an experimental model. Hatami et al. (2007) showed that murine 
ESCs treated or not with OT could effectively differentiate into functional cardiomyocytes. 
This conclusion was based on the contractility of the differentiated cultures, the response of 
these differentiated cells to cardioactive drugs, the typical ultrastructure of cardiomyocytes, 
and by the specific expression of multiple cardiac-associated molecular markers by the 
differentiated cells. In addition, this report revealed that OT led to an increase in the 
differentiation of ESCs into cardiomyocytes and, perhaps, the acceleration in the maturation 
of ESCs-derived cardiomyocytes. Also, the expression of OTR was detected in the 
undifferentiated ESCs and OT-induced cells had an up-regulated expression of OTR (Hatami, 
Valojerdi et al. 2007).  
Oyama et al. (2007) reported the presence of SP cells in the neonatal rat heart, these cells 
when treated with OT, expressed cardiac specific transcripts (GATA-4, Nkx2.5, MLC-2v) 
and proteins (cTnT, MLC-2v, ANP), and they also showed spontaneous beating (Oyama, 
Nagai et al. 2007).  
 
2.2.15 Oxytocin pharmacokinetics and therapeutic use 
Even though the wide therapeutic use of OT, in animals and humans obstetrics, the 
pharmacokinetics of OT have been reported only in a few studies (Homeida and Cooke 1984; 
Seitchik, Amico et al. 1984; Thornton, Davison et al. 1990; Morin, Del Castillo et al. 2008). 
The time course of OT plasma concentrations following an intravenous bolus administration 
in humans is usually described with an open two-compartment model. The pharmacokinetic 
profile described for animals is similar to that of humans. It has been reported that in goats 
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after receiving a single intravenous injection of OT (2000 ng/kg), the plasma concentrations 
of this hormone also followed a bi-exponential decay, with an initial (distribution phase) 
mean (SD) half-life of 1.94 (0.21) min, a terminal (elimination phase) half-life of 22.3 (0.3) 
min, and a total body clearance of 0.85 (0.02) L/(h·kg). However, the apparent volume of 
distribution of OT in goats is 0.46 (0.02) L/kg (Homeida and Cooke 1984), a three times 
higher value than in men (De Groot, Vree et al. 1995). A study on anesthetized rats receiving 
a constant infusion of 6040 ng/(min·kg) reported a systemic clearance of 1.46 (0.22) L/(h·kg) 
and an elimination half-life of 20.70 (1.55) min, as estimated from steady-state plasma 
concentrations (Lundin, Broeders et al. 1993). 
Recently, a study performed in anesthetized rats provided evidence for non-linear 
pharmacokinetics, concluding that The pharmacokinetic properties and persistence of 
exogenous OT are not proportional to dose (Morin, Del Castillo et al. 2008). 
In humans, the recommended method of OT administration for labour induction is the CRI at 
an initial rate of 0.5 – 1 mU/min (0.85 – 1.71 ng/min), followed by subsequent increases of 1 
mU/min (1.71 ng/min) for 40 to 60 minutes. These recommendations are based on a study 
performed in 11 patients in the early 80’s. It was found that this rate of perfusion produces a 
linear increase in the plasma concentrations of OT, and that a perfusion of around 40 minutes 
is needed to reach the steady state. This finding suggested that the increase of the doses 
before this 40 minutes period will carry out an inutile exposure of the patient to higher doses 
than those actually needed (Seitchik, Amico et al. 1984). 
It is important to highlight that OT plasma concentrations do not reflect the actual response of 
the uterus or labour progression. Moreover, no correlation has been found between the 
increases in plasma concentrations of administered OT and the increases in uterine 
contractions (Perry, Satin et al. 1996). 
Pulsatile OT administration during birth has been used in order to better approximate normal 
physiology; this fact reduces the total quantity of OT required in comparison to the CRI 
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(Cummiskey, Gall et al. 1989). Therefore, it is still controversial, which is the best method 
for labour induction, even if OT has been used for several years. 
Oxytocin is well absorbed after oral and nasal administration (Seitchik, Amico et al. 1984). 
After oral administration, OT is metabolized by enzymatic destruction in the gastrointestinal 
tract.  Once, absorbed OT is distributed in the extracellular volume and it does not bind to 
plasma proteins (Arias 2000).  
The plasma half-life of OT is of only a few minutes, the reported half-life values of OT go 
from 10 - 12 minutes, this was reported in women but it was not specified if women were 
pregnant or not (Arias 2000). In other studies, a plasma half-life of 5 minutes has been 
described in pregnant women (Seitchik, Amico et al. 1984). 
Baseline plasma concentrations of OT have been described in humans. Leake et al. (1981) 
measured the baseline plasma OT in 25 healthy men, 102 non-pregnant women, and 59 
pregnant women from 15–42 weeks gestation. In addition, plasma OT levels were measured 
at the onset, peak, and immediately after a single uterine contraction in 6 women in the latent 
phase and 14 women in the active phases of labour, as well as in 19 women at initial 
presentation of the foetal head on the perineum, and 11 women at the time of delivery of the 
head during a normal vaginal delivery. Baseline plasma OT concentrations (mean SE) did not 
vary significantly among men, (1.5 ± 0.2 µU/ml), non-pregnant women (1.4 ± 0.2 µU/ml), or 
pregnant women before labour (1.3 ± 0.1 µU/ml) and did not differ in an additional subgroup 
of 20 women receiving oral contraceptive medication (1.8 ± 0.7 µU/ml) (Leake, Weitzman et 
al. 1981). 
In studies conducted during labour, plasma OT concentrations did not correlate with uterine 
pressure measurements and did not increase significantly over baseline pregnancy 
concentrations during the latent (1.3 ± 0.2 µU/ml) or active (1.6 ± 0.2 µU/ml) phases of 
labour. But there was a significant increase in plasma OT levels from the time of initial 
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visualization of the foetal head to the time of delivery of the head (1.1 ± 0.1 to 4.2 ± 1.1 
µU/ml, respectively; P < 0.05) (Leake, Weitzman et al. 1981).  
In men, after the intravenous administration of 1 IU or (1.71 µg) of OT, the pharmacokinetics 
of the OT can be described using a two compartment model, the obtained parameters were 
(mean SE): distribution half-life 2.94 ± 0.96 min, elimination half-life 19.8 ± 13.8 min, total 
clearance 67.1 ± 13.4 L/h, volume of distribution 33,2 ± 28,1 L, steady state volume of 
distribution 12.2 ± 5,6 L (De Groot, Vree et al. 1995). 
2.2.15.1 Oxytocin elimination 
 
The OT is metabolised mainly in the liver, in the plasma (by oxytocinase) and the kidney, 
and only a small fraction of unchanged OT is excreted in urine (Seitchik, Amico et al. 1984). 
  
Metabolic clearance of oxytocin 
The proteolytic enzymes metabolically degrade the peptides by hydrolyzing peptide bonds. 
Depending on the site of activity the enzymes are classified either as exopeptidases 
(hydrolyze peptides from either the C- or N- terminal region) or endopeptidases (cleave 
internal bonds of the peptide). In addition to whole body clearance, there is evidence that OT 
released at synaptic sites in the brain is also subject of degradation by peptidase enzymes 
(Claybaugh and Uyehara 1993; McEwen 2004). 
The enzymes that participate in the metabolism of OT and other peptides by causing a 
nonspecific cleavage can give origin to the formation of metabolites (Claybaugh and Uyehara 
1993). 
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These enzymes are: 
Table 1. Enzymes participating in oxytocin metabolism 
Enzyme Type Metabolites 
Post-Proline cleaving enzyme Serine protease Leu-Gly-NH2 
Chymotrypsin-like enzyme Carbosypeptidase Gly- NH2 
Disulfide bond cleaving enzyme Thiol: protein disulfide 
oxydoreductase 
 
(Claybaugh and Uyehara 1993) 
The OT is removed from the circulation to be principally metabolized by the oxytocinase 
(OTase), this enzyme has been studied a few years ago by Nakamura et al. (2000) who 
studied the tissue distribution of the enzyme by locating the mRNA, finding that the enzyme 
has a broad distribution and it is not limited to the placenta. The sites of location of this 
aminopeptidase include vascular endothelium, gastrointestinal mucosa, pancreas, bile duct, 
bronchial epithelium, renal tubules (where OT is metabolized and eliminated), sweat glands, 
adipocytes and skeletal muscle (Nakamura, Itakuara et al. 2000). 
To elucidate the mechanism of action of OTase and its relationship with OT/OTR system 
Nakamura et al. (2000) developed a study in which they used a cell line of human umbilical 
vascular endothelial cells (HUVEC), It is recognized that these cells express OTR 
(Nakamura, Itakuara et al. 2000). 
It was surprising to find the effects of OT on (OTase) activity, they reported that there is an 
increase in the OTase activity on the cell surfaces of HUVEC probably caused by the 
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interaction with OTR, suggesting that the receptor stimulation results in a translocation of 
intracellular OTase to the plasma membrane via signal transduction pathway, so the 
mechanism of translocation of intracellular OTase in response to OT give as a consequence 
an increase in the degradation of OT at the cell membrane level. This interesting finding 
suggests a mechanism of negative feedback of peptide hormones at the cellular level; 
bioactive peptides stimulate degrading protease activity on cell membranes (Nakamura, 
Itakuara et al. 2000). 
Renal clearance of oxytocin 
As previously mentioned OT is mainly inactivated by the enzyme OTase, which is present in 
the plasma and different tissues, but as mentioned above OT is also eliminated in an 
unchanged state in the urine.  
Normally a drug that is filtered, not secreted or reabsorbed by the kidney will have a renal 
clearance equal to the glomerular filtration rate (LeBlanc PP 1997). In the specific case of 
OT, since it affects the renal and cardiovascular functions depending on many factors 
previously discussed, OT could also influence its own elimination by reducing renal 
clearance.  
It has been suggested that OT clearance is increased during gestation. Most of the studies 
have been focused on humans. Initial investigations in women failed to find differences in 
metabolic clearance rate of OT during gestation (Amico, Seitchik et al. 1984). However, 
more recently, Thornton et al. (1990) reported a four- to fivefold increase in OT clearance in 
pregnant compared with nonpregnant women (Thornton, Davison et al. 1990).  
While it is generally agreed that OT is rapidly inactivated in plasma from pregnant women 
(50 % of OT disappears in 5 min at 38o C from plasma obtained at term (Mendez-Bauer CJ 
1961), reports of its stability in plasma from non-pregnant subjects vary. Ultrafiltration of 
human plasma containing exogenous OT and AVP at concentrations ranging from 50-400 
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µU/ml showed that OT was completely unbound to plasma proteins, while AVP binding was 
30% independently on the concentration (Fabian, Forsling et al. 1969).  
 
2.2.15.2 Evidences of non-linear oxytocin pharmacokinetics 
While no evidence could be found for the binding of OT, its apparent volume of distribution 
was not very different from that of AVP that is about two thirds of the extracellular volume 
(intersticial and intravascular compartments). Fabian et al. (1969) reported that after an OT 
bolus of 2 U, volume of distribution was 7.4 L, and for an OT CRI of 500 mU/min the 
volume of distribution was 10.5 L. The authors reported that both OT and AVP volumes of 
distribution exceeded the plasma volume and that diffusion presents an additional 
complicating factor (Fabian, Forsling et al. 1969).  
As the distribution volumes of OT might include the interstitial volume, the determination of 
their half-life in the blood, following an infusion, may be influenced by diffusion across the 
capillary membrane (Fabian, Forsling et al. 1969).  
Some studies have described OT binding to cloned human OTR in COS-1 transfected cells, 
in this study the affinity of the cloned OTR to different ligands was analyzed. The authors 
reported that OTR had a single high-affinity binding site with a dissociation constant (Kd) of 
6 ± 1.1 nmol/l, this value is similar to previous reports of binding assays in human 
myometrium (Fuchs, Fuchs et al. 1984) and rat mammary gland (Muller, Soloff et al. 1989). 
The maximum density of the OT binding sites in the COS-1 transfected cells was 8.9 x 105 
sites/cell (Kimura, Makino et al. 1994).  
More recently, Tahara et al. (2000) studied the binding of radioactive labelled OT to receptor 
found in human uterine smooth muscle cells (USMC), finding that specific binding of OT to 
USMC plasma membranes was dependent upon time, temperature and membrane protein 
concentration. Scatchard plot analysis of equilibrium binding data revealed the existence of a 
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single class of high-affinity binding sites with an apparent equilibrium dissociation constant 
(Kd) of 0.76 nM and a maximum receptor density (Bmax) of 153 fmol mg-1 protein.  
Competitive inhibition of radioactive labelled OT binding showed that OT and AVP receptor 
agonists and antagonists displaced radioactive OT in a concentration-dependent manner. The 
order of potencies for peptide agonists and antagonists was: oxytocin> [Asu1,6]-
oxytocin>AVP=atosiban>d(CH2)5Tyr(Me)AVP>[Thr4,Gly7]-oxytocin>dDAVP (Tahara, 
Tsukada et al. 2000).  
As previously discussed, OT is closely related to AVP, that produces opposite vascular 
effects to those described for OT (vasorelaxatory effects). Vasopressin acts through its 
receptors classified as V1a vascular, V2 renal, and V3 pituitary (also known as V1b). The V1a 
vascular receptor has been located in endothelial cells and vascular smooth muscle cells. The 
V1a receptor is found at high densities in vascular smooth muscles causing vasoconstriction 
by an increase in intracellular calcium via the phosphatidyl–inositol-bisphosphonate cascade 
(Holmes, Landry et al. 2003).  However, it has been demonstrated that AVP binding to V1a 
receptor produces vasoconstriction only in non-vital circulations, whereas in vital circulations 
like coronary and basilar arteries, as well as renal circulation, AVP causes endothelium-
dependent relaxation mediated by NO signalling pathway (Katusic, Shepherd et al. 1986; 
Hirata, Hayakawa et al. 1997; Evora, Pearson et al. 2003).  
The selectivity of OT to OTR and AVP’s subtype receptors has been studied, showing that 
AVP receptors are very selective to AVP.  However, in vitro experimentations demonstrated 
that high concentrations of OT (>10 8 M) caused vasoconstriction that was eliminated by a 
specific vasopressin V1a receptor antagonist, demonstrating that high concentrations of OT 
can cause an erratic binding (Miller, Davidge et al. 2002). This fact could explain the 
different cardiovascular and renal effects observed in the different pharmacokinetic studies 
reported until today, not only in humans but also in animal models. It is possible that all the 
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observed discrepancies are related to OT dosing regimens, and subject preparation (species, 
gender, and physiological state). These were the general explanations proposed to explain the 
observed differences among the reports. 
On the other hand, most of OT pharmacokinetic studies have used an open two-compartment 
model to describe the disposition of OT after intravascular administration,  but in a recent 
study from our group (Morin, Del Castillo et al. 2008), in which the pharmacokinetic profile 
after the bolus administration of several doses of OT was analyzed, the authors reported that 
a two-compartment open model best described the time-course of plasma OT concentration at 
doses of 1000, 3000, 5000 and 10000 ng/kg, but that of the 200, 300 and 500 ng/kg OT doses 
was best described with the one-compartment model. The administered dose significantly 
affected the distribution and elimination clearances (CLd and CLt), as well as the central 
volume of distribution (Vc; hypothetical volume into which a drug initially distributes upon 
administration), but marginally affected the steady-state volume of distribution (Vss; the 
volume of distribution observed after the drug has distributed into the tissues). Overall, 
systemic OT exposure did not increase following the principle of superposition (Wagner 
1973) as the time-course of plasma OT concentrations became biexponential at increasing 
doses (non-linear pharmacokinetics). The main problem of this study was the use of sparse 
blood sampling; this fact implies limitations for elaborating a more realistic pharmacokinetic 
model. However, the results obtained in the study performed by Morin et al. (2008) allowed 
revealing that other types of modelling could better explain OT disposition after intravascular 
administration.  
Levy introduced the term target-mediated drug disposition (TMDD). The TMDD model 
captures the capacity limited binding and saturation of a drug–receptor complex, where a 
significant portion of the drug binds to its target such that this interaction impacts the 
disposition of the drug per se (Levy G., 1994). Whereas plasma concentrations of most drugs 
greatly exceed receptor or target concentrations, agents exhibiting TMDD are bound with 
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high affinity and to a significant degree (relative to dose), such that this interaction influences 
the temporal profile of plasma drug concentrations. Although originally posed to describe the 
effects of extensive drug–target binding in tissues, TMDD has received considerable interest 
owing in part to its role in saturable clearance mechanisms for specific peptide and protein 
pharmaceuticals (e.g., receptor-mediated endocytosis) (Lobo, Hansen et al. 2004; Tang, 
Persky et al. 2004). 
It is possible that the pharmacokinetics of exogenous OT depend on its binding kinetics to 
OTR, and that the time-course of cardiovascular and renal OT effects described in the several 
studies previously mentioned are linked to the rate of OT-OTR complex formation.  
Due to the possible therapeutic potential of pharmacological doses of OT in cardiac 
regeneration, related with its properties of cardiomyogenic differentiation in adult and ES 
cells, and its role during cardiomyogenesis, in addition to the recent report of cardio-
protective effects related to a reduction in the extent of myocardial damage after induced 
myocardial infarction, it will be important to better characterize the pharmacokinetic profile 
of OT in order to minimize the possible side effects related to the use of OT as a therapy.  
 
2.3 Nitric oxide  
2.3.1 Definition and synthesis 
Nitric oxide is an uncharged free radical gas produced in biological tissues. It exerts a large 
number of critical regulatory functions and also plays an important role in pathogenesis of 
cellular injury (Mujoo, Krumenacker et al. 2006; Li, Cui et al. 2008). Indeed, NO possesses 
multiple biological actions that contribute to the maintenance of cardiovascular homeostasis 
(Moncada, Palmer et al. 1991). It is synthesized from its precursor L-arginine by the enzyme 
NOS, which utilize oxygen (O2) and reduced nicotinamide adenine dinucleotide phosphate as 
co-substrates. L-citrulline is generated as a co-product (Palmer, Ashton et al. 1988; Wang-
Rosenke, Neumayer et al. 2008). The NOS system consists of 3 distinct NOS isoforms, 
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encoded by 3 distinct NOS genes, including neuronal (nNOS), also known as NOS-1, 
inducible (iNOS) or NOS-2, and endothelial NOS (eNOS) or NOS-3 (Ignarro 1990; Tsutsui, 
Shimokawa et al. 2009).  
Initial studies indicated that nNOS and eNOS are constitutively expressed mainly in the 
nervous system and the vascular endothelium, respectively, synthesizing a small amount of 
NO in a Ca2+-dependent manner, both under basal conditions and upon stimulation (Tanaka, 
Hassall et al. 1993; Ursell and Mayes 1995). The localization of eNOS in the vascular 
endothelium is of particular importance for cardiovascular physiology, as eNOS maintains 
basal vascular tone through its release of low levels of NO (Loscalzo and Welch 1995). 
Initial studies also indicated that iNOS is induced only when stimulated by microbial 
endotoxins or certain pro-inflammatory cytokines, producing a greater amount of NO in a 
Ca2+-independent manner (Stuehr, Cho et al. 1991). However, recent studies have revealed 
that both nNOS and eNOS are subject to expressional regulation, meaning that these 
constitutive isoforms are subjected to up-regulation or down-regulation depending on the 
stimuli to which NOS expressing cells are subjected (Forstermann, Boissel et al. 1998). Also, 
iNOS is constitutively expressed at low levels under physiological conditions in various cells 
and not only in cells involved with immune response (Park, Park et al. 1996). It has also 
become apparent that in addition to eNOS and iNOS, nNOS plays important roles in the 
cardiovascular system. Apparently, nNOS plays a role in suppressing 
arteriosclerotic/atherosclerotic vascular lesion formation. Upregulation of nNOS may play a 
compensatory role in the presence of reduced eNOS activity (e.g., inflammation and 
arteriosclerosis) to maintain vascular homeostasis (Wilcox, Subramanian et al. 1997). 
 
Thus, NO is involved in more physiological activities than previously anticipated (Tsutsui, 
Shimokawa et al. 2009). 
55 
 
Nitric oxide exerts its effect through either cGMP-dependent or -independent mechanisms 
(Mujoo, Krumenacker et al. 2006). The enzyme sGC converts guanosine triphosphate to 
cGMP (Wang-Rosenke, Neumayer et al. 2008). Soluble guanylyl cyclase is a heme-
containing, heterodimeric NO receptor. It consists of two subunits α and β, which make up 
the active enzyme, this sGC enzyme becomes active when NO diffuses into the cell and binds 
to the heme domain of sGC (Mujoo, Krumenacker et al. 2006). The cGMP is an intracellular 
second messenger which regulates various effector systems, such as cGMP-depending 
protein kinases (PKG), phosphodiesterases (PDE) and ion channels, thus modifying many 
physiological processes (Wang-Rosenke, Neumayer et al. 2008).  
 
2.3.2 Nitric oxide cardio-protective effects 
Nitric oxide has been extensively studied in animal models of MI using I/R injury as a model. 
Some studies demonstrated that the deficiency of eNOS exacerbates myocardial I/R injury 
(Jones, Girod et al. 1999; Sharp, Jones et al. 2002), while the over-expression of eNOS in 
transgenic mice (Jones, Greer et al. 2004; Elrod, Greer et al. 2006), the administration of NO 
donors (Pabla and Curtis 1996), and inhaled NO gas therapy (Hataishi, Rodrigues et al. 
2006), conferred protection after MI induction. Some of NO physiological properties make it 
a potent cardio-protective signalling molecule (Calvert and Lefer 2009). Nitric oxide is a 
potent vasodilator, which could allow for an improved reperfusion of the injured tissue. 
Moreover, NO reversibly inhibits mitochondrial O2 consumption, therefore the inhibition or 
modulation of mitochondrial O2 consumption during early reperfusion leads to a decrease in 
mitochondrial-driven injury by extending the zone of adequate tissue cellular oxygenation 
away from vessels (Loke, Laycock et al. 1999). Also, NO is a potent inhibitor of neutrophil 
adherence to vascular endothelium (Ma, Weyrich et al. 1993). Neutrophil adherence is an 
important event initiating further leukocyte activation and superoxide radical generation, 
which in turn leads to injury to the endothelium and perivascular myocardium (Palazzo, Jones 
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et al. 1998). Besides inhibiting neutrophil adherence to vascular endothelium, NO prevents 
platelet aggregation, both actions attenuate clot formation (Walter and Gambaryan 2004). 
Finally, it has been reported that NO has anti-apoptotic properties in hepatocytes, either 
directly or indirectly by inhibiting caspase-3-like activation via a cGMP-dependent 
mechanism and by direct inhibition of caspase-3-like activity through protein S-nitrosylation 
(Kim, de Vera et al. 1997; Li and Billiar 1999). Even though, most of the experimental 
studies investigating the effects of NO after MI induction have reported that NO protects the 
ischemic myocardium, there are some studies reporting negative effects of NO. An important 
consideration when evaluating the nature of NO effects in cardiovascular disease models is 
the concentration or dose of NO that is used. It is now well known that physiological levels 
(nanomolar) of NO promote cytoprotection and higher levels (high micromolar and 
millimolar) mediate cellular necrosis and apoptosis  (Hibbs, Taintor et al. 1988; Beckman, 
Beckman et al. 1990; Beckman 1991; Gaillard, Mulsch et al. 1991; Radi, Beckman et al. 
1991; Siegfried, Carey et al. 1992; Calvert and Lefer 2009).  
A number of studies have evaluated the cytoprotective signalling pathways activated by NO 
in various experimental systems including isolated cardiac cells and intact hearts. Nitric oxide 
has been shown to activate a number of cellular targets that are linked to cardio-protection, 
including components of the reperfusion injury salvage kinase pathway, such as PKC and 
Erk1/2 (Xuan, Guo et al. 2007). Nitric oxide has also been shown to directly protect cultured 
rat neonatal cardiomyocyte mitochondria by modulating mitochondrial Ca2+ handling, which 
in turn diminishes reoxygenation-associated Ca2+ overload. Mitochondrial Ca2+ overload is 
critical in the pathogenesis of irreversible ischemic cell death. During ischemia, mitochondrial 
Ca2+ uptake limits the increase in cytosolic Ca2+ concentration. Cell studies suggest that the 
extent of rise in mitochondrial Ca2+ concentration during ischemia determines the likelihood 
of reoxygenation-induced hypercontracture and cell death (Rakhit, Mojet et al. 2001). Nitric 
oxide inhibits the activity of L-type Ca2+ channels through S-nitrosylation modifications (Hu, 
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Chiamvimonvat et al. 1997), leading to less sarcoplasmic reticulum Ca2+ loading and less 
Ca2+ induced ischemic injury (Sun, Steenbergen et al. 2006). Furthermore, an increase in NO 
has been shown to be involved in cardio-protection via activation of PKG, which leads to 
activation of mitochondrial pathways including activation of an ATP-regulated mitochondrial 
channel that allows transport of K+ into the mitochondria KATP channel, mitochondrial 
depolarization secondary to opening KATP channels protects the heart by reducing 
mitochondrial Ca2+ uptake (Garlid, Paucek et al. 1996; Costa, Pereira-Junior et al. 2005).  
 
2.3.3 Nitric oxide in cardiomyogenesis 
Preliminary studies have implicated the importance of NO signalling during early 
cardiomyogenesis in embryonic development. Bloch et al. (1999) investigated the expression 
pattern of NOS isoforms and of the target signalling components of NO pathway, sGC and 
cGMP, during rat and mouse embryonic cardiomyogenesis. They demonstrated that iNOS 
and eNOS isoforms are expressed early during mouse and rat embryonic heart development, 
and that these isoforms were down-regulated starting from embryonic day 14.5 (E14.5). The 
authors also reported drastic changes in sGC expression and cGMP. To further confirm the 
role of NO pathway components during cardiomyogenesis, the authors used ESC system as 
in vitro development model or cardiomyogenesis. They confirmed in vivo observations, 
reporting an identical NOS-expression pattern at different stages of cardiomyogenesis (Bloch, 
Fleischmann et al. 1999). 
Krumenacker et al. (2006) had studied the role of the NO signalling pathway components 
(eNOS, iNOS, nNOS), sGC (sGC α1 and β1) and PKG genes and sGC activity in murine 
ESCs subjected to differentiation by EB formation, again ESCs were used as model of in 
vitro embryonic development.  The authors reported that un-differentiated ESCs expressed 
nNOS, eNOS, and sGCβ1. When cells were subjected to differentiation (EB formation), 
nNOS decreased and iNOS became detectable, also eNOS expression was up-regulated. In 
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addition, expression levels of both subunits of sGC, and PKG increased gradually over the 
time of differentiation in EB outgrowths. Purification of ESC-derived cardiomyocytes 
revealed that transcript expression on NOS isoforms was very low while both sGC subunits 
transcripts were abundant and cGMP production mediated by sGC was apparent in this 
population of cells (Krumenacker, Katsuki et al. 2006). In addition, it has been reported the 
expression of NO signalling pathway components in human ESCs. The expression of these 
components followed a similar pattern of that observed in murine ESCs, besides the 
expression of NO signalling components, when cells were subjected to EB differentiation, 
cardiac specific markers were detected along with NO components, suggesting the role of 
NO pathway in the differentiation events of human ESC-derived cardiomyocytes (Mujoo, 
Krumenacker et al. 2006).  
 
2.3.4 Nitric oxide in cardiomyogenic differentiation of stem cells 
It has been proposed that NO is a potential differentiation signal. Nitric oxide and NOS 
isoforms have been shown to be involved in the differentiation of several cell types, including 
nerve cells (Peunova and Enikolopov 1995), some tumour cell types (Magrinat, Mason et al. 
1992), and the heart (Bloch, Fleischmann et al. 1999). For instance, in vitro studies 
performed using murine ESCs have shown that NOS inhibitors arrest differentiation toward a 
cardiac phenotype and that this effect can be rescued by NO donors (Bloch, Fleischmann et 
al. 1999). 
Kanno et al. (2004) reported that NO facilitates cardiomyogenesis in murine ESCs. They 
reported that exposure to NO, either using NO donors or iNOS transfection, increased both 
the number and the size of beating foci in EB outgrowths. Cardiac specific genes and protein 
expression were significantly increased in NO-treated ESCs. These data showed that murine 
ESC cardiomyogenic differentiation is improved by NO treatment. The authors also 
suggested that NO may influence cardiac differentiation by either inducing a switch toward a 
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cardiac phenotype or by inducing apoptosis in cells not committed to cardiac differentiation 
(Kanno, Kim et al. 2004).  
It has also been reported that treatment with NO donors increases the expression of cardiac 
specific genes and proteins in adult stem cells. Rebelatto et al. (2009) reported the effects of 
two NO donors on two different sources of adult stem cells. Bone marrow and adipose tissue 
derived MSC were exposed to NO donors. Both S-nitroso-N-acetyl-d,l-penicillamine (SNAP)  
and 2-(N,N-diethylamino)-diazenolate-2-oxide (DEA/NO) are able to activate cGMP-
dependent and -independent pathways. The authors found that untreated (control) adipose 
tissue and bone marrow-derived MSC expressed some muscle markers, and that after 
treatment with NO donors, the cells presented an up-regulation of some cardiac markers. 
Moreover, NO donors considerably increased the pro-angiogenic potential mostly of bone 
marrow-derived MSCs as determined by an increased expression of vascular endothelial 
growth factor (VEGF) transcripts (Rebelatto, Aguiar et al. 2009). 
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2.4 Problematics, hypothesis and objectives  
Due to the beneficial effects related to OT administration after MI, we attempted to 
characterize the hemodynamic effects of pharmacological doses of OT, using swine as an 
animal model. Based on the literature review, OT hemodynamic effects are controversial, and 
have been described to be dependent on the dosing administration or even species-specific. 
We hypothesize that these controversial effects among the species are related with the 
complex pharmacokinetics of exogenous OT administration. Therefore, the objectives of the 
first article, here included were: 
• To develop a pharmacokinetic model for OT that will include both endogenous and 
exogenous OT inputs. 
• To evaluate the fitting of the data to the selected pharmacokinetic model. 
• To evaluate the time-course relationship of the hemodynamic effects with the time-
course of the selected pharmacokinetic model. 
In addition, OT has been described as a potent cardiomyogenic differentiation inducer of 
ESCs, and it has been shown that OT cardiomyogenic differention of ESCs is mediated by 
the NO pathway, which is also implicated in cardiomyogenic differentiation.  
Our hypothesis for the second article was that OT induces cardiomyogenic differentiation of 
bone marrow derived stem cells, which can be easily obtained and their use does not 
represent any ethical concerns. Therefore the objectives of this second article were: 
• To isolate and characterize porcine bone marrow stem cells (pBMSC). 
• To induce OT-mediated cardiomyogenic differentiation of pBMSC. 
• To compare the effects of OT differentiation induction with 5-azacytidine, which has 
been widely described as a cardiomyogenic inducer of adult stem cells.  
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The hypothesis of the third article was that OT-cardiomyogenic differentiation of pBMSC is 
also mediated by the NO-sGC pathway. The objectives were: 
• To reproduce OT-induced pBMSC cardiomyogenic differentiation  
• To elucidate the involvement of the NO-sGC pathway in the OT-mediated 
differentiation by using pharmacological manipulation. 
• To evaluate the effects of the pharmacological manipulation (inhibitors of NO 
pathway) on the OT-mediated cardiomyogenic differentiation process. 
 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 3. FIRST ARTICLE 
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3.1 ABSTRACT 
INTRODUCTION: Due to oxytocin therapeutic potential not only in obstetrics, e.g. 
myocardial regeneration, oxytocin (OT) use represents big challenge not only related to its 
previously demonstrated pharmacodynamical (PD) effects, but also to its recently observed 
nonlinear pharmacokinetics (PK). Using conscious and anæsthetized pigs, the aims of the 
study were to 1) confirm its nonlinear PK; 2) develop a physiologically-based PK (PBPK) 
modeling to describe its fate after administration, with i) a target-mediated drug disposition 
(TMDD) PK model, and ii) PK/PD modelization on associated hæmodynamic effects. 
METHODS: Single i.v. bolus of OT was given in conscious male pigs (n=5) 20-25 kg, at 
doses of 298, 993, 2979, 4964 pmol kg-1, and a single i.v. bolus of OT at doses of 298 (n=3), 
or 4964 pmol kg-1 (n=9), or a constant rate infusion (CRI) at doses of 6.6 (n=3) or 49.6 pmol 
kg-1 min-1 (n=9), were given to anæsthetised male pigs. Hæmodynamic effects (systemic 
mean arterial pressure and heart rate) of OT administered as a bolus or a CRI were collected. 
The individual time-course of plasma OT concentration was subject to moment PK analysis. 
As a null-hypothesis model, an open two-compartment model was tested, as well as the 
alternative-hypothesis TMDD model. RESULTS: The PK profiles of OT showed a triphasic 
pattern, with a short-lived distribution phase, a convex transition segment that evolves into an 
elimination phase. The assessment of goodness of fit revealed that the null-hypothesis model 
failed to accurately predict plasma concentrations and underestimated the observed values. 
The goodness of fit of the TMDD model better described OT PK and the saturable binding 
kinetics of OT with its receptor. Moreover, TMDD model revealed the linear relationships 
between the observed increases in mean arterial pressure and predicted concentrations. 
CONCLUSION: The diversity and persistence of OT hæmodynamic effects were strongly 
connected with the complex PK profile of OT. The CRI input rate offered advantage to a 
progressive exposure of OT receptors to low plasma OT concentrations that would allow 
taking most advantage of the TMDD fate of OT in living organism. 
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3.2 INTRODUCTION 
Oxytocin (OT) is a versatile neuropeptide that accomplishes many physiological activities 
besides parturition and milk ejection, both in males and females. Indeed, OT receptor (OTR) 
expression is not limited to uterus and mammary gland (Gutkowska, Jankowski et al. 2000; 
Gimpl and Fahrenholz 2001), but also in several peripheral tissues such as the thymus, fat 
cells, pancreas, adrenal glands, kidney, heart and large vessels; suggesting that OT exerts 
effects over these organs (Gimpl and Fahrenholz  2001; Petersson 2002). 
Recent reports have shown that OT reduced infarct size in an in vitro Langendorff-perfused 
rat myocardial infarction model, decreasing post-ischemic cardiac stunning. Apparently the 
negative chronotropic, but not inotropic action of OT appeared to be involved in the 
mediation of its protective effects (Ondrejcakova, Ravingerova et al. 2009). Also, OT 
improved cardiac function and remodeling in an in vivo rabbit MI model (Kobayashi, Yasuda 
et al. 2009). 
But the therapeutic use of OT may cause untoward side effects. Cardiovascular effects of OT 
have been studied mainly in rats. For instance, subcutaneous or intracerebroventricular OT 
daily injections caused a decrease in mean arterial pressure (MAP) with no heart rate (HR) 
repercussions, that outlasted the duration of the dosing regimen (Petersson, Alster et al. 
1996). In contrast, other authors reported a short-lived increase in MAP accompanied by a 
simultaneous decrease of HR after intravenous OT administration (Costa, Pereira-Junior et al. 
2005). In ex vivo heart preparations, OT caused negative inotropic and chronotropic effects 
through mechanisms that remain to be elucidated (Mukaddam-Daher, Yin et al. 2001; Costa, 
Pereira-Junior et al. 2005).  
In the vasculature, OT effects are controversial, as in vitro experimentations have shown that 
OT can cause both vasorelaxation and vasoconstriction. Vasodilatative effect of OT was 
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demonstrated using isolated canine basilar arteries; OT caused vasorelaxation only if the 
endothelium was preserved (Katusic, Shepherd et al. 1986). On the other hand, high OT 
doses caused a potent vasoconstriction of uterine arteries, an effect that was only partially 
counteracted with the administration of an OT antagonist. This finding suggests the 
interaction of OT with arginine vasopressin (AVP) receptor V1a-type located on vascular 
smooth muscle cells (Chen, Shepherd et al. 1999).  
In a previous study in rats from our group (Morin, Del Castillo et al. 2008), we found 
evidence that OT has nonlinear pharmacokinetics (PK). The administered dose significantly 
affected the distribution and elimination clearances (CLd and CLt) of OT, as well as its 
central volume of distribution (Vc), but marginally affected its steady-state volume of 
distribution (Vss). Overall, systemic OT exposure did not increase following the principle of 
superposition (Wagner 1973) as the time-course of plasma OT concentrations became 
biexponential at increasing doses. Because this study used sparse blood sampling designs, the 
structure of a physiologically realistic PK model could not be elucidated. However, our 
results revealed the hallmarks of target-mediated drug disposition (TMDD) kinetics (Levy 
1994; Mager and Jusko 2001), where the time-course of plasma drug concentrations depends 
on the binding capacity of its receptor. Versatile PK models of TMDD have been developed 
in the last decade (Mager and Jusko 2001; Mager 2006), and the influence of its parameters 
on the shape of the PK profile has been tested through partial derivatives sensitivity analyses 
(Abraham, Krzyzanski et al. 2007). 
We hypothesize that the PK of exogenous OT depends on its binding kinetics to OTR, and 
that the time-course of cardiovascular OT effects are linked to the rate of OT-OTR complex 
formation. Hence, our study objectives are to develop a TMDD PK model for OT that 
includes both endogenous and exogenous inputs, evaluate the fitting of the data to the TMDD 
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model, and to evaluate the relationship of the time-courses of cardiovascular effects with the 
time-course of the OT-OTR complex pool. 
3.3 MATERIALS AND METHODS 
Animals, housing and dosing regimens  
All experiments described in this report were approved by the Université de Montréal animal 
care and use committee (09-Rech-1234). The animals were handled according to Canadian 
Council on Animal Care guidelines (Olfert 1993). 
To elucidate the structure of the PK system, a pilot study was performed with conscious male 
pigs (n=5), and a main study using anæsthetized male pigs (n=24) (Table 1). All conscious 
pigs (20-30 kg BW) were dosed a single i.v. OT (Bachem Americas, Inc., Torrance, CA, 
USA) bolus (at least one-week interval) at two doses of 993 and 4964 pmol kg-1 BW, and one 
pig was given all four doses (298, 993, 2979 and 4964 pmol kg-1 BW) at 1-wk intervals (see 
Table 1), giving a total of n=12 bolus experiments. In the main PK study, anaesthetized pigs 
were dosed a single i.v. bolus of OT at doses of 298 or 4964 pmol kg-1 BW, or a constant rate 
infusion (CRI) at doses of 6.6 or 49.6 pmol kg-1 min-1 (n=3 pigs/dose/dosing), giving a total 
of n=6 bolus experiments and n=6 CRI experiments. Moreover, one bolus (4964 pmol kg-1 
BW) and one CRI (49.6 pmol kg-1 min-1) were each administered to n=3 pigs with limited 
sampling time-points. 
The OT cardiovascular effects were investigated in separate experiments using 23-31 kg BW 
male pigs (n=6). For each experiment, the pigs were randomized across two OT dosing 
groups consisting in a 4964 pmol kg-1 BW i.v. bolus or a 49.6 pmol kg1 min-1 CRI of 90 
minutes duration (n=3 pigs/dose/experiment). 
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Therefore, in total, 12 bolus and 12 CRI experiments were completed under anæsthesia, and 
12 bolus administrations in conscious pigs. 
General anæsthesia protocol 
Anesthetized pigs were premedicated with azaperone 2 mg kg-1 i.m. and ketamine 15 mg kg-1 
i.m. After induction of anæsthesia with propofol 4 mg kg-1 i.v., and tracheal intubation for 
dispensing a 1.5 - 2% isofluorane/O2 mixture, a Lactated Ringer’s solution fortified with 0.43 
mg/mL lidocaine was infused intravenously at a rate of 7 ml kg-1 h-1 to meet fluid 
maintenance and analgesia needs during the surgery. Ceftiofur sodium 3 mg kg-1 i.m. was 
administrated for prevention of infection during surgery. A two-lumen indwelling catheter 
(Arrow International, CS-16702) was inserted in the external jugular vein of all pigs to enable 
drug administration and blood sampling. 
In all anæsthetized pigs, electrocardiogram tracings (ECG), pulse oximetry (SpO2), 
capnography (CO2), temperature, inspired fraction of oxygen (FiO2) and inspired-expired 
anæsthetic gas were monitored continuously during the procedure with the 
LifeWindow™6000 system (Digicare™ Biomedical Technology, Inc., Boynton Beach, FA, 
USA). At the end of surgical preparations, a period of at least 30 minutes was allowed for 
stabilization before starting the evaluation of OT effects on cardiovascular and renal systems. 
Cardiovascular instrumentation 
For this experiment, the carotid artery was fitted with a Micro-Renathane® catheter (MRE-
065®, Braintree Scientific, Inc., Braintree, MA, USA) connected to a pressure transducer 
(Medex LogiCal®, MedExSupply Medical Supplies, Inc., Monsey, NY, USA) for invasive 
MAP monitoring with the LifeWindow™6000 system.  A Swan-Ganz catheter (Medex 
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LogiCal®) was advanced through the left femoral vein up to a capillary of the pulmonary 
artery, and connected to identical pressure transducer and monitor for simultaneous recording 
of  pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP) by 
wedging a segment of the pulmonary artery, central venous pressure (CVP) and cardiac 
output (CO). 
Cardiovascular measurements 
Before OT administration, at least three baseline values were recorded every five minutes for 
HR, MAP, PAP, PCWP, CVP, and CO. After OT administration, the above-listed parameters 
were continuously recorded for 150 minutes (i.v. bolus) or 200 minutes (CRI). Other 
hemodynamic parameters such as systemic vascular resistance (SVR) and pulmonary 
vascular resistance (PVR) were calculated additionally using standard equations (Troncy, 
Francoeur, et al. 1997).  
Plasma OT concentration measurements 
The table 1 lists the timing of serial blood sampling (2 mL) used in each experiment. 
Blood samples were transferred to chilled EDTA vacuum tubes (Vacutainer, BD, Franklin 
Lakes, NJ, USA), fortified with 50 nmol pepstatin A, and 100 nmol phenylmethanesulfonyl 
fluoride (PMSF). Upon blood collection, blood samples were processed and stored as 
described above. Plasma OT concentration was determined by radioimmunoassay, as 
previously described by our group (Morin, Del Castillo, et al. 2008). Plasma samples were 
serially diluted to obtain a concentration in the linear analytical range, Standard curves 
generated with 125I-OT demonstrated a sensitivity of 0.1 pg and linearity in the range of 0.25-
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199 pmol. The cross-reactivity of the antibody was <1% with AVP and vasotocin 
(Jankowski, Hajjar et al. 1998). 
Pharmacokinetic/pharmacodynamic modeling 
The individual time-course of plasma OT concentration was subject to moment PK analysis 
(Yamaoka, Nakagawa et al. 1978) in order to derive the initial estimates of CLt, Vc after 
bolus i.v. administration, and Vss to be used in the compartmental modeling. The general 
TMDD PK model proposed by Mager and Jusko (Mager and Jusko 2001) was modified to 
account for endogenous OT production. Briefly, the PK system is composed of two 
subsystems: the first predicts the fate of plasma and tissue free OT, and consists in an open 
two-compartment model with exogenous (CRI) and endogenous rate inputs into the central, 
exogenous i.v. bolus input and steady-state clearance output (i.e. endogenous input rate, 
divided by CLt) from the central compartment. The second subsystem predicts the turnover 
of OTR, with production and degradation of free OTR, saturable binding kinetics of the OT-
OTR complex using the apparent dissociation constant (Kd) reported by Kimura et al. (1994) 
(Kimura, Makino et al. 1994), and metabolism of the OT-OTR complex, according to 
Nakamura et al. (2000) (Nakamura, Itakuara et al. 2000). As a null-hypothesis model, an 
open two-compartment model with time and dose-invariant parameters was used. Data from 
all pigs was fitted simultaneously with the ADAPT software, version 5 using the 
nonparametric expectation minimization algorithm (Wang, Schumitzky et al. 2009). The 
relative goodness of fit of each model was assessed by comparison of their respective Akaike 
information criterion values (Yamaoka, Nakagawa et al. 1978). 
In order to further verify the proportionality of plasma OT concentration with respect to 
administered dose (i.e. the null hypothesis), plasma OT concentrations were normalized with 
respect to dose by using the following transformation: 
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ܥ݌ሺݐሻᇱ ൌ ܥ݌ሺݐሻ · ܦ݋ݏ݁௠௜௡ܦ݋ݏ݁  
Where Cp(t)’ and Cp(t) are respectively the predicted and raw plasma OT concentration at 
time t, Dosemin is the lowest dose used in a given experiment, and Dose is the actual dose 
administered to the pig. 
The changes on cardiovascular parameters over the total time of monitoring (before and after 
OT administration) were examined separately for each dosing regimen with an ANOVA 
repeated-measures linear model. A Dunnett’s post hoc test was used to compare each interval 
after OT administration with baseline values. All tests were performed at a 0.05 alpha level. 
3.4 RESULTS 
Dose-proportionality in pharmacokinetic response 
The individual time-courses of plasma OT concentration associated with i.v. bolus or CRI OT 
administration are depicted in Figure 1. In all experiments using i.v. bolus dosing (Fig. 1 A to 
C), the OT PK profiles showed a triphasic pattern, with a short-lived distribution phase, a 
convex transition segment that evolves into an elimination phase. The latter resumes back to 
baseline plasma OT concentrations. The PK profiles of the two highest OT bolus doses (2979 
and 4964 pmol kg-1) were not superimposable to those of the lower doses, especially during 
the distribution phase and the transitional phase between elimination and back to baseline 
(Fig. 1-A). In addition, the dose-normalized PK profiles for the 4964 pmol kg-1 OT bolus 
dose were shifted upwards with respect to those for the 2979 pmol kg-1 (Fig. 1-B). We 
observed that the elimination of the highest dose seems to be more abrupt. A similar lack of 
superposition in dose-normalized plasma OT concentration was recorded for the two tested 
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levels of CRI (6.6 or 49.6 pmol kg-1 min-1): steady state plasma OT concentration was 
reached faster in pigs dosed with the highest rate of CRI (Fig. 1-D). 
Modeling 
The assessment of goodness of fit with both models revealed that the plasma concentration 
data could not be predicted accurately with the null-hypothesis model (Figure 2 A to E). The 
lack of fit of this model was greater for the CRI data, as it could not discriminate between 
baseline concentration values and plasma concentrations associated with the exogenous OT 
input. In contrast, the TMDD model correctly predicted the accumulation of OT during the 
CRI. The standardized regression residuals of each model are plotted against measured OT 
concentration (Fig. 2-A and 2-B) and time (Fig. 2-C and 2-D). The range of dispersion is 
largely in favour of the alternative-hypothesis. 
These graphs reveal that the lack of fit is greater for the null-hypothesis model, especially 
during the distribution phase, and leverages the regression curve to a point that trough 
concentrations are systematically underestimated. As a result, the scattering of predicted 
concentrations generated by the null-hypothesis model (Fig. 2-E) was considerably larger 
than the one of the TMDD model. The predictive values from the H0 model underestimated 
the observed values. 
The Table 2 presents the average moment PK parameters and variables of OT as a function of 
administered dose. Interestingly, the estimates of lambda Z (terminal elimination rate), mean 
residual time (MRT; average amount of time that a drug spends in the body), Vss and Vc are 
affected both by dose and OT input rate. In contrast, CLt (total body clearance, rate at which 
a drug is removed from the body, considered as a single unit, the sum of renal clearance and 
metabolic (hepatic) clearance, expressed as volume per unit time), R (endo) (endogenous 
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secretion) and IC(1) (constant of proportionality between stationary plasma concentration and 
constant of drug elimination) are only affected by the highest dose. 
The estimates of clearance (CLT) and IC(1) were similar between bolus and CRI 
administrations Interestingly, the estimates of steady state (Vss), and peripheral (Vp) volumes 
were significantly affected by OT input rate, with higher values with CRI compared to bolus. 
In contrast, central volume (Vc) was lower after CRI compared to bolus. 
Cardiovascular effects 
Statistical analysis showed (Table 3) that the i.v. bolus administration of OT caused 
pronounced increases in vascular pressure, with significant differences being recorded for 
MAP (p<0.0001), PCWP (p=0.004) and CVP (p=0.04). In contrast, the effects of the OT CRI 
administration were only significant for MAP (p=0.009). The time-courses of MAP and HR 
associated with i.v. bolus administration of OT (plasma OT concentration superposed) are 
depicted in Figure 3-A. The increase in MAP following OT administration is immediate, and 
parallels the decay in plasma OT concentration during its distribution phase. In contrast, the 
decrease in HR lags for some minutes the time of OT administration.  
The results of Dunnett’s post-hoc tests performed to compare each time of measurement of 
cardiovascular parameters with the baseline values of each parameter are reported in Table 3. 
This type of test allowed obtaining the duration of statistically significant changes in the 
parameters over time. Changes were considered significant when p<0.05. 
The time-courses of MAP and HR associated with predicted OT concentrations after i.v. 
bolus administration (n=3) using the alternative-hypothesis model are depicted in Figure 3. 
The increase in MAP following OT administration is immediate, and parallels the decay in 
plasma OT concentration during its distribution phase (data not shown). In consequence, a 
linear relationship is observed between MAP and predicted OT concentration (Fig. 3-A). In 
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contrast, the decrease in HR lags for some minutes the time of OT administration and looks 
more as reactive to changes induced in MAP. When looking for the same correlation with 
CRI administration (n=3), the result was less evident (Fig. 3-B) and must be related to the 
lower plasma OT concentration observed with this mode of administration and dosage.  
The plasma concentrations modelized with the hæmodynamics changes observed on n=3 pigs 
receiving 4964 pmol kg-1 BW i.v. bolus or 49.6 pmol kg-1 min-1 CRI were predicted to the 
time-points of hæmodynamic measurements using the alternative-hypothesis (TMDD) model. 
3.5 DISCUSSION 
Most drug possess PK parameters that are independent of the administered dose and of the 
duration of the dosing regimen, which implies that systemic exposure to the drug increases 
linearly with the administered dose. In the case of OT, we demonstrated a non-stationarity of 
OT PK parameters with respect to dose in anæsthetized rats (Morin, Del Castillo et al. 2008). 
Studies reporting the PK of OT after an i.v. bolus all used a two compartment model to 
describe the plasma concentration-time curves (Seitchik, Amico et al. 1984; Conrad, Gellai et 
al. 1993; Lundin, Broeders et al. 1993; De Groot, Vree et al. 1995). In our previous study, a 
one compartment model best described the PK parameters at doses of 200, 300 and 500 
ng⋅kg-1 OT. However, an open two compartment model best described profiles observed at 
doses of 1000, 3000, 5000 and 10000 ng⋅kg-1 OT in anæsthetized rats (Morin, Del Castillo et 
al. 2008). At this time, to explain why the peptide did not follow a dose-independent 
relationship in body, we proposed that, at least partially, this would result from the 
physiological effects of OT that modulate its own PK. 
Indeed, the results obtained on the CLT supported the hypothesis of a possible dose-
dependent saturation of the enzyme oxytocinase with a plateau reached at the dose of 1000 
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ng·kg-1 OT, but also, may suggest a modification in the renal functions induced by OT at that 
dose. This point of saturation is found again in the present study, and is important to be kept 
in mind. Secondly, the changes observed on the volumes of distribution, Vc and Vp, strongly 
suggested that Vp would represent the population of OTR found on the vascular bed. The 
receptors, present in limited number, appear to have saturated at the plateau dose of 1000 
ng·kg-1 OT. The presence of OTR in the vascular endothelium was demonstrated and is well 
characterized (Thibonnier, Conarty et al. 1999). Because no distribution process was 
observed for doses lower than 1000 ng⋅kg-1 OT, as shown with the compartment model, we 
hypothesized that the number of OTRs exceeded the OT molecules and no saturation was 
observed at these doses. Then, OT binds rapidly to the receptors without saturation and the 
homogenization is free of impairment. As the OT dose increases, metabolism and elimination 
processes, via the OTR/oxytocinase couple, influence the equilibrium in the homogenization 
between the two compartment (Vc and Vp). A rapid decline in that homogenization is 
observed with doses of 1000 ng⋅kg-1 OT and above. 
Pharmacokinetic and pharmacodynamic modeling 
Though using a narrower range of dosing regimens, the results of this study confirm our 
previously published observations in a rat model (Morin, Del Castillo et al. 2008). 
Noteworthy, the two highest bolus doses (2979 and 4964 pmol kg-1) were not superimposable 
to the lower 993 pmol kg-1 dose (Figure 1), and the principle of superposition was also not 
applicable between the two highest bolus doses, as well as between the two CRI doses (6.6 
and 49.6 pmol kg-1 min-1).  So, once again we could propose the hypothesis of a saturation of 
OTR pool to explain such results. This OTR pool in close relationship with the central 
(blood) volume could be located on the endothelium and would represent Vp. 
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The goodness of fit of the alternative-hypothesis (TMDD) model in comparison to the null-
hypothesis of an open two-compartment model (Figure 2) highlights new physiologically-
based PK explanations. It is very interesting to note that the CRI administration, compared to 
bolus administration, led to increased Vss, and mostly Vp. Indeed, with i.v. bolus 
administration (data not shown), Vss and mean residence time (MRT) decreased with the 
dose, as well as CLT. Our PK TMDD system was composed of two subsystems: the first 
predicts the fate of plasma and tissue free OT, and consists in an open two-compartment 
model with exogenous and endogenous rate inputs into the central compartment (Vc). The 
second subsystem predicts the turnover of OTR, with production and degradation of free 
OTR, saturable binding kinetics of the OT-OTR complex using the apparent dissociation 
constant (Kd) reported by Kimura et al. (2000) (Kimura, Makino et al. 1994), and 
metabolism of the OT-OTR complex, according to Nakamura et al. (Nakamura, Itakuara et 
al. 2000). 
Finally, the time-course of MAP associated with predicted OT concentrations after i.v. bolus 
administration using the alternative-hypothesis TMDD model presented linear relationships 
between the measured increase in MAP and the increase in predicted concentrations. 
To link together these apparently independent discoveries related to OT, we could propose 
the following scenario: 
The binding kinetics of OT-OTR is saturable, but it is also the signal of membrane 
translocation of oxytocinase. The latter activity is in consequence saturable and 
would mainly explain the dose-dependency in CLT, and PK non-linearity observed in 
our studies in rats and pigs. But once OT is degraded and metabolized by OTase, this 
leads to an immediate availability of OTR. Remaining OT in the central 
compartment, which did not yet have access to OTR, is therefore able to bind to OTR 
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and induce its physiological action. And the higher is the plasma OT concentration, 
the higher is the increase in MAP. There is close relatedness of OT with the 
neuropeptide AVP, another vasoactive peptide. The latter acts through specific 
receptors classified as V1a vascular, V2 renal, and V3 pituitary (also known as V1b). 
The V1a vascular receptor has been located in endothelial cells and vascular smooth 
muscle cells. The V1a receptor is found at high densities in vascular smooth muscles 
causing vasoconstriction by an increase in intracellular calcium via the phosphatidyl–
inositol-bisphosphonate cascade (Holmes, Landry et al. 2004). However, it has been 
demonstrated that AVP binding to V1a receptor produces vasoconstriction only in 
non-vital circulation, whereas in vital circulation like coronary and basilar arteries, as 
well as renal circulation, AVP causes endothelium-dependent relaxation mediated by 
NO signalling pathway (Katusic, Shepherd et al. 1986; Hirata, Hayakawa et al. 1997; 
Evora, Pearson et al. 2003).  
The selectivity of OT to OTR and AVP’s subtype receptors has been reported, 
showing that AVP receptors are very selective to AVP.  However, in vitro 
experimentations demonstrated that high concentrations of OT (>10-8 M) caused 
vasoconstriction that was eliminated by a specific vasopressin V1a receptor 
antagonist (Miller, Davidge et al. 2002), demonstrating that high concentrations of 
OT may cause an erratic binding. Plasma concentrations reached after OT bolus and 
CRI administration were superior to 10-8 M, therefore it is very possible that these 
high plasma concentrations of OT caused OT binding not only to its receptors but 
also to vasopressinergic V1a receptors, resulting in an additive effect and a very 
striking and relatively sustained vasoconstriction on peripheral vasculature.  
On the other side, because the oxytocinase metabolic pathway is saturable, the initial 
plasma OT “in excess” in the circulating central compartment will be exposed to a 
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renal elimination presenting a lower rate of elimination, explaining the decrease in 
CLT observed with increasing doses.  
When administering OT by CRI, the Vss, and mostly Vp, increase as the progressive 
exposure of Vc to OT allows to not reach saturation of OTR/oxytocinase. But as 
demonstrated on Fig. 3-B, the challenge would be to administer dosing rate high 
enough to induce significant PD effects. Moreover, too low CRI dosing rates would 
lead to a potential lag in the expected PD effects. Because OT has potential 
usefulness in the regenerative therapy of post-ischæmic myocardial disease, finding 
an appropriate dosing regimen for this new therapeutic use has crucial importance. 
Finally, it would remain to explore the potential consequences of the physiologically-
induced changes on cardiovascular and renal functions on OT own PK. Indeed, we 
observed a ceiling diuretic effect of OT bolus administration in rats, with a peak 
around 3000 ng·kg-1 OT. Higher doses led to a decrease in glomerular filtration rate 
that would reduce the elimination of OT (Morin, Del Castillo et al. 2008). 
Clinical perspective 
When comparing the PK/PD with i.v. bolus versus CRI administration, it is evident that the 
intensity of PD effects was lower with CRI, or more exactly with the lower plasma 
concentrations predicted by the TMDD model with CRI administration. This has its 
importance with regards to the objective of determining an appropriate dosing regimen in 
post-ischæmic myocardial disease. The present discovery of a PK TMDD model describing 
adequately the PK of OT opens promising avenues to detect this appropriate dosing regimen 
in the near. 
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3.8 TABLES AND FIGURES 
Table 1. Time-points of serial blood sampling for determining plasma oxytocin 
concentrations 
Experiment Anæsthesia 
 
Dose amount 
(pmol kg-1) 
Dosing 
rate 
Sampling time (min) 
Pre-OT Post-OT 
PK 
No 
(n=1) 
298 
Bolus 
-60, -50, -40, -30, -20, -10 2, 3, 4, 5, 6, 10, 30, 
60, 90, 120, 150, 180, 
190, 200, 230, 250. 
993 
2979 
4964 
No 
(n=4) 
993 
Bolus 
 
-10, -5, -1 2, 4, 6, 8, 10, 15, 20, 
25, 30, 40, 50, 60, 70, 
80, 90 
4964 
 
Yes 
(n=3 for each 
dose) 
 
298 
Bolus 
 
-60, -50, -40, -30, -20, -10 2, 3, 4, 5, 6, 7, 10, 20, 
30, 45, 60, 75, 90, 
120, 150, 180, 200, 
220 
4964 
596 
CRI 
90 min 
-60, -50, -40, -30, -20, -10 15, 30, 60, 75, 90, 95, 
100, 120, 150, 180, 
210 
4468 
4964 Bolus -60, -30 2, 16, 60, 110, 130 
4468 
CRI 
90 min 
-60, -30 4, 60, 105, 133, 231 
PK/PD 
Cardio-
vascular 
Yes 
(n=3 for each 
dose) 
4964 Bolus 
-50, -40, -30, -20, -10 1.3, 1.4, 2.6, 16.3, 21, 
60, 61, 62, 131, 132, 
150 
4468 
CRI 
90 min 
-50, -40, -30, -20, -10 1.46, 1.47, 1.52, 62, 
105, 133.6, 135.8, 
229.8, 230.1, 231 
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Legend: Summary of the experimental groups with the administered doses and number of 
animals in each group, the time-points for blood sampling are alse explained. Abbreviations: 
CRI, constant rate infusion; PK, pharmacokinetics; PK/PD, pharmacokinetic/ 
pharmacodynamic; Post-OT, sampling times following the onset of OT administration; Pre-
OT, baseline sampling times. 
 
Table 2. Average moment pharmacokinetic parameters and variables as a function of 
oxytocin administered dose 
PK  
variable Unit 
Estimates for Bolus 
Administration 
Estimates for CRI  
 
Population 
estimates 
Mean SE Mean SE Mean         SE 
       
CLt L·min-1·kg-1 1.89 x 10-2 0.0013 1.73 x 10-2 0.0014  
R(endo) pmol·min-1·kg-1 0.3485 0.0163 0.4783 0.0451 0.376 0.020
IC(1) pmol·kg-1 3.6672 0.2905 3.8446 0.4182 3.42 0.353
Vss L·kg-1 0.4194 0.0152 0.9856 0.2141 0.398 .045
Vc L·kg-1 0.3257 0.0206 0.2127 0.0214 0.270 0.028
Vp L·kg-1 0.0936 0.0135 0.7729 0.2295 0.128 0.017
 Legend: PK, pharmacokinetic; CRI, constant rate infusion; Clt, total clearance; R(endo), 
endogenous secretion; IC(1), constant of proportionality between stationary plasma 
concentration and constant of drug elimination; Vss, steady-state volume of distribution; Vc, 
central volume of distribution; Vp, peripheral volume of distribution.  
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Table 3. Summary of mean overall changes in cardiovascular parameters after bolus or 
constant rate infusion of oxytocin in pigs. 
Variable  
 
(units) Bolus 
4964 pmol kg-1 
 CRI 
49.6 pmol kg1 min-1 
Trend, peak,  
% 
Duration  
(min) 
Trend, peak,  
% 
Duration  
(min) 
MAP mmHg  28.06±3  
+42% 
0-50   10.45±3  
16% 
10-90 
HR bpm  5.01±2  
-5% 
0-10  none 0 
CO L min-1   0-5  none 0 
SV mL beat-1  0-5  none 0 
PCWP mmHg  3.56±1  
+47% 
0-20   3.13±1  
+35% 
20-60 
CVP mmHg  0.99±0.3  
+15% 
0-5   1.4±0.4  
-18% 
0-5 
PAP mmHg None 0  none 0 
SVR dynes s-1 cm5  756.2±292  
+52% 
0-20   512.71±207  
+24% 
20-100 
PVR dynes s-1 cm5 None 0  none 0 
Legend. Trend (decreased or increased compared to baseline value and duration (min) after 
oxytocin bolus or constant rate infusion administration. Peak are statistically significant differences 
and these changes were considered significant p<0.05. Abbreviations: mean arterial pressure (MAP), 
heart rate (HR), cardiac output (CO), stroke volume (SV), pulmonary capillary wedge pressure 
(PCWP), central venous pressure (CVP), pulmonary artery pressure (PAP), systemic vascular 
resistance (SVR), pulmonary vascular resistance (PVR). 
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Figure 1. Plasma oxytocin concentrations associated with intravenous administration of 
exogenous OT in pigs. 
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Legend. Panel A: Pilot experiment conducted on a conscious pig dosed with i.v. bolus 
administration of oxytocin (OT) at the doses described in the chart, discontinuous grey lines 
represent the ratios of Cp’(plasma concentration reached after each dose multiplied by the 
ratio of the lower dose/each given dose). Panel B: Pilot experiment on conscious pigs dosed 
with i.v. bolus administrations at doses of 993 pmol kg-1 (black lines with closed symbols), 
and 4964 pmol kg-1 (lines with open symbols). Panel C: Main experiment in anæsthetized 
pigs dosed with i.v. bolus administration at 298 pmol kg-1 (black lines with closed symbols), 
or 4964 pmol kg-1 (lines with open symbols). Panel D: Main experiment in anæsthetized pigs 
dosed with i.v. constant rate infusions at 6.6 pmol kg-1 min-1 (black lines with closed 
symbols), or 49.6 pmol kg-1 min-1 (lines with open symbols). Pigs a (low dose), pigs b (high 
dose). In all panels, discontinuous lines represent the ratio of dose-normalized plasma OT 
concentration (Cp’) of higher dose, divided by the concurrent raw plasma OT concentration 
(Cp) of the lowest dose used in the experiment. Under the null hypothesis, the ratio should 
not differ significantly from 1. 
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Figure 2. Comparison of null-hypothesis and alternative-hypothesis models adequacy. 
 
Stdt. Res. (y-axis) vs. Cp(OT) (x-axis)  H0 model  
 
Fig. 2-A. Standardized regression residuals versus the measured plasma OT (pmol/L) 
concentration for the null-hypothesis model, which attempted to verify the proportionality of 
plasma OT concentration with respect to administered dose using the two-compartment 
pharmacokinetic model. 
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Fig. 2-B. Standardized regression residuals versus the measured plasma OT (pmol/L) 
concentration for the alternative-hypothesis model, which attempted to verify the 
proportionality of plasma OT concentration with respect to administered dose using the 
target-mediated drug disposition (TMDD) model. 
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Stdt. Res. (y-axis) vs. Time (x-axis) H0 model  
 
Fig. 2-C. Standardized regression residuals (y-axis) versus time in minutes (x-axis) for the 
null-hypothesis model, which attempted to verify the proportionality of plasma OT 
concentration with respect to administered dose using the two-compartment pharmacokinetic 
model. 
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Stdt. Res. (y-axis) vs. Time (x-axis)  Ha model  
 
Fig. 2-D. Standardized regression residuals (y-axis) versus time in minutes (x-axis) for the 
alternative-hypothesis model, which attempted to verify the proportionality of plasma OT 
concentration with respect to administered dose using the target-mediated drug disposition 
(TMDD) model. 
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Fig. 2-E. Predicted concentrations from the null-hypothesis model, which attempted to verify 
the proportionality of plasma OT concentration with respect to administered dose using the 
two-compartment pharmacokinetic model, compared to the observed plasma OT 
concentrations. 
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Figure 3. Oxytocin pharmacokinetic / pharmacodynamic (cardiovascular) correlation. 
 
Fig. 3-A. Oxytocin pharmacokinetic (PK)/pharmacodynamic (PD) (cardiovascular) 
correlation with bolus administration on anæsthetized pigs (n=3). Correlation of measured 
parameters with oxytocin predicted plasma concentrations. Abbreviations: MAP (mean 
arterial pressure), HR (heart rate). 
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Fig. 3-B. Oxytocin pharmacokinetic (PK)/pharmacodynamic (PD) (cardiovascular) 
correlation with CRI administration on anæsthetized pigs (n=3). Correlation of measured 
parameters with oxytocin predicted plasma concentrations. Abbreviations: MAP (mean 
arterial pressure), HR (heart rate). 
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4.1 ABSTRACT 
 
The bone marrow stem cells (BMSCs), when 5-azacytidine induced, are a source of stem 
cells with myogenic differentiation potential. Oxytocin (OT) induces cardiomyogenic 
differentiation of murine embryonic and cardiac stem cells. The role of OT as a 
cardiomyogenic differentiation inducer of BMSCs has never been studied. Here, we 
attempted to isolate, characterize, and induce OT-mediated cardiomyogenic differentiation of 
porcine BMSCs (pBMSCs). The pBMSCs were characterized by surface marker expression 
using fluorescent-activated cell sorting. Expression of Oct4, GATA4, and cardiomyocyte 
structural protein (CSP) transcripts were assessed by RT-PCR from passage 0 to 4. First 
passage pBMSCs were divided into 3 treatment groups: control, OT, and 5-azacytidine (as 
positive control of myogenic differentiation). After induction, gene and protein expression of 
GATA4 and CSP were assessed by RT-PCR, immunocytochemistry and western blot, 
respectively. The CD29+, CD90+, and CD45- pBMSCs expressed the transcripts of Oct4, 
GATA4, OT receptor, and phospholamban during early passages. After induction, RT-PCR 
showed upregulation of GATA4 in OT- and 5-azacytidine-induced groups. By 
immunocytochemistry, expression of cardiac troponin T and myosin heavy chain was 
significantly more abundant in OT than in 5-azacytidine-induced groups (p=0.01). Western 
blot analysis showed significant upregulation of cardiac troponin I in OT-induced pBMSCs 
(p=0.01). The pBMSCs should be induced during early passages when they expressed 
transcription factors related to pluripotency and cardiomyogenesis, as well as OT receptor. 
These results show that expression of cardiac specific proteins was more abundant in OT-
treated pBMSCs than in 5-azacytidine treated cells, OT could be a more potent 
cardiomyogenic inducer of pBMSC. 
Keywords: Bone marrow stem cells; Cardiomyogenic differentiation; Oxytocin. 
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4.2 INTRODUCTION 
The possibility of reconstituting the damaged heart has introduced a new paradigm in 
cardiovascular biology and created the potential for a new therapeutic approach in the 
cardiovascular medicine.1 Restoration of cardiovascular function is the ultimate goal of stem-
cell-based therapy. In principle, cardiovascular stem cells can improve cardiac function via 
de novo cardiomyogenesis, enhanced myocardial neovascularization, and prevention of post-
infarct remodeling. Stem cell transplantation to improve cardiac function has generated 
mixed results in animal models and human clinical trials.1-4  
Although no major adverse events have been reported in the small studies completed thus far 
(100–300 patients), cases of patients developing intractable ventricular tachycardia,5 
aggravation of in-stent restenosis,6 or luminar loss of the infarct-related artery after cell 
infusion have been described.7 As with any experimental strategy, the likelihood of benefit 
must outweigh the risk of harm. Beyond safety, the next most important issue is the 
mechanism for the observed clinical benefit.  
Clinical studies using bone-marrow-derived adult stem cells (BMSC) infused by 
intracoronary injection after a recent myocardial infarction suggest the possibility of a 
functional benefit.1 In 1999, Tomita et al. showed that bone marrow cells had little effect 
when injected directly into cryoinjury induced cardiac scar tissue, but that bone marrow cells 
differentiated with 5-azacytidine (5-Aza) into cardiomyocyte-like cells were of benefit to 
heart function.8 Later studies showed that the infusion of purified (expanded and labeled) 
BMSCs into the ascending aorta led to their subsequent accumulation in both the infarct-
induced scar tissue (as fibroblasts) and normal myocardium (as cardiomyocytes).9 Even later, 
it was suggested that direct cell-to-cell contact between cardiac myocytes and mesenchymal 
stem cells (MSC, bone marrow subpopulation of stem cells), was necessary for the 
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differentiation of stem cells into cardiac myocytes.10 Regardless of the mechanism 
responsible, fusion vs. transdifferentiation, it is generally agreed that the number of reported 
cardiomyocytes derived from exogenously delivered BMSCs remains relatively low and 
cannot physically account for the observed functional improvements. As such, one alternative 
proposed mechanism is stem cell–mediated paracrine effects, stem cells produce cytokines 
that improve neovascularization or reduce inflammation.11, 12 
Rather than using stem cells directly as therapy, strategies that target the mobilization, 
expansion, activation or differentiation of endogenous stem cells by the introduction of drugs 
or biological molecules may be more promising. Recent evidences suggest that oxytocin 
(OT), a hormone mostly known for its role during childbirth and lactation, could exert 
protective effects after induced myocardial infarction (MI). Oxytocin reduced infarct size in 
an in vitro Langendorff-perfused rat MI model,13 and improved cardiac function and 
remodeling in an in vivo rabbit MI model.14 A potential role of OT during cardiomyogenesis 
has been suggested. Oxytocin and OT receptors (OTR) protein expression are strongly 
upregulated in the developing rat heart. Moreover, OT improves cardiomyogenic 
differentiation of P19 murine embryonic carcinoma (EC) cells and murine embryonic and 
cardiac stem cells (CSCs).15-18 Furthermore, embryonic stem cells (ESCs), P19 EC and CSCs 
express OTR and they are up-regulated when OT, dimethyl sulfoxide (DMSO) or retinoic 
acid are added to the culture medium for differentiation induction purposes.15-18 Recently, in a 
pig model of MI, our group added information about the potential role of OT in cardiac 
regenerative therapy.19 In particular, pre-treatment endogenous OT levels, dose of OT, and 
timing of OT administration post-MI appear to impact outcome in this porcine MI model. 
Porcine BMSCs (pBMSC) have been poorly studied yet, with a few studies reporting that 
they express some cardiac transcription factors and structural proteins after in vitro induction 
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with 5-Aza, without reaching full differentiation.20, 21 Moreover, to the best of our knowledge, 
the role of OT/OTR system in BMSCs cardiomyogenic differentiation has not been 
considered. The experiments reporting OT as a cardiomyogenic inducer have been performed 
using stem cells mostly from murine origin, which represents certain clinic translational 
limitations, due to species differences. Therefore, it would be interesting to test the potential 
use of OT, as a cardiomyogenic inducer of BMSCs obtained from a more suitable animal 
model, based on the future perspective of testing these OT-induced pBMSCs in a porcine MI. 
Our hypothesis is that OT is a more potent in vitro cardiomyogenic inducer of BMSCs than 
5-Aza. Therefore, we attempted to isolate, characterize, find the best time for cardiomyogenic 
differentiation induction of pBMSCs, and finally estimate OT-induced differentiation of 
pBMSCs into cardiomyocytes by quantifying the number of cells expressing cardiac specific 
proteins and by semi-quantifying the total protein expression of cardiac troponin I.   
4.3 MATERIALS AND METHODS 
Experiments were performed according to the guidelines from the Canadian Council on 
Animal Care with the approval of the institutional animal care and use committees before 
initiation of the study (#09-Rech-1234). 
 4.3.1 Isolation and culture of pBMSCs 
All the reagents used in this study, unless stated, were purchased from GIBCO Invitrogen, 
Burlington, ON, Canada.  
Bone marrow (BM) was aspirated from the humeral head of ten different juvenile pigs under 
general anesthesia. The animals, weighing 25 to 30 kg, were anesthetized with a combination 
of ketamine (Vetalar, Bioniche Animal Health Canada Inc., Belleville, ON, Canada) 15 
mg/kg body weight i.m., and xylazine (Anased, Novopharm, Toronto, ON, Canada) 2 mg/kg 
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body weight i.m. BM aspirates, approximately 10 ml, were obtained using an 11 gauge 
biopsy aspiration needle (Tyco Healthcare Kendall, Mansfield MA, USA) attached to a 
syringe containing 10,000 I.U. of heparin (Leo Pharma, Inc., Thornill, ON, Canada). BM 
samples were immediately transported to the laboratory for further processing. For isolation 
of pBMSCs, mononuclear cells (MNCs) were separated by density gradient centrifugation 
using a commercially available solution (Histopaque-1077 Hybri-Max, Sigma, MO, USA), 
following the manufacturer’s instructions. Briefly, 5 ml of phosphate buffered saline (PBS) 
were added to 3 ml of BM/blood mix and gently mixed in a 15 ml centrifuge tube. The cell 
suspension was deposited over 3 ml of Histopaque, and centrifuged at 400 x g for 30 min at 
room temperature. MNCs were recovered from the opaque interface with a Pasteur pipette 
and PBS washed thrice by centrifugation (300 x g for 10 min). After washing, MNCs were 
re-suspended in Dulbecco's Modified Eagle Medium-low glucose (DMEM-LG) 
supplemented with 15% of fetal bovine serum (FBS), and antibiotic-antimycotic, plated on T-
75 plastic flasks (BD Falcon, Bedford, MA, USA) at a density of approximately 500,000 
cells/cm2 and incubated in a humidified 5% CO2 atmosphere at 37oC. Non-adherent cells 
were washed away by changing medium 24 h after first plating. Adherent fibroblast-like cells 
pBMSCs colonies were observed at 5 to 7 days after plating. Cells were allowed to grow, 
medium was changed every third day. When cells reached 80 to 90% of confluence, they 
were passaged by trypsinization (0.25% Trypsin with EDTA) and reseeded at a density of 
5000 to 6000 cells/cm2 in T-75 plastic flasks. 
4.3.2 Characterization 
Confluent pBMSCs collected at passage 1 were analyzed for surface epitopes by Fluorescent-
activated cell sorting (FACS). Cells were trypsinized, washed in PBS and re-suspended in 1 
ml of blocking buffer (20% FBS/PBS) and incubated on ice for 30 min, to avoid non-specific 
binding. Cells (about 2.5 x 105), were re-suspended in staining buffer (2% FBS/PBS) 
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containing an appropriate concentration of conjugated antibodies: R-phycoerythrin (RPE) 
conjugated CD90 (Clone 5E10, BD Pharmingen, San Diego, CA, USA) and CD31 (Clone 
TLD-3A12, BD Pharmingen, San Diego, CA, USA), fluorescein isothiocyanate (FITC) 
conjugated CD29 (Clone MEM-101A, Abcam, Cambridge, MA, USA) and CD45 (Clone 
K252.1E4, AbD Serotec, Kidlington, Oxford, UK). The adequate concentration of antibody 
was determined by previous titration. Negative controls used for the analysis were isotype 
match control immunoglobulins conjugated to a fluorochrome, either IgG1 FITC-conjugated 
(CloneW3/25, AbD Serotec, Kidlington, Oxford, UK) or IgG1к RPE-conjugated (Clone 
MOPC-21; BD Pharmingen, San Diego, CA, USA). Cells were incubated on ice for at least 
45 min. pBMSCs were washed and re-suspended in 500 µl of staining buffer. Analysis of 
stained cells was performed on FACSvantage SE flow cytometry system (Becton Dickinson, 
Mississauga, ON, Canada) and data analyzed by Cellquest software (Becton Dickinson, 
Mississauga, ON, Canada). 
The pBMSCs collected from passage 0 to 4 were analyzed qualitatively by RT-PCR for gene 
expression of transcription factors and cardiac structural proteins, in an attempt to determine 
the best time for OT differentiation induction. Three different isolates were analyzed. Total 
RNA was extracted from pBMSCs collected by trypsinization from passage 0 to 4, using an 
RNeasy Mini Kit (Qiagen, Gaithersburg MD, USA) following manufacturer’s instructions. 
Briefly, pBMSCs pellet was exposed to a lysis buffer and transferred to the QIAshredder spin 
column (Qiagen), for cell homogenization. Ethanol 70% was added to the homogenized cell 
lysate and transferred to RNeasy spin column. After appropriate washing steps, using buffers 
provided with the kit, RNA was eluted from the column by adding 30 μl of RNase-free water. 
Total RNA was measured by loading 1 μl of undiluted RNA directly onto the lower 
measurement pedestal of a NanoDrop Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). Two micrograms of total RNA were treated with one unit of DNase 
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I (amplification grade) to avoid genomic DNA contamination. cDNA was synthesized in a 
final volume of 20 μl, containing 4 μl of first-strand buffer, 2 μg of RNA, 1 μl of 
Oligo(dT)20 Primer 50 μM, 1 μl of 10 mM dNTP Mix, 1 μl of RNAseOUT Recombinant 
Ribonuclease Inhibitor 40 U/μl, 1 μl of 0.1 M Dithiothreitol and 1 μl SuperScript™ III 
Reverse Transcriptase (200 units/μl). cDNA (2 μl) was then used for PCR amplification in a 
25 μl reaction mixture following the protocol for Platinum Taq DNA Polymerase, using 
specific primers sequences for Oct4 (POU5F1), GATA4, phospholamban (PLB), desmin, 
cardiac troponin I (cTnI), OTR and β-actin genes.  
Primer sequences, specific annealing temperatures, number of cycles and amplicon size, are 
summarized in Table 1. Negative controls for PCR amplification were run at the same time as 
samples, either water or non-reverse transcribed RNA were used instead of cDNA to discard 
genomic DNA contamination.  
The PCR products were size-fractioned by 1-1.5% agarose gel electrophoresis and 
photographed under UV light (Chemi genius 2, Bioimaging system, Syngene, Frederick, MD, 
USA.).   
4.3.3 Cardiomyogenic differentiation  
For cardiomyogenic differentiation, pBMSCs collected at passage 1 were subcultured at a 
density of 20,000 cells/cm2 in DMEM-LG medium containing 15% FBS and antibiotic-
antimycotic mix. After one day of subculture, cells were divided into three treatment groups: 
control group (no treatment), OT treated group, and 5-Aza treated group (as a positive control 
of differentiation). For the control group, the medium was replaced by the same medium 
described before without adding any differentiation inducer (OT or 5-Aza). In OT group, 
medium was replaced with medium containing OT (Bachem, King of Prussia, PA, USA) at a 
concentration of 10-5 M. In the 5-Aza group, differentiation was induced by adding medium 
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containing 5-Aza (Sigma, St. Louis, MO USA) at a 10 μM concentration, as previously 
described.20, 22 Cells were exposed (day 0) to the medium containing or not the differentiation 
inducers. Medium was changed twice a week for three weeks until termination of the 
experiment. The optimal time for differentiation induction and the optimal concentration of 
OT, in OT-mediated differentiation induction, were determined from previous assays (data 
not shown). Cardiomyogenic differentiation was assessed  qualitatively by  RT-PCR as 
described above (Table 1), cardiac specific proteins expression was assessed by  
immunocytochemistry (ICC) and by western blot. Also, the ultrastructure of induced (OT and 
5-Aza groups) and non-induced (control group) cells was analysed using transmission 
electron microscopy (TEM). 
4.3.4 Immunocytochemistry  
Induced (OT and 5-Aza groups) and non-induced (control group) cells, from three different 
isolates, grown on glass coverslips were collected three weeks after differentiation induction. 
Cells were washed twice in PBS (Roche, Indianapolis IN, USA) and fixed in ice-cold 
methanol for 10 min and stored at -20oC, pending analysis. Fixed cells were washed thrice for 
5 min in PBS. To avoid non-specific binding, cells were incubated overnight at 4oC in a 
blocking solution consisting in 10% of normal goat serum in PBS. Then, cells were again 
incubated overnight at 4oC with primary antibodies directed against: PLB 1:200 (ABR 
Affinity BioReagents, Golden, CO, USA),cardiac isoform troponin-T (cTnT) 1:100 (Lab 
Vision, Fremont, CA, USA), and cardiac myosin heavy chain (cMHC) 1:100 (ABR Affinity 
BioReagents). After 3 x 5 min washing steps in PBS, cells were incubated with Alexa fluor 
conjugated goat anti-mouse IgG secondary antibody 1:1000 for 1 h at room temperature. 
After 3 x 5 min washing steps in PBS, nucleus were stained by a 3 min incubation with 
Hoechst 33342 solution 1:1500, washed twice and mounted using Vectashield mounting 
medium for fluorescence (Vector laboratories Inc., Burlingame, CA, USA). For ICC negative 
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controls, cells were incubated only with secondary antibody. Slides were observed under a 
fluorescence microscope (Leica ASLMD microscope; Leica Cambridge, Cambridge, UK) 
equipped with a mercury lamp (HBO 103 W/2; LEJ, Jena, Germany). Micrographs were 
acquired with a Leica DC500 camera and a DFC Twain Software (Leica).  
To determine the degree of cardiomyogenic differentiation induced by OT and 5-Aza, cells 
expressing cMHC and cTnT, were counted from three different micrographs taken from three 
different microscopic fields (200x magnification). Cell counts are reported as a percentage of 
cells expressing these cardiac specific proteins, the percentage being calculated by counting 
the total number of cells (nucleus counted) in each microscopic field and from these cells the 
number of cells expressing the cardiac specific proteins mentioned above. Cell counts were 
performed from three different isolates. 
4.3.5 Western Blot analysis  
Total protein expression of cTnI was determined by semi-quantitative analysis. Two weeks 
after differentiation, induced and non-induced cells were washed once with Dulbecco’s PBS. 
Cells were collected and lysed with cell lysis/extraction buffer (CelLyticTM M, Sigma 
Aldrich, Oakville, ON, Canada), supplemented with protease inhibitor cocktail (Sigma 
Aldrich), according to the supplier’s recommendations. Briefly, cell lysates were centrifuged 
at 17,000 x g for 15 min; supernatants were stored at -80° C pending analysis. Protein 
concentration was determined using Bio-Rad Protein Assay (Bio-rad Laboratories, Hercules, 
CA, USA), based on Bradford method.23 Protein samples (80 µg) from collected cells 
obtained form three different isolates, and protein from porcine heart (40 µg) were subjected 
to electrophoresis on a 12% sodium dodecyl sulfate-polyacrylamide gel and the separated 
proteins were blotted onto polyvinylidene difluoride membranes at 90 V for 90 min (Hybond-
P; Amersham GE Healthcare, Buckinghamshire, UK). Membranes were incubated with 
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blocking buffer, 5% nonfat dry milk in Tris buffered saline (TBS) with Tween 20 pH 8 
(Sigma, St. Louis, MO, USA), for 2 h at room temperature, followed by an overnight (12–16 
h) incubation at 4°C, with primary antibody directed against cTnI (AbD Serotec, Cat. No. 
MCA1208, Cedarlane Laboratories Ltd., Burlington, ON, Canada), at a 1:500 concentration. 
Membranes were washed thrice with Tween 20-TBS and incubated for 30 min at room 
temperature, with the horseradish peroxidase-conjugated rabbit anti-mouse secondary 
antibody (Calbiochem, VWR CANLAB Mississauga, ON, Canada), at a dilution of 1:15 000. 
The antigen-antibody complex was visualized using a highly sensitive chemiluminescence 
system (Immun-StarTM WesternCTM, Bio-Rad Laboratories, Hercules, CA, USA), according 
to the supplier’s recommendations. Signal was visualized with an imaging system equipped 
with a cooled CCD camera (Chemi genius2, Syngene, Perkin Elmer, Woodbridge, ON, 
Canada). Semi-quantitavive analysis was performed by densitometry using GeneSnap from 
Syngene (Perkin Elmer). Protein expression was represented as a value relative to ß-actin 
expression. Triplicate gels and immunoblots were run for all samples, from three different 
isolates.  
4.3.6 Transmission electron microscopy 
 Ultrastructural analysis was performed by TEM. Induced and non-induced obtained from 
three different isolates cells were grown in plastic coverslips (Nalge Nunc International, 
Rochester, NY, USA). Three weeks after treatment cells were washed in PBS and fixed 
overnight at 4oC, in cacodylate buffer (0.05 M pH 7.4) containing 2.5% glutaraldehyde. Cells 
were then rinced thrice in cacodylate buffer, and post-fixed in 2% osmium tetroxide in 
cacodylate buffer, dehydrated and stained in uranyl acetate 0.5% in maleate buffer 0.05 M pH 
5.2 for 1 h at 4oC. Cells were then embedded in epoxy resin. Ultrathin sections, cut 
transversal to the growing surface were viewed under a TEM Philips 300 (Royal Philips 
Electronics, Eindhoven, the Netherlands). 
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 4.3.7 Statistical analysis 
The analysis for cell counts and western blot was performed from three different cell isolates. 
Data from cell counts percentages and western blot ratios were ranked within each individual 
across treatments and an ANOVA was performed on the ranked values with treatment as a 
factor. This is the equivalent of the Friedman test for repeated measures. Tukey’s post-hoc 
tests were used to compare mean values between pairs of treatments. The significance level 
was set at 0.05 and SAS version 9.1 (Cary, N.C.) was used for the analysis.  
4.4 RESULTS 
 
 4.4.1 Isolation and characterization of pBMSCs  
The pBMSCs were successfully isolated from BM aspirates. Most of non-adherent cells were 
removed with medium changes at 24 and 72 h after the first plating. Small colonies of 
adherent fibroblast-like cells attached to the plastic were evident after 5 days in culture. The 
number of cells and the size of colonies increased progressively. Cells reached 80-90% of 
confluence at 10 to 15 days after first seeding. 
The pBMSCs from passage 1 analyzed for surface epitopes were positive for CD29 (β1-
integrin), and CD90 (Thy-1), and were partially negative for CD31 (PECAM-1), as shown in 
Figure 1. As expected, these cells were negative for CD45, a leukocyte marker. 
Before differentiation induction, pBMSCs expressed Oct4, GATA4, OTR and PLB, as shown 
in Figure 2. These markers were found only during passages 0 and 1, and disappeared or 
were down-regulated in subsequent passages. Porcine BMSCs did not express other 
cardiomyocyte structural proteins, such as cTnI and desmin (data not shown).   
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4.4.2 Cardiomyogenic differentiation induction 
 Both induced and non-induced cells expressed genes involved in cardiomyogenesis. RNA 
was extracted for cDNA synthesis at days 4, 6, 10, and 14 after differentiation induction, 
showing a pattern of early and late gene expression. Four days after differentiation induction, 
none of the genes listed in table 1 were expressed (data not shown). Six days after treatment, 
induced and non-induced cells expressed only GATA4, with a clear up-regulation in treated 
cells (Fig. 3). GATA4 expression was down-regulated or not apparent 10 days after treatment 
(data not shown). Conversely, gene expression of cardiomyocyte structural proteins: PLB, 
desmin and cTnI were observed only 10 days after treatment, in induced and non-induced 
cells, without visible differences in transcripts expression among the groups, as shown in 
Figure 3. 
By ICC analysis, it was observed that, two weeks after differentiation induction, PLB protein 
was expressed in all groups. However, the fluorescence signal was weaker in the control 
group or non-induced cells, without significant differences. On the other hand, expression of 
cTnT (13.6±2.7 SD %) and cMHC (12.8±6.9 SD %), was lower in the control group and 5-
Aza-treated group, cTnT (12.5±5.2 SD %) cMHC (11.5±4 SD %), compared to the 
expression observed in OT-treated, which was significantly stronger cTnT p=0.01 (26.2±7.1 
SD %), cMHC p=0.01 (26.3±7.7 SD %). Moreover, there was no significant difference on 
cTnT and cMHC expression, between non-induced cells and 5-Aza-induced cells (Fig. 4). 
The percentages mentioned above refer to the immunopositive cells found in each 
microscopic field, as described in the methods section. 
On semi-quantitative protein analysis, it was observed that protein expression of cTnI was 
more abundant in OT-treated cells compared with control cells and 5-Aza-treated cells (Fig. 
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5). There was a significant effect of OT treatment in the up-regulation of cTnI protein 
expression (p<0.01). Post-hoc Tukey’s analysis indicated that the mean of the ranks was 
significantly more elevated in the OT-treated cells when compared with control cells and 5-
Aza-treated cells, but there was no significant difference when control cells and 5-Aza-
treated cells were compared.  
The ultrastructural analysis of the transversal sections of induced pBMSCs showed that, three 
weeks after induction with OT and 5-Aza, the cells presented centrally positioned nucleus, 
numerous mitochondria and myofilaments in the cytoplasm, aligned in a parallel fashion but 
without forming typical striated sarcomeres (Fig. 6). 
4.5 DISCUSSION 
 
Stem cells, especially BMSCs, are a promising source for MI cell-based therapy. The BMSCs 
can be obtained from patient’s bone marrow by performing a minor procedure, or they can be 
obtained from a donor. Since they apparently are not immunogenic, there are no 
complications related to allogenic rejection.24 They can be easily expanded in vitro. 
Moreover, BMSCs are able to express cardiac markers after induction with 5-Aza, growth 
factors cocktails, and difluoromethylornithine.21, 25, 26 Some reports have shown that BMSCs 
delivered into the infarct area have the ability to promote angiogenesis and prevent apoptosis 
of surviving cardiomyocytes. Moreover, these effects were mediated by paracrine factors 
secreted by BMSCs.12, 27 By using BMSCs, ethical concerns and the possible teratoma 
formation related to the use of ESCs are avoided.28  
In this study, we were able to isolate and characterize pBMSCs. There are many factors 
influencing the capabilities of BMSCs differentiation, such as: culture medium, presence and 
concentration of undetermined growing factors in the FBS, number of passages, as well as 
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differentiation inducer(s) added to the medium. In fact, some reports have shown that 
BMSCs, particularly MSC subpopulation, have certain predisposition to differentiate into 
cardiomyocytes or have passage-restricted differentiation potential into cardiomyocyte-like 
cells, depending on the time they have been in culture with a very possible variation among 
species.29 Specifically, porcine MSCs phenotype and differentiation potential are affected 
during culture.30 
Here, we report that pBMSCs are affected by the time in culture and the number of passages, 
not only in size and shape, but also gene expression was altered through the passages, in the 
culture conditions previously described for this study. Based on the results obtained during 
pBMSC characterization, it seemed appropriate to induce differentiation during early 
passages, specifically during passage 1, when pBMSCs correspond to the phenotypic profile 
of surface epitopes described for MSCs.21, 31, 32 
At passage 1, they also expressed important levels of OTR transcripts, which could be an 
indication of responsiveness to OT stimulation. As mentioned before, OT/OTR system is 
actively expressed during early cardiogenesis, and OTR are upregulated in P19 EC cells, 
ESCs and CSCs upon cardiomyogenic differentiation induction with OT, DMSO and retinoic 
acid.15-17, 33 In addition, pBMSCs also expressed transcription factors, Oct4 previously related 
to pluripotency,34 and GATA4 implicated in cardiac differentiation and regulation of 
expression of most cardiac genes. Indeed, GATA4 binds and transactivates the promoters or 
enhancers of cMHC35 and cardiac troponins, and it is also involved in heart tube formation.36 
Finally, pBMSCs expressed PLB, integral membrane protein that regulates the Ca2+ pump in 
cardiac and skeletal muscle cells. It is likely that pBMSCs expressed PLB transcripts, 
because as previously reported,37 MSCs experience a certain degree of myogenic 
differentiation once they are expanded in vitro, even without differentiation induction. 
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However, if not induced they fail to express cardiac specific markers present in fully 
differentiated cells. For example, they failed to express cardiac troponin I and SERCA-2,37 
possibly because they cannot fully differentiate, or because they only have the potential to 
differentiate in myogenic phenotypes, without appropriate stimulation.  
After differentiation induction of pBMSCs, the expression of GATA4, desmin, PLB, and 
cTnI transcripts was more abundant in the OT- and 5-Aza-induced cells than in non-induced 
cells. It is noteworthy to mention that when pBMSCs were passaged at 80-90% of confluency 
for characterization purposes, desmin and cTnI transcripts were not observed. However, 
when cells were subcultured for differentiation purposes, desmin and cTnI transcripts were 
even expressed in pBMSCs control group cells, meaning pBMSCs experienced a certain 
degree of differentiation, even without induction. This could be related to the role that 
cellular density and/or aggregation have over differentiation. It is known that maintenance of 
undifferentiated nature is closely related to cell density.38-40 
Conversely, protein expression of cardiomyocyte specific proteins was more abundant in the 
induced groups. Even though there was no clear difference in gene transcripts expression in 
the induced groups, protein expression of cardiac specific proteins was more abundant in OT-
induced cells. Expression of cardiac MHC and cTnT was more abundant in OT- vs. 5-Aza-
induced cells, and this difference was statistically significant, the percentage of cells 
expressing these cardiac specific proteins was higher in OT-treated vs.5-Aza-treated cells. 
Nevertheless, PLB expression was similarly up-regulated in all groups, but PLB is expressed 
not only in cardiomyocytes but also in skeletal and smooth muscle cells. In addition, semi-
quantitative protein analysis revealed that OT- induced cells have more abundant expression 
of cTnI compared to control group and 5-Aza-induced cells, with no significant difference 
between control and 5-Aza groups cells. 
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The 5-Aza being a cytidine analog and demethylating agent, inhibitis DNA 
methyltransferase, improving BMSC transdifferentiation potential by hypomethylating 
regulatory genes. Therefore, 5-Aza is not a cardiac specific differentiation inducer.41 It also 
activates the expression of genes and proteins not involved in cardiomyogenic differentiation. 
Some have been characterized,42 but others remain unknown. In addition, 5-Aza inhibits the 
synthesis of total cellular proteins, while RNA synthesis overall rate remains nearly 
unchanged43, 44 or even up-regulated, as observed here for GATA4, PLB, and cTnI transcripts 
expression. If 5-Aza inhibits protein synthesis by affecting the function of several types of 
RNA that are essential for the process of protein synthesis, it is a highly toxic agent and 
produces cell death.45 In consequence, in our study 5-Aza caused a lower expression of 
cardiac structural proteins: cardiac MHC and troponin T. This might also interfere with the 
cardiomyogenic differentiation, without mentioning the cellular toxic effects caused by this 
agent. In accordance with the results observed in this study, 5-Aza induction of CSCs, 
another source of adult stem cells with cardiomyogenic potential, also induced expression of 
cardiac genes but did not induce protein expression of cardiac troponin T.18 These results 
suggest that treatment with 5-Aza induced incomplete differentiation of CSCs, as observed 
here for pBMSCs. 
Ultrastructural analysis of pBMSCs revealed that both non-induced and induced cells 
presented an inner cytoplasmic zone rich in organelles, especially mitochondria and Golgi 
apparatus, as observed in human MSCs.22 On the other hand, OT-induced cells presented 
numerous myofilaments, but the formation of visible sarcomeres was not observed neither in 
the OT-, nor in 5-Aza-induced cells. This is in accordance with the ultrastructure 
observations of human MSCs, 5-Aza-induced, but in contrast with the observations reported 
in murine MSCs, which presented typical striation and sarcomere formation eight weeks after 
treatment with 3 µM 5-Aza.46  
114 
 
These variations in the ultrastructural analysis of BMSCs could be related with the difference 
in stem cell biology among the species, as previously described for the specific case of ESCs 
[For review see ref.47]. The differences in stem cells biology could be related with the great 
disparity in life-span between murine models and humans. Fukuda found sarcomeres 
formation only 8 weeks after 5-Aza differentiation induction.46 But, Xu et al. found no 
sarcomere formation in human MSCs two weeks after treatment with 10 µM 5-Aza.48 It is 
likely that the time for observing sarcomere formation in human and porcine BMSCs is 
longer since life-span is notoriously longer in porcine and humans compared to mice. 
The signaling pathway by which OT induces cardiomyogenic differentiation of P19 EC cells, 
ESCs and CSCs has not been elucidated yet. In the case of pBMSCs, we observed an up-
regulation of GATA4, which is closely related to cardiogenesis.49 But further investigation 
needs to be carried out, in order to understand and clarify the possible mechanisms related 
with OT-induced cardiomyogenic differentiation. A better understanding of the signaling 
pathways stimulated after OTR activation could improve the potential of OT as 
cardiomyogenic inducer. 
In this study, we observed that OT is able to increase the expression of cardiac specific 
structural proteins in pBMSCs, as previously described for murine P19 EC cells, ESCs and 
CSCs.16-18 Oxytocin was a more potent inducer of cardiac differentiation of pBMSCs than 5-
Aza, because cardiac structural proteins were more abundant in the OT-induced cells 
compared with 5-Aza cells. These results on OT-induced pBMSCs look promising for testing 
their cardioregenerative potential on a porcine MI model. The MI murine models have 
important differences related to their size and life-span compared to those of humans. The 
porcine model is more suitable, considering its similarities with human anatomy, physiology, 
and life-span.50 Moreover, the in-vivo porcine model of reperfused MI is well-established and 
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largely used,51, 52 it offers the possibility of actively choosing the location of the occlusion of 
the coronary artery, and control over the duration of the ischemia. Also, there is low 
additional morbidity related with the experimental model itself, it is possible to use a minimal 
invasive approach, therefore avoiding any possible additional influence on experiments, and 
collect repeated blood and tissue samples. Finally the porcine model has been demonstrated 
as a well-suited model for acute and chronic myocardial infarctions.51 Post-infarct OT 
treatment with 10 mg/kg SC (once a day for 5 consecutive days) reduced MI size and 
improved left ventricle function and remodeling by activating OTR and prosurvival signals 
and by exerting antifibrotic and angiogenic effects.14 Our group, using the swine MI model, 
recently demonstrated that endogenous pre-MI OT levels and timing of administration post-
MI are important criteria, if OT is intended to be used as a therapeutic strategy for ischemic 
heart disease.19 Pigs with low endogenous OT level receiving OT subcutaneous infusion (10 
ng·kg−1·hr−1) starting 8 days post-MI, as well as pigs with high endogenous OT level 
receiving saline presented lower MI area measured by planimetry, and cardiac function was 
also less affected. Moreover, high endogenous OT level pigs receiving OT infusion had 
highly-affected cardiac function associated to bigger MI area, as well as down-regulation of 
myocardial OTR. Such results highlighted the major interest of OT-based therapeutics in 
ischemic heart disease, but also the apparent narrow therapeutic window for direct 
administration of OT endogenous peptide.19 
Considering the importance of the microenvironment in determining the differentiation of 
BMSCs,53 it is probable that pBMSCs require in vitro pre-programming before the 
implantation. Therefore, OT-predifferentiated pBMSCs with concomitant OT treatment could 
improve the recovery in a porcine MI model, by supporting a better engraftment and survival 
of the cells in the MI area, improving angiogenesis, reducing apoptosis and promoting 
recruitment of circulating progenitor stem cells in the injured tissue, while minimizing side 
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effects occurrence.54 A major discrepancy between animal studies and clinical trials is the age 
of the cells delivered. Animal models have tested BMSCs harvested from young healthy 
animals, which are then injected into young animal models with a single myocardial injury. 
Proliferative and transdifferentiation potential of those cells is high. By contrast, the 
mobilised BMSCs from middle-aged or elderly patients with heart failure55 or coronary 
disease56 are dysfunctional, and the likelihood that they have significant capacity to 
transdifferentiate into cardiomyocytes is low. It is important to better stimulate grafting, 
transdifferentiation of purified and pre-differentiated BMSCs, and/or mobilization and 
homing of endogenous BMSCs,57 it will be interesting to test OT potential to improve these 
conditions. Finally, OT use could be considered in the avenue of induced pluripotent stem 
cells while testing if OT could facilitate cardiac differentiation of reprogrammed somatic 
cells,58 as this has been the case with 5-Aza, ascorbic acid, bone morphogenetic proteins and 
vascular endothelial growth factor.59, 60 
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4.8 TABLES AND FIGURES 
 
Table 1. PCR primers and reaction conditions. 
Gene 
 
GenBank 
Accession No. 
Primer sequence Annealing 
Temp, oC 
PCR 
cycles 
Product  
size, bp 
Oct4  AJ251914 F: AGGTGTTCAGCCAAACGACC   
R: TGATCGTTTGCCCTTCTGGC 
60 35 341 
GATA4 
 
NM_214293 F: GCCTCTACCACAAGATGAAT 
R: AGTGATTATGTCCCCATGAC 
53.3 35 598 
PLB 
 
NM_214213 F: CTTTTTCAGCTTTCTCTTG 
R: ACCCCTAGTTCATCCTCA 
51 35 530 
Desmin  
 
NM_001001535 F: CCAGCGGCTACCAGGACAACAT 
R: CCAAGGGCCAGGCTCACTCACT 
62 33 587 
cTnI 
 
NM_001098599 F: CCCACCTCAAGCAGGTGAAGA 
R: GCCAGCTCAGCCCTCAAACTT 
65 35 128 
OTR  
 
NM_214027 F: GGCCGAGCGGCTCTGGCCCGCGTCA 
R:CGTGGATGGCTACGAGCAGCTCTTCTG 
61 35 408 
β-Actin 
 
U07786 F: GGACTTCGAGCAAGGAGATGG 
R: GCACCGTGTTGGCGTAGAGG 
54 30 233 
 
F= Forward and R= reverse primer sequences for semi-quantitative RT-PCR. Abbreviations: 
Octamer 4 = POU class 5 homeobox 1 (Oct4 = POU5F1); GATA4 (GATA binding protein 
4); phospholamban (PLB), cardiac troponin I (cTnI), oxytocin receptor (OTR).   
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Figure 1. Fluorescent-activated cell sorting analysis of porcine bone marrow stem cells 
(pBMSCs) surface markers. 
 
Fig. 1. Antibodies used were conjugated CD90-RPE (A), CD29-FITC (B), CD31-RPE (C), 
CD45-FITC (D). Normal line curves represent isotype controls used for calibration. Bold line 
curves represent cells incubated with the conjugated antibody. The pBMSCs used here were 
at passage 1. Abbreviations: FITC (Fluorescein isothiocyanate isomer 1), RPE (R-
phycoerythrin). 
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Figure 2. Semi-quantitative RT-PCR analysis of gene expression profile in porcine bone 
marrow stem cells (pBMSCs). 
 
Fig. 2. Transcripts expressed by pBMSCs (porcine bone marrow stem cells) collected from 
passage (P) 0 to 4. Oct4, GATA4, oxytocin receptor (OTR), phospholamban (PLB), and β-
actin used as an internal control. Representative images of gene expression profile observed 
in three different cell isolates. 
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Figure 3. Semi-quantitative RT-PCR analysis of gene expression profile after 
differentiation induction. 
 
 
Fig. 3. Gene expression profile of GATA4 after 6 days of differentiation induction (A). 
Phospholamban (PLB), desmin, and cardiac troponin I (cTnI) after 10 days of differentiation 
induction (B). Non-induced (NI), oxytocin (OT)-induced, 5-azacytidine (5-Aza)-induced 
cells. ß-actin was used as an internal control. Representative images of gene expression 
profile observed in three different cell isolates after differentiation induction. 
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Figure 4. Cardiac protein expression on pBMSCs.  
 
Fig. 4. Protein expression of phospholamban (PLB) (A); cardiac troponin-T (cTnT) (B); and 
cardiac myosin heavy chain (cMHC) (C) in non-induced (Ctrl), oxytocin (OT)-induced, and 
5-azacytidine (5-Aza)-induced porcine bone marrow stem cells (pBMSCs). Magnification x 
400. The pBMSCs were collected and fixed three weeks after differentiation induction. 
Representative images of protein expression observed in three different cell isolates. 
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Figure 5. Western blot analysis of cardiac troponin I 
 
Fig. 5. Effects on cardiac troponin I (cTnI) expression in control (non-induced cells), 
oxytocin (OT)-, and 5-azacytidine (5-Aza)-induced cells, protein extracted from swine heart 
was used as positive control. Representative image of three different cell isolates (A). Protein 
was extracted from three different isolates and western blot analysis was performed in 
triplicates. Error bars represent ± SEM; * indicates significant increase in OT-induced cells 
(P < 0.05), compared with control and 5-Aza-induced cells (B). 
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Figure 6. Transmission electron microscope images of pBMSCs  
 
Fig. 6. Transmission electron microscope images of pBMSCs non-induced cells 7,000x (A), 
cells induced with 5-azacytidine 15,000x (B), and cells induced with oxytocin 15,000x (C) 
with closer view of myofilaments found in oxytocin treated cells 30,000x (D), after 4 weeks 
of differentiation. Induced cells show a certain degree of transdifferentiation, with 
cardiomyocyte-like structures: multiple mitochondria (white arrows, B and C) and 
myofilaments aligned in a paralleled manner (black arrows C and D). Representative images 
of similar structures observed in three different isolates.  
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5.1 ABSTRACT  
 
Bone marrow stem cells (BMSCs) express cardiac markers in vitro and in vivo upon 
induction. Cardiomyogenic differentiation of embryonic stem cells induced by oxytocin (OT) 
involves the nitric oxide (NO)-soluble guanylyl cyclase (sGC) pathway. Also, OT improved 
cardiomyogenic differentiation of porcine BMSCs (pBMSCs). Here, we document the role of 
NO pathway in OT-mediated cardiomyogenic differentiation of pBMSCs obtained from bone 
marrow aspirates of juvenile pigs. Cells were exposed (OT cells) or not (control cells) to OT, 
in presence or absence of a NO synthase inhibitor (L-NAME) and a sGC inhibitor (ODQ). 
Gene (RT-PCR) and protein expression (immunocytochemistry) of NOS was up-regulated 
after OT induction. Exposure of OT cells to L-NAME, ODQ, or both, leaded to a significant 
reduction in cardiac troponin I transcripts, and protein (Western Blot) expression. For the 
latter, ODQ looked more performing in inhibition than L-NAME. Expression of cardiac 
troponin T and myosin heavy chain (immunocytochemistry) was less abundant in OT cells 
exposed to inhibitors without apparent synergic effect between L-NAME and ODQ. In 
control cells, protein expression remained low. Moreover, OT induced cell proliferation, and 
this effect was counteracted by NOS/sGC inhibitors. Inhibiting NO production and NO 
effector, sGC, affected the OT-mediated differentiation of pBMSCs, because abundance of 
cardiac proteins was reduced to levels similar to those observed in control cells. We propose 
that following treatment with OT, activation of NO pathway directs pBMSCs to a preferential 
cardiomyogenic phenotype and stimulates cell proliferation. 
Keywords: Bone marrow stem cells; Cardiomyogenic differentiation; Oxytocin 
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5.2 INTRODUCTION 
Myocardial infarction (MI), characterized by a massive necrosis of heart tissue, is a leading 
cause of death in developed countries. Cell therapy has been identified as a promising 
treatment for myocardial regeneration through cardiomyocyte replacement or by preventing 
apoptosis of surviving myocardium and improving neovascularization (for review see [1]). 
There is a special interest in using stem cells, due to their differentiation potential and 
capacity of symmetrical self-renewal (for review see [2]). Embryonic stem (ES) cells are able 
to differentiate into any cell type, and are useful tools for the study of functional genomics, 
developmental processes, and the elucidation of signalling pathways involved in cell 
differentiation [3]. It has been reported that oxytocin (OT), a hormone mostly known for its 
role during childbirth and lactation, is involved in cardiac differentiation during embryonic 
development [4] and has acted as a potent and specific inducer of the differentiation of P19 
murine embryonic carcinoma cells [5], ES cells [6,7], and cardiac stem cells [8] into beating 
cardiomyocytes. Moreover, the OT receptors (OTR) expressed in ES cells have been shown 
to up-regulate when OT and dimethyl sulfoxide are added to the culture medium for inducing 
cell differentiation [5].  
Nitric oxide (NO) has been shown to promote ES cell differentiation [9], including 
cardiomyogenic differentiation. Uncharged free radical gas, NO is synthesized from L-
arginine by three isoforms of nitric oxide synthase (NOS): the constitutively active neuronal 
(nNOS) and endothelial (eNOS) isoforms, and the inducible isoform (iNOS) that is expressed 
in response to stress and inflammatory conditions (for review see [10]). Both eNOS and 
iNOS isoforms are prominently expressed during early stages of cardiomyogenesis. The 
synthesis of NO is required for cardiomyogenesis because NOS inhibitors are reported to 
prevent the maturation of ES cells in terminally differentiated cardiomyocytes [11]. In 
addition, exposure to the NO donor SNAP (S-nitroso-N-acetylpenicillamine), and iNOS gene 
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transfection improved cardiomyogenic differentiation of ES cells by increasing the number 
and the size of beating foci in embryoid body outgrowths [12]. 
In addition to NO, it has been shown that its main effector, soluble guanylyl cyclase (sGC), is 
important in the OT-mediated cardiomyogenic differentiation of P19 EC cells. Indeed, the 
NOS inhibitor N (G)-nitro-L-arginine methyl ester (L-NAME), and the sGC inhibitor 1H-
(1,2,4) oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), both reduced the OT-evoked 
cardiomyogenic differentiation of ES cells [13]. The exact mechanism by which OT induces 
or improves cardiomyogenic differentiation of ES cells has not been elucidated y. It has been 
reported that OT could induce cell proliferation, depending on the subcellular localization of 
its receptor [14]; therefore, it is likely that OT additionally induces proliferation of cells 
committed to cardiac differentiation. 
The use of human ES cells for cell therapy is still a subject of debate, due to ethical concerns 
related to the destruction of a viable embryo. Therefore, an interesting alternative of stem 
cells with cardiomyogenic potential are bone marrow-derived stem cells (BMSCs), which are 
obtained from adult tissues. Indeed, these cells have been used for cell therapy after 
myocardial infarction in preclinical [15] and clinical studies (for review see ref. [16]) 
obtaining promising results. 
In vitro studies have shown that BMSCs express cardiac specific proteins that can be up-
regulated in the presence of 5-azacytidine [15], of a cardiomyogenic differentiation medium 
containing insulin, dexamethasone, linoleic acid, and ascorbic acid [17], and when BMSCs 
are co-cultured with cardiomyocytes [18]. We have previously demonstrated that the 
OT/OTR system is present in porcine BMSCs (pBMSCs), which we consider a more suitable 
animal model, based on the future perspective of testing OT-induced pBMSCs in a porcine 
MI animal model. Moreover, OT seemed to be a more potent and specific in vitro 
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cardiomyogenic inducer of pBMSCs than 5-azacytidine, as based on the expression of 
cardiac specific structural proteins [19]. 
We hypothesized that NO-sGC pathway is involved in the OT-mediated cardiomyogenic 
differentiation of pBMSCs, and the proliferation of pBMSCs expressing cardiac markers 
while OT-induced. Therefore, in the present study we aimed to elucidate the role of the NO-
sGC pathway in the OT-mediated cardiomyogenic differentiation of pBMSCs. 
 
5.3 MATERIAL AND METHODS 
 
Experiments were performed according to the guidelines from the Canadian Council on 
Animal Care with the approval of the institutional animal care and use committee before 
initiation of the study (#09-Rech-1234). 
5.3.1 Isolation and culture of pBMSCs 
All the reagents used in this study, unless stated, were purchased from GIBCO Invitrogen, 
Burlington, ON, Canada.  
The BM was aspirated from the humeral head of three juvenile pigs, weighing 25 to 30 kg, 
that were anesthetized with a i.m. combined injection of ketamine (Vetalar, Bioniche Animal 
Health Canada Inc., Belleville, ON, Canada) at 15 mg/kg body weight, and xylazine (Anased, 
Novopharm, Toronto, ON, Canada) at 2 mg/kg body weight. Approximately 10 mL BM 
aspirates were obtained using an 11-gauge biopsy aspiration needle (Tyco Healthcare 
Kendall, Mansfield, MA, USA) attached to a syringe containing 10 000 I.U. of heparin (Leo 
Pharma, Inc., Thornill, ON, Canada). The BM samples were immediately transported to the 
laboratory for pBMSCs isolation. To this end, mononuclear cells (MNCs) were separated by 
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density gradient centrifugation using a commercially available solution (Histopaque®-1077 
Hybri-Max, Sigma Aldrich, Oakville, ON, Canada), following the manufacturer directions. 
Briefly, 5 mL of phosphate buffered saline (PBS) were added to 3 mL of BM/blood mix and 
gently mixed in a 15 mL centrifuge tube. The cell suspension was poured over 3 mL of 
Histopaque®, and centrifuged at 400 × g for 30 min at room temperature. The MNCs were 
recovered from the opaque interface with a Pasteur pipette, being washed thrice with PBS 
and centrifugation (300 × g for 10 min). Then, MNCs were resuspended in Dulbecco's 
Modified Eagle Medium, low glucose (DMEM-LG) supplemented with 15% of fetal bovine 
serum (FBS), and Antibiotic-Antimycotic mix, plated on T-75 plastic flasks (BD Falcon, 
Bedford, MA, USA) at an approximate density of 500 000 cells/cm2 and incubated at 37oC in 
a humidified atmosphere with 5% CO2. Non-adherent cells were discarded by changing the 
medium 24 h after first plating. Adherent fibroblast-like cell colonies were observed 5 to 7 
days after plating. Cells were allowed to grow, and medium changed every third day. When 
cells reached 80 to 90% of confluence, they were harvested by trypsinization (0.25% trypsin 
with EDTA) and distributed evenly in 7 treatment groups. 
5.3.2 Cell treatment 
To explore the role of NO-sGC pathway in the OT-mediated cardiomyogenic differentiation 
of pBMSCs, first-passage cells were subcultured at a density of 20 000 cells/cm2 in DMEM-
LG containing 15% FBS and Antibiotic-Antimycotic mix. After one day of being subcultured 
(day 0), the cells were assigned to one of the following conditions. For differentiation 
induction, cells were exposed for one day either to (induced cells) 10-5 M OT (Bachem, King 
of Prussia, PA, USA), or culture medium alone (control cells), and then were exposed (or 
not) to NOS inhibitor, 10-4 M L-NAME (Sigma Aldrich, Oakville, ON, Canada), sGC 
inhibitor, 10 µM ODQ (Sigma Aldrich), or to the combination of both inhibitors at identical 
concentrations. The concentrations of the inhibitors used were selected from previous 
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publications [13]. Exposure to the inhibitors was maintained for six days, with daily 
replacement of the fortified (containing inhibitors in the above mentioned concentrations) 
culture media. After this period, the fortified media were changed twice a week for the 
remaining period of experiment, up to day 15.  
5.3.3 Effect of the treatments on OT-mediated cardiomyogenic differentiation  
Semi-quantitative RT-PCR  
First, the expression of eNOS and iNOS isoforms was assessed in control and OT-induced 
cells. Second, the effect of the inhibitors on gene expression of cardiomyogenic (cardiac 
troponin I, cTNI3) and myogenic (desmin and phospholamban, PLB) markers was assessed. 
The pBMSCs were collected by trypsinization at days 1, 5, and 10. Total RNA was extracted 
from collected pBMSCs using an RNeasy Mini Kit (Qiagen, Gaithersburg, MD, USA). 
Briefly, the pBMSC pellet was treated with lysis buffer and homogenized in a QIAshredder 
spin column (Qiagen, Gaithersburg, MD, USA). Ethanol (70%) was added to the 
homogenized cell lysates and transferred to RNeasy spin column. After the appropriate 
washing steps using the buffers provided with the kit, RNA was eluted from the column by 
adding 30 μL of RNase-free water. 
Total RNA was measured by loading 1 μL of undiluted RNA directly onto the lower 
measurement pedestal of a NanoDrop Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). Two micrograms of total RNA were treated with one unit of DNase 
I, amplification grade to avoid genomic DNA contamination. The cDNA was synthesized in a 
final volume of 20 μL, containing 4 μL of first-strand buffer, 2 μg of RNA, 1 μL of 
Oligo(dT)20 Primer 50 μM, 1 μL of 10 mM dNTP Mix, 1 μL of RNAseOUT Recombinant 
Ribonuclease Inhibitor 40 U/μl, 1 μL of 0.1 M Dithiothreitol, and 1 μL SuperScript™ III 
Reverse Transcriptase (200 units/μL). Then, cDNA (2 μL) was then used for PCR 
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amplification in a 25 μL reaction mixture following the protocol described for Platinum Taq 
DNA Polymerase (Invitrogen), using specific primers sequences for eNOS, iNOS, cTNI3, 
desmin, PLB and β-actin genes.  
Primer sequences, specific annealing temperatures, number of cycles and amplicon product 
size are summarized in Table 1. Negative controls for PCR amplification were run at the 
same time as samples, either water or non-reverse transcribed RNA were used instead of 
cDNA to discard genomic DNA contamination. The PCR products were size-fractioned by 1-
1.5% agarose gel electrophoresis, visualized by ethidium bromide staining and photographed 
under UV light (Chemi genius 2, Bioimaging system, Syngene, Frederick, MD, USA.). 
Ratios of band density of specific products to β-actin were evaluated. 
Immunocytochemistry 
The inducing effect of OT on NOS expression and the effect of the inhibitors on cardiac 
specific proteins expression were verified qualitatively. For this purpose, pBMSCs grown on 
glass coverslips were collected two weeks after initial treatment, washed twice in PBS 
(Roche, Indianapolis, IN, USA), fixed in ice-cold methanol for 10 min, and stored at -20oC 
pending analysis. Fixed cells were then washed thrice for 5 min in PBS. To avoid non-
specific binding, cells were incubated overnight at 4oC in a blocking solution consisting in 
10% of normal goat serum in PBS. Then, cells were incubated again overnight at 4oC with a 
solution of primary antibodies directed against universal NOS at 1:100 (v/v) (uNOS, detects 
three NOS isoforms; ABR Afffinity BioReagents, Golden, CO, USA), 1/200 cardiac isoform 
troponin-T (TNNT2; Lab Vision, Fremont, CA, USA), or 1/200 cardiac myosin heavy chain 
(cMHC; ABR Afffinity BioReagents, Golden, CO, USA). After three 5-min washing steps in 
PBS, cells were incubated for 1 h at room temperature in a 1:100 solution of an FITC 
conjugated goat anti-rabbit IgG secondary antibody (uNOS; Zymed, Invitrogen), and a 1:1 
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000 solution of Alexa fluor 594 conjugated goat anti-mouse IgG secondary antibody (TNNT2 
and cMHC; Molecular Probes, Invitrogen). After three other 5 min washing steps in PBS, 
nuclei were stained by a 3-min incubation in a 1:1 500 solution of Hoechst 33342, washed 
twice and mounted using Vectashield mounting medium for fluorescence (Vector 
laboratories, Inc., Burlingame, CA, USA). For the negative controls, cover slips were 
incubated only with the secondary antibody. The signal was visualized by fluorescence 
microscopy (Leica ASLMD microscope; Leica Cambridge, Cambridge, UK) with a mercury 
lamp (HBO 103 W/2; LEJ, Jena, Germany). Micrographs were acquired with a Leica DC500 
camera and a DFC Twain Software (Leica, Cambridge, UK).  
Western Blot Analysis 
Protein expression of cTNI3 in pBMSCs was semi-quantitatively assessed after exposure of 
the cells to OT and NO-sGC inhibitors. Two weeks after initial treatment, cells were washed 
once with Dulbecco’s PBS, collected and lysed with cell lysis/extraction buffer (CelLyticTM, 
Sigma Aldrich, Oakville, ON, Canada) supplemented with the Protease Inhibitor Cocktail 
(Sigma Aldrich, Oakville, ON, Canada), according to supplier’s guidelines. Afterwards, cell 
lysates were centrifuged at 17 000 × g for 15 min, and supernatants stored at -80° C pending 
analysis. Protein concentration was determined using the Bio-Rad Protein Assay (Bio-rad 
Laboratories, Hercules, CA, USA), based on Bradford’s method [20]. Briefly, protein 
samples (60 µg) were separated electrophoretically on 12% SDS-polyacrylamide gel, and 
then blotted onto polyvinylidene difluoride (PVDF) membranes at 90 V for 90 min (Hybond-
P; Amersham GE Healthcare, Buckinghamshire, UK). Membranes were incubated for 2 h at 
room temperature in a blocking buffer made of 5% nonfat dry milk in Tris buffered saline 
(TBS) with Tween 20, at a pH value of 8 (Sigma Aldrich, Oakville, ON, Canada). After an 
overnight (12–16 h) incubation at 4°C with the primary antibody directed against cTNI3 
1:500 (AbD Serotec, Cedarlane Laboratories Ltd., Burlington, ON, Canada), membranes 
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were washed thrice with TBS-Tween 20 and incubated for 30 min at room temperature with 
1:15 000 horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody 
(Calbiochem, VWR CANLAB Mississauga, ON, Canada). The antigen-antibody complexes 
were visualized by chemiluminescence system (Immun-StarTM WesternCTM, Bio-Rad 
Laboratories, Hercules, CA, USA), according to the manufacturer’s instructions. The signal 
was visualized with a cooled CCD camera (Chemi genius2, Syngene, Perkin Elmer, 
Woodbridge, ON, Canada). Protein bands were quantified by densitometry using the 
GeneSnap image acquisition software (Syngene, Frederick, MD, USA). Protein expression 
was represented as a value relative to ß-actin expression. Triplicate gels and immunoblots 
were run for all samples. 
Cell proliferation 
To determine whether OT treatment induces a proliferation of pBMSCs that depends on NO 
synthesis, pBMSCs seeded on glass coverslips at a density of 20 000 cells/cm2 were collected 
two weeks after being exposed to the different treatments. Cells were fixed and stained with 
Hoechst 33342 nuclear staining and counted using the ImageJ freeware (National Institutes of 
Health). For each treatment, cells were counted from three different micrographs taken from 
three different microscopic fields. Cell counts were performed on all cell isolates. 
5.3.4 Statistical analyses  
All statistical tests were performed at the α=0.05 significance level with SAS software 
version 9.1 (SAS Institute Inc., Cary, NC, U.S.A.). First, a generalized linear model [21] was 
built to estimate the effects of various OT, L-NAME, and ODQ treatment combinations on 
net cell proliferation. Cell counts were modeled with the Poisson distribution and the log link 
function. The value of the Pearson Q statistic, divided by the model degrees of freedom, was 
used as scaling factor to adjust for overdispersion (i.e. to comply with the equivalence of 
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mean and variance assumption of the Poisson distribution). The generalized estimating 
equations method was used to account for the correlated counts of replicated experiments 
with each cell isolate [22]. The within-cell correlation was modeled with a structure-free 
covariance matrix. A priori contrasts were computed to examine the effect of OT on cell 
counts, to compare cell counts in cells exposed to OT alone or combined with L-NAME 
and/or ODQ, and to examine a possible synergistic inhibitory effect of exposing OT-treated 
cells to both L-NAME and ODQ, as compared to either inhibitor alone. 
Following this analysis, a repeated-measures linear mixed model was used to estimate the 
effects of treatment combinations on the expression of cardiac markers transcripts (cTNI3, 
desmin, and PLB), as well as, on the expression of cTNI3 protein [23]. Treatment was a 
fixed-effect factor, and random factors were cell line and replicate within cell. Because 
cTNI3 transcript expression was shown to be heteroscedastic, its statistical analysis was 
performed on log-transformed data. A second model where cell count was added as a 
covariate was used to examine whether the expression of the protein of cTNI3 resulted from 
direct OT stimulation or was secondary to OT-induced cell proliferation. Selection of the 
covariance model was made following a strategy proposed by Littell et al [24]. Differences 
between treatment groups were assessed with least-square means.  
5.4 RESULTS 
The population of cells selected in our culture conditions was positive for CD29 (β1-
integrin), and CD90 (Thy-1), and was partially negative for CD31 (PECAM-1), and negative 
for CD45 (a leukocyte marker). These pBMSCs expressed transcription factors related to 
pluripotency and cardiomyogenesis only during passage 0 and 1 [19]. 
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5.4.1 Expression of NOS in pBMSCs cardiomyogenic differentiation 
Gene expression in pBMSCs during the process of OT-differentiation was up-regulated for 
both NOS transcript products, especially for eNOS (Fig. 1A). In addition, protein expression 
of NOS was abundantly detected in the cytoplasm of OT-treated cells (Fig. 1B). 
 
5.4.2 Effect of the inhibitors on OT-mediated cardiomyogenic differentiation of 
pBMSCs 
The statistical analysis revealed significant effects of treatments on the gene expression of 
cTNI3, desmin and PLB genes (Fig. 2). Treatment of pBMSCs with 10–5 M OT (induced 
cells) produced a significant up-regulation (p=0.0003) in the gene expression of cardiac 
specific marker cTNI3 with no change for desmin and PLB, compared to control cells. The 
inhibitors had no statistically significant effect on control cells, but in OT-induced cells, both 
L-NAME and ODQ, alone or in combination, induced a down-regulation of the cTNI3 
transcript, as shown in OT vs. OT+L-NAME (p=0.0001), OT vs. OT+ODQ (p=0.0001), and 
OT vs. OT+L-NAME+ODQ (p=0.0001). A similar down-regulation was noted for desmin in 
OT-induced cells, but only in groups exposed to ODQ either alone (p=0.0048) or in 
combination (p=0.0167). For PLB, there was no significant effect when groups were 
compared.  
Immunocytochemistry analysis showed that both control and OT-induced pBMSCs expressed 
cardiac specific proteins TNNT2 and cMHC, but their expression appeared more abundant in 
OT-induced cells. Conversely, when control and OT-induced cells were exposed to the NOS 
and sGC inhibitors, the expression of these cardiac specific proteins was significantly lower 
(B, C, E, G, in Fig. 3 and Fig. 4) without additional effect when mixing both inhibitors on 
OT-induced cells (F in Fig. 3 and Fig. 4). 
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The Western Blot analysis of cTNI3 protein expression in cells exposed to OT-induction and 
NO-sGC inhibitors paralleled the results recorded for cTNI3 transcript expression (Fig. 5). 
The cTNI3 protein expression increased significantly in OT-induced cells compared to 
control cells (Ctrl vs. OT; p=0.0002). In addition, cTNI3 protein expression was significantly 
reduced when OT-induced cells were exposed to both inhibitors alone or in combination (OT 
vs. OT+inhibitors; p<0.0001), but there was no significant effect in protein expression when 
control cells were exposed to the inhibitors. The effect of ODQ on the reduction of cTNI3 
expression was stronger than the one of L-NAME in OT-induced cells. 
 
5.4.3 Effect of treatments on cell count 
Statistical analysis showed that the only treatment that significantly increased cell 
proliferation compared to control was the use of OT alone (p<0.0001). The statistical a priori 
contrast used to verify the effect of inhibitors on OT-induced cell proliferation revealed that 
cell counts of OT-induced cells exposed to inhibitors used alone or in combination were 
significantly lower than the cell counts of OT-induced cells (p=0.0052). There was no 
significant potentiating effect with the combined use of the inhibitors L-NAME and ODQ 
(p=0.9074). 
5.4.4 Cell count as potential confounding factor of cTNI3 induction by OT? 
A statistical model devised for testing whether the expression of cTNI3 protein resulted from 
direct OT-induction or if it was secondary to OT-induced cell proliferation revealed that 
cTNI3 protein expression was not affected by cell proliferation (p=0.1111), but only by direct 
OT induction (p=0.0011). Therefore cTNI3 protein expression is primarily mediated by OT-
induced cardiomyogenic differentiation and not by the OT stimulation of cell proliferation. 
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The effects of cell treatment, presented as mean ± SE, on cell counts and the expression of 
transcripts and proteins expressed as ratios are summarized in Table 2. 
5.5 DISCUSSION 
 
Previous studies have shown that OT improves cardiomyogenic differentiation of P19 EC [5], 
ES [6,7], cardiac [8], and pBMSCs [19] cells. It has been previously reported that NO 
pathway components, such as NOS isoforms and sGC subunits α1 and β1, are expressed 
during cardiomyogenic differentiation of murine [25], and human [26] ES cells. Specifically, 
it has been reported that nNOS is expressed in undifferentiated ES cells and that this 
expression is down-regulated upon differentiation; together with this, up-regulation of iNOS 
and eNOS isoforms are observed in ES cells [25]. This led us to hypothesize that the NO 
pathway should be involved as well in the cardiomyogenic differentiation of adult stem cells. 
In the present study, nNOS was detected neither in undifferentiated nor in differentiated 
pBMSCs. However, eNOS and iNOS isoform transcripts were expressed in both non-induced 
and OT-induced pBMSCs, and OT induction up-regulated the expression of both isoforms, 
especially eNOS. It is possible that the nNOS isoform could not be detected because 
pBMSCs possess a more limited differentiation potential than ES cells. Noteworthy, nNOS 
has been recorded only in undifferentiated ES cells, and upon differentiation by embryoid 
body formation the expression of this isoform was down-regulated and even undetectable 
[25]. Bloch et al. [11], have observed that eNOS and iNOS are prominently expressed during 
early stages of cardiomyogenesis (differentiation phase), and that eNOS presents a sustained 
expression up to the adult stage. The results obtained in the present study with adult stem 
cells support similar findings.  
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Danalache et al. have reported the functional involvement of iNOS/eNOS/sGC in OT-
mediated cardiomyogenic differentiation of murine P19 embryonic carcinoma cells [13]. 
Additionally, OT exhibited a more efficient cardiomyogenic action than did NO donor SNAP, 
as assessed by the size and number of beating cell cultures and by the expression of cardiac 
marker MLC-2v associated to the expression of reporter gene GFP. The authors suggested 
that this could be related to a fine regulation of NO synthesis mediated by OT/OTR action, or 
to the contribution of additional NO-independent transduction pathways triggered by OT. In 
addition, upon OT induction of P19 cells, eNOS gene expression was upregulated, together 
with cardiac markers while the iNOS transcript was undetectable [13]. However, they found 
that when blocking with 1400W, a specific inhibitor of iNOS, P19 cell cardiomyogenic 
differentiation was greatly reduced [13]. In our study, we were able to detect eNOS and iNOS 
transcripts in pBMSCs, which expression was up-regulated after OT-induction. Particularly, 
the expression of eNOS looked upregulated after pBMSC OT-induction. It has been reported 
that neonatal administration of OT increases the expression of eNOS transcripts in the rat 
heart [27]. OT additionally enhanced iNOS transcripts and protein expression in fetal 
membranes, though the mechanism by which OT increases iNOS expression in this tissue has 
not been yet clarified [28].  
Because most structural proteins expressed in cardiomyocytes are expressed both in skeletal 
and smooth muscle cells as well, there are few cardiac-specific proteins that could be used as 
markers of cardiomyogenic differentiation of pBMSCs. For this reason, in the present study, 
to semi-quantify the effect of NOS and sGC inhibitors on the OT-mediated cardiomyogenic 
differentiation of pBMSCs, we used cTNI3, a protein widely used as a cardiac specific 
marker for the detection of myocardial necrosis [29]. We found that NO, and its effector 
sGC, contribute to the OT-mediated cardiomyogenic differentiation of pBMSCs: when OT-
induced cells were exposed to L-NAME, and/or ODQ, the transcript and protein expressions 
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of cardiac specific cTNI3 were significantly down-regulated. The combination of both 
inhibitors did not cause a greater reduction of cTNI3 transcripts, but ODQ looked more 
performing in inhibiting cTNI3 protein expression. This would need further investigation. In 
addition, the signal of TNNT2 and cMHC protein expression, as observed by 
immunocytochemistry analysis, was weaker in cells exposed to the inhibitors used alone or in 
combination. It has been previously reported that BMSCs express cardiac or myogenic 
markers even without induction. Apparently, to expose the cells to inhibitors in the absence 
of OT did not affect the differentiation process that BMSCs experiment under in vitro 
conditions [30], since cTNI3 and skeletal muscle markers (PLB and desmin) expression was 
also found in non-induced and induced cells exposed to the inhibitors at similar levels to 
those observed in the control cells. On the other hand, the expression of cTNI3 protein was 
significantly higher in OT-induced cells compared to non-induced cells, suggesting that OT 
improves the expression of this cardiac marker and possibly the cardiac specific 
differentiation of pBMSCs. The increased cTNI3 expression elicited by OT was significantly 
down-regulated in OT-induced cells exposed to inhibitors, and the expression levels of cTNI3 
in OT-induced cells exposed to inhibitors was similar to those observed for control group. 
These results suggest that the increased expression of cardiac specific markers in OT-induced 
cells is strictly dependent to the NO-sGC signalling pathway. The transcripts of non-cardiac 
specific markers, desmin and PLB, were also affected in some cases by the exposure to the 
inhibitors. For example desmin was importantly down-regulated in OT-induced cells exposed 
to inhibitors (particularly ODQ), but it was slightly but not significantly up-regulated in non-
induced cells exposed to L-NAME (Fig. 2). In the case of PLB, transcript expression was 
more constant in all analyzed groups. It has been mentioned above that BMSCs have 
myogenic potential, and taking together the observations of transcripts expression in different 
treatment groups, it seems that myogenic differentiation is also, though slightly, affected by 
treatment with NO/sGC pathway inhibitors. These results are in accordance with the results 
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previously reported by Danalache et al., in which they observed that, when OT-induced P19 
cells were exposed to L-NAME, the inhibitor predominantly reduced the production of 
ventricular cardiomyocytes and had a minimal effect on simultaneously generated 
populations of skeletal myocytes [13].  
It seems clear that cardiac specific differentiation of pBMSCs is elicited by OT treatment, 
because cardiac specific markers are importantly up-regulated. Moreover, this up-regulation 
is mediated by the NO/sGC pathway, while expression of cardiac specific markers is 
significantly down-regulated (coming back to non-induced cells levels) when induced cells 
are exposed to the inhibitors. Apparently, OT has no effect in the myogenic differentiation of 
pBMSCs, because myogenic markers (desmin and PLB) were not up-regulated in OT-
induced cells.  
Some reports have shown that OT possesses proliferative properties depending on the cell 
type and the subcellular localization of OTR. Recent data on the membrane localization of 
OTR indicate that, when the vast majority of OTR are excluded from lipid rafts enriched in 
caveolin-1, OT inhibits cell proliferation; but when OTR are targeted to lipid rafts, OT has a 
strong mitogenic effect [14]. The same anti-proliferative [31], and proliferative effects have 
been described for NO [32], especially in endothelial cells. Thibonnier et al., reported that 
human vascular endothelial cells expressed OTR and that when these cells were stimulated 
with OT, the nonapeptide induced proliferation of endothelial cells, and that this proliferation 
was mediated by NO release [33]. BMSCs and even MSCs are a heterogenous population of 
cells, in which probably a reduced number have cardiomyogenic potential, and therefore it 
could be possible that OT promotes the proliferation only of cells with cardiomyogenic 
potential. Here, we observed that OT-induced cardiomyogenic differentiation of pBMSCs is 
mediated by NO, and it has been reported that NO may influence cardiac differentiation by 
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both inducing a switch toward a cardiac phenotype and inducing apoptosis in cells not 
committed to cardiac differentiation [12]. In addition, by analyzing cell counts of pBMSCs 
exposed to the different treatments, we observed that OT increased the number of cells, but 
when OT-induced cells were exposed to the inhibitors, the number of cells was similar to that 
found in control conditions. Moreover, control cells exposed to inhibitors did not present any 
proliferation. Therefore, it seems that OT has an effect on cell proliferation and that this 
effect is also mediated by NO. Further studies need to be carried out in order to determine the 
mechanism by which OT improves cardiomyogenic differentiation of stem cells. We 
suspected that OT, by inducing cell proliferation, will indirectly increase the expression of 
cTNI3, since it has been documented that cell aggregation (more abundant in presence of cell 
proliferation) plays an important role on stem cell differentiation [34]. Using a statistical 
model specifically devised to explore this possibility, we rejected this hypothesis: The 
increased expression of cTNI3 most likely results from direct OT-induced cardiomyogenic 
differentiation rather than OT-mediated cell proliferation. It will also be important to 
determine if the derived cells expressing the cardiac markers could perform as functional 
cardiomyocytes. 
In the present report we describe that the inhibition of NO production and the inhibition of 
NO effector, sGC, affect the OT-mediated differentiation of pBMSCs. Abundance of cardiac 
specific proteins was reduced to levels similar to those of control group.  Endogenously 
produced NO and the activation of sGC-dependent pathway(s) seem to be important in OT-
mediated specific cardiomyogenic differentiation of pBMSCs, since only cardiac specific 
proteins expression was affected. These results suggest that treatment with OT and NO 
pathway activation direct the pBMSCs to a preferential cardiomyogenic phenotype, and 
opens attractive therapeutic avenues for MI based on OT-mediated cardioregeneration. 
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5.8 TABLES AND FIGURES 
 
 
Table 1. PCR primers and reaction conditions. 
Gene 
 
GenBank 
Accession No. 
Primer sequence* Annealing 
Temp, oC 
PCR 
cycles 
Product  
size, bp 
eNOS NM_214295 F: TCTGCAGAGACTGGCCTTATTCCT   
R: TGGCTCTAGTCTCCGGAATACCAC 
62.5 35 116 
iNOS 
 
NM_001143690 F: CCATGGAACACCCCAAATACGAGT 
R: GTGTGTTTCCAGGCCCATCCTTCT 
60.6 35 224 
cTNI3 
 
NM_001098599 F: CCCACCTCAAGCAGGTGAAGA 
R: GCCAGCTCAGCCCTCAAACTT 
65 35 128 
Desmin  
 
NM_001001535 F: CCAGCGGCTACCAGGACAACAT 
R: CCAAGGGCCAGGCTCACTCACT 
62 33 587 
PLB 
 
NM_214213 F: CTTTTTCAGCTTTCTCTTG 
R: ACCCCTAGTTCATCCTCA 
51 35 530 
β-Actin 
 
U07786 F: GGACTTCGAGCAAGGAGATGG 
R: GCACCGTGTTGGCGTAGAGG 
54 30 233 
 
Legend: *F=Forward primer sequence; *R= Reverse primer sequence. Abbreviations: 
endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), cardiac 
troponin I (cTNI3), phospholamban (PLB). 
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Table 2. Effect of cell treatment expressed as mean ± SE of transcripts and 
protein ratios, as well as total cell counts. 
 
 Ratio Mean ± SE  
 Transcripts Protein  
Treatment 
groups 
cTNI3 Desmin PLB CTNI3 Cell 
counts (No.) 
Ctrl 0.19 ± 0.02 1.59 ± 0.21 0.39 ± 0.12 4.0 ± 1.05 311 ± 21.77 
OT 0.26 ± 0.04 1.65 ± 0.04 0.33 ± 0.11 6.1 ± 1.08 564 ± 32.36 
Ctrl+L-NAME 0.20 ± 0.03 1.92 ± 0.14 0.31 ± 0.08 4.4 ± 1.18 301 ± 50.17 
OT+L-NAME 0.15 ± 0.01 1.66 ± 0.04 0.32 ± 0.07 5.3 ± 1.12 323 ± 16.34 
OT+L-NAME+ODQ 0.15 ± 0.02 1.39 ± 0.11 0.31 ± 0.05 3.9 ± 0.49 333 ± 22.71 
Ctrl+ODQ 0.19 ± 0.04 1.64 ± 0.13 0.31 ± 0.03 3.9 ± 0.68 329 ± 35.64 
OT+ODQ 0.17 ± 0.02 1.34 ± 0.10 0.26 ± 0.07 3.5 ± 0.75 347 ± 32.18 
 
Effect of cell treatment groups on cell counts, and transcripts and protein ratios of 
cardiac troponin I (cTNI3), desmin, and phospholamban (PLB). Abbreviations: L-
NAME, N,G-nitro-L-arginine-methylester; ODQ, 1H-(1,2,4)oxadiazolo[4,3-
a]quinoxalin-1-one; Ctrl, control; OT, oxytocin. Ratios were normalized using β-actin 
as a housekeeping. 
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Figure 1. Effects of oxytocin (OT) on endothelial (eNOS) and inducible (iNOS) nitric 
oxide synthase transcripts and proteins expression of both enzymes.  
 
Fig. 1 Effects of oxytocin (OT) on endothelial (eNOS) and inducible (iNOS) nitric oxide 
synthase transcripts (A) and proteins (B) expression of both enzymes (uNOS). An antibody 
which detects both isoforms was used. Non-induced pBMSCs were used as negative controls. 
β-actin was used as an internal control (A). 
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Figure 2. Representative image of semi-quantitative RT-PCR analysis of cardiac 
markers gene expression 10 days after initial treatment 
 
Fig. 2. Representative image of semi-quantitative RT-PCR analysis of gene expression of 
cardiac markers 10 days after initial treatment in control cells, OT-induced cells, and both 
control and OT-induced cells exposed to inhibitors L-NAME and ODQ, or both. mRNA 
levels were normalized to β-actin. Abbreviations: L-NAME, N,G-nitro-L-arginine-
methylester; ODQ, 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one; Ctrl, control cells; OT, 
oxytocin. 
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Figure 3. Expression of cardiac troponin-T protein on treated cells in the presence and 
absence of nitric oxide pathway inhibitors. 
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Fig. 3. Expression of cardiac troponin-T (TNNT2) protein in Ctrl cells (A), Ctrl+L-NAME 
cells (B), Ctrl+ODQ cells (C), OT-induced cells (D), OT+L-NAME cells (E), OT+L-
NAME+ODQ cells (F), OT+ODQ cells (G). Abbreviations: Ctrl, control; OT, oxytocin; L-
NAME, N,G-nitro-L-arginine-methylester; ODQ, 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-
one. Magnification 200x. 
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Figure 4. Expression of cardiac myosin heavy chain protein on treated cells in the 
presence and absence of nitric oxide pathway inhibitors. 
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Fig. 4. Expression of cardiac myosin heavy chain (cMHC) protein in Ctrl cells (A), Ctrl+L-
NAME cells (B), Ctrl+ODQ cells (C), OT-induced cells (D), OT+L-NAME cells (E), OT+L-
NAME+ODQ cells (F), OT+ODQ cells (G). Abbreviations: Ctrl, control; OT, oxytocin; L-
NAME, N,G-nitro-L-arginine-methylester; ODQ, 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-
one. Magnification 200x. 
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Figure 5. Semi-quantitative western blot analysis of protein expression of the cardiac 
specific marker cardiac troponin I, effects of inhibitors of nitric oxide pathway 
 
Fig. 5. Semi-quantitative western blot analysis of protein expression of the cardiac specific 
marker cardiac troponin I (cTNI3) two weeks after initial treatment in: control cells, OT-
induced cells, and both control and induced cells exposed to inhibitors L-NAME and ODQ, 
or both. Protein levels were normalized to β-actin. Protein was extracted from three different 
isolates and western blot analyses were performed in triplicates. Error bars represent ± SEM; 
* indicates significant increase when control cells were compared with OT-induced cells 
(p=0.0002); Ŧ significant decrease in cTNI3 expression of OT-induced cells in the presence 
of the inhibitors, OT vs. OT+L-NAME+ODQ (p=0.0002); OT vs. OT+ODQ (p<0.0001). 
Abbreviations: L-NAME, N,G-nitro-L-arginine-methylester; ODQ, 1H-
(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one; Ctrl, control cells; OT, oxytocin. 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 6. GENERAL DISCUSSION 
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6.1 Oxytocin pharmacokinetics and pharmacodynamics  
 
Due to the potential beneficial effects of OT in regenerative medicine in post-ischemic 
myocardial disease, it was considered that finding an appropriate dosing regimen for this new 
therapeutic use of OT requires knowledge of its dose-concentration relationship. Therefore, 
the objectives of the article entitled “Oxytocin receptor-mediated pharmacokinetics and its 
hemodynamic implications in pigs” together with the article “Evidence for non-linear 
pharmacokinetics of oxytocin in anesthetizetized rat”, written by a member of our group 
Valerie Morin, were to characterize the pharmacokinetic profile of different doses and dosing 
regimens of OT (Morin, Del Castillo et al. 2008). We also considered important to 
characterize the renal and cardiovascular effects of this hormone, using the rat and the pig as 
animal models. We observed that the intravenous administration of OT, at the doses and 
administration regimens used, caused changes in cardiovascular and renal parameters in some 
cases similar to previous reports using lower doses of OT. Regarding OT pharmacokinetics, 
the results of this study performed in pigs confirmed the previously published observations in 
the rat model. In particular, the volume of distribution of OT decreased significantly with the 
bolus dose amount, which generated strong evidence of nonlinear pharmacokinetics. 
Oxytocin pharmacokinetics have been previously described using the open two-compartment 
model, but the long lasting cardiovascular effects found in the previously mentioned articles 
of our groups could be better explained with the type of modelization presented in the above 
mentioned article. The TMDD pharmacokinetic model takes in account the binding of drugs 
to their cellular receptors which additionally are characterized by low dissociation constants, 
therefore increasing the drug effects duration, as observed here with the dosing regimens of 
OT used in the first article here included. Moreover, dose-concentration and concentration 
effect relationship will be dependent of the expression drug receptors, as well as, the affinity 
of the drug to its receptor. 
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The significant and in some cases long lasting changes in renal and cardiovascular parameters 
highlight the importance of choosing an appropriate dosing regimen which could provide the 
“cardio-protective” effects of OT reported recently.  
 
Our group, using the swine MI model, recently demonstrated that endogenous pre-MI OT 
levels and timing of administration post-MI are important criteria, if OT is intended to be 
used as a therapeutic strategy for ischemic heart disease (Authier, Tanguay et al. 2010). Pigs 
with low endogenous OT level receiving OT subcutaneous infusion (10 ng·kg−1·hr−1) 
beginning 8 days post-MI, as well as pigs with high endogenous OT level receiving saline, 
presented lower MI area measured by planimetry, and cardiac function was also less affected. 
However, high endogenous OT level pigs receiving OT infusion had highly-affected cardiac 
function associated to bigger MI area, as well as down-regulation of myocardial OTR 
(Authier, Tanguay et al. 2010). These results highlight the importance of an adequate dosing 
regimen and the knowledge of basal endogenous OT since these two factors importantly 
affect the outcome after MI. Indeed, non-linear pharmacokinetics (Morin, Del Castillo et al. 
2008) associated with potentially dramatic pharmacodynamics responses of OT on the 
electrolytes / renal homeostasis or cardiovascular function are potential serious adverse 
effects of this peptide, when administered as therapeutic agent for cardiac regeneration to 
patient with cardiovascular disease. In our previous study, treatment of pigs (n=4) with OT 
(10 ng·kg−1·hr−1) for 7 days commencing immediately after MI presented significantly 
decreased fraction shortening. One animal treated with OT immediately after MI died on Day 
2. Necropsy of this animal did not reveal any gross pathology lesion and a fatal ventricular 
arrhythmia, as suspected. Planimetry with double staining in situ at D8 post-MI did not reveal 
any effect of treatment with OT on the infarct size (58.4% ± 8.3% with OT vs. 58.3 ± 12.2% 
with placebo-saline infusion, n=3) (Authier, Tanguay et al. 2010). The outcome was 
completely different when the same treatment was initiated one-week after MI, after 
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inflammation had mostly resolved, hypothesizing that early treatment with OT after MI could 
indeed worsen the pathophysiological ischemia/reperfusion situation, and that the 
cardiovascular and renal side effects related to different OTR presence could be highly 
deleterious. 
The disturbances in cardiovascular hemodynamics vary with the severity of the MI. In mild 
cases there are no significant abnormalities. But in cases of cardiogenic shock, the most 
marked disturbances are the serious reduction of the SV of the heart and the marked increase 
in total SVR. The moderately severe and severe cases form an intermediate group between 
the mild and the cardiogenic shock cases, in hemodynamic abnormalities. Thus, the severity 
of the MI appears to be correlated directly with the degree of depression of SV. If a MI is 
extensive or if it involves a previously damaged myocardium, there is diminished 
contractility and hence a failure of stroke output. The consequent reduction of arterial 
pressure immediately results in the activation of neurogenic reflexes and possibly other 
compensatory mechanisms which produce an increase in total peripheral resistance (SVR) 
and tachycardia (Freis, Schnaper et al. 1952). Thus, the hemodynamic response is not unlike 
the compensated phase of hypovolemic shock, except that the disturbance is due to 
ineffectual contraction of the myocardium rather than to blood loss (Freis, Schnaper et al. 
1952). 
Based on the results obtained in this report of a MI swine model, it seems appropriate to 
conclude that the endogenous basal levels of OT are variable and that they affect the outcome 
after a MI. In the first article here included, we observed that high plasma OT concentrations 
cause significant alterations on cardiovascular hemodynamics. For instance, we observed 
increases in MAP and SVR, and these two variables are seriously affected after a MI. 
Therefore, the plasma concentrations reached after OT administration in pigs with high 
endogenous levels will be high enough to additionally alter cardiovascular hemodynamics. 
And the situation could even be worse with a negative feedback of this high OT expression 
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on OTR expression, a result observed in our study of OT therapy efficacy on the pig MI 
model (Authier, Tanguay et al. 2010). Moreover, we did not report in the first article that OT 
CRI also causes diuresis, kaliuresis and natriuresis, which will alter the volemia and the 
electrolyte homeostasis, compromising even more the outcome after a MI. This was 
corroborated by the fact that in pharmacodynamical evaluation of OT on anaesthetized rats 
(data not shown), where we observed induction of arrhythmia (premature ventricular 
contractions observed in two different rats) with high dose of OT, and the suspicion that one 
OT-treated pig immediately after MI died from arrhythmia. 
Nevertheless, OT beneficial effects after MI have been recently reported, based on the 
observations of the studies performed by our group. It seems important to consider the basal 
levels of OT and the best moment of OT administration, as well as the complex 
pharmacokinetic profile of this neuropeptide.  
Considering the other report on OT cardio-protective effects, in one of the reports the authors 
(Ondrejcakova, Ravingerova et al. 2009) used an ex vivo model therefore the alterations in 
hemodynamics are not taken in account, for the other two reports (Kobayashi, Yasuda et al. 
2009; Jankowski, Bissonauth et al. 2010), it will be interesting to monitor if the species used 
in these also have subpopulations with low and high basal endogenous OT concentrations, of 
if there is a mechanism altering the basal concentrations in the pig model.  
A very interesting feature of OT is that it has improved the cardiomyogenic differentiation 
potential of embryonic and cardiac stem cells, and cell therapy is thus an interesting alterative 
in patients affected by MI and congestive heart failure. We therefore decided to test the 
hypothesis of OT-mediated pBMSCs cardiomyogenic differentiation potential, as mentioned 
before these cells offer the possibility of being obtained from the patient’s bone marrow, 
therefore there is no possibility of rejection. Also these cells are obtained from adults tissue, 
avoiding the ethics problematic related to the use of embryos. 
170 
 
Unfortunately, full differentiation of BMSCs into cardiomyocytes has not been achieved 
completely. There is still a lack of understanding of the differentiation process of stem cells, 
and in order to achieve full differentiation (functional) other possibilities need to be explored. 
It is important to take in account the complex process of differentiation of stem cells within 
their niche. The studies reported in the present thesis showed that pBMSCs have a potential 
to express cardiac markers when induced with OT, and that this process is mediated by the 
NO pathway. As mentioned in the discussion enclosed in the second article, it is important to 
test the functionality of these cells, but also it will be interesting to try different culture 
conditions that could improve the differentiation attained with OT alone. Once the 
differentiation and functionality of these cells are achieved, it will be very interesting to test 
their potential to improve cardiac function after MI. Eventhough these cells have been 
already used in preclinical and clinical trials obtaining promising results, these results have 
been more related to the possible anti-inflammatory and pro-angiogenic effects that they 
provide when transplanted after MI. Some propositions of future experiments that could be 
performed in order to improve the potential use of BMSCs for MI cell therapy are discussed 
more in detail in the subsequent sections. 
 
6.2 Cell therapy in cardiovascular disease: why promote adult stem cells and 
particularly bone marrow derived stem cells? 
During the last decades stem cell research has revealed many aspects related to embryonic 
and adult stem cell biology, which in turn has led to potential uses of stem cells in 
regenerative medicine. Even though general knowledge about stem cells has greatly 
increased during the past years, there are still many unknown aspects of stem cell biology 
that need to be elucidated in order to exploit the full potential of these cells. 
The use of stem cells for myocardial regeneration has received a great deal of attention, and 
there are many reports of pre-clinical and clinical studies showing in general beneficial 
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effects.  Stem cell therapy reflects a new form of therapy for heart disease that is otherwise 
refractory to conventional pharmacological therapy (Kovacic, Harvey et al. 2007).  
As mentioned before, ESCs have the potential to differentiate into cardiomyocytes in vivo 
and in vitro even without induction, but ESCs and ESC derived cardiomyocytes have only 
been used in pre-clinical trials after MI induction. Most of the pre-clinical studies have used 
ESCs in the undifferentiated state, which implies the possible risk of teratoma formation 
(Boyd, Higashi et al. 2005), which works against the possible therapeutic benefits of ESCs. 
Alternatively, when using ESC derived cardiomyocytes some beneficial effects have been 
observed, for example: ventricular function, regional blood flow and arteriolar density were 
improved, and moreover there was a reduction in the myocardial remodelling process 
(Hodgson, Behfar et al. 2004; Singla, Hacker et al. 2006). Using ESC derived 
cardiomyocytes the possibility of teratoma formation is reduced. Unfortunately, even when 
ESC derived cardiomyocytes have many of the phenotypic properties of authentic 
cardiomyocytes (Abdul Kadir, Ali et al. 2009), recent reports have shown that Ca2+ handling, 
crucial to excitation-contraction coupling of ES-derived cardiomyocytes is functional but 
immature (Liu, Lieu et al. 2009). Therefore full and efficient differentiation of ESC derived 
cardiomyocytes has not been achieved yet. In addition, it has been previously reported that 
ESC derived cardiomyocytes are potentially arrhythmogenic, which means that they might 
not be an optimal cell source for cardiac cell therapy (Zhang, Hartzell et al. 2002). There is 
also the possibility of immune rejection (Nussbaum, Minami et al. 2007), as well as the 
ethical concerns related to the use of ESCs, previously discussed (2009).  
On the other hand, pre-clinical and clinical studies using adult stem cells for myocardial 
regeneration after MI have reported similar beneficial effects to those reported in pre-clinical 
studies using ESCs and ESCs derived cardiomyocytes. By using stem cells from adult origin 
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the problems related to ethical concerns, teratoma formation, and the possible rejection of the 
grafted cells are negligible, as previously discussed. Recently, the discovery of iPS has 
generated expectations, but the manipulation of the somatic cell genome could generate 
insertional mutagenesis [for review see ref.(Rolletschek and Wobus 2009)], as previously 
observed in certain cases of gene therapy (Herzog, Cao et al. 2010). Adult stem cells used in 
pre-clinical and clinical studies are mainly derived from the mononuclear population cells of 
the bone marrow (BM MNC). Recent clinical studies have reported how BMSCs proliferate, 
mobilize and incorporate into the myocardium (Wollert, Meyer et al. 2004; Engelmann, 
Theiss et al. 2006; Zohlnhofer, Ott et al. 2006; Tse and Lau 2007; Meyer, Wollert et al. 2009; 
Overgaard, Ripa et al. 2009).  
The BMSCs exhibit a high degree of plasticity and participate in the repair process after MI. 
These cells, attracted to the site of ischemic injury, improve vascularization and reduce 
cardiac remodelling process (Wang, Haider et al. 2006; Wang, Johnsen et al. 2006), but the 
potential of differentiation of these cells into real cardiomyocytes is a continuous source of 
debate, as mentioned before. On the other hand, there are no reports of arrhythmogenic 
potential of adult stem cells in the clinical assays performed using these cells. 
Recent studies have focused on a local, intramyocardial deposit of BMSCs, selected for their 
immature nature such as the IMPACT-CABG project (Implantation of autologous CD133+ 
stem cells in patients undergoing coronary artery bypass grafting) (UdeMNouvelles, 13 avril 
2010). 
 Although both embryonic (pre-clinical studies) and adult stem cells (pre-clinical and clinical 
studies) have shown to be beneficial as an alternative therapy after MI, there are still some 
aspects that need to be improved. These aspects are mainly related to the efficient 
cardiomyogenic differentiation, the long-term survival of both cell sources, together with the 
incorporation of the grafted cells to the host myocardium. Also, in the special case of BM 
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MNC the low percentage of stem cells contained in the BM aspirates, together with the low 
delivery efficiency, and finally, poor survival, engraftment and integration of the implanted 
cells.  
The beneficial effects observed after treatment with BMSCs have been described as transient 
or marginal. As previously described, the effects of BMSCs are mainly related to paracrine 
molecules expressed and secreted by the cells.  
 
6.3 How to optimize BMSCs for cell therapy 
In the future, it will be of great importance to understand the direct mechanisms of the 
transplanted cells on the heart as a whole. Basically, it is crucial to track the fate of implanted 
cells in vivo and their interactions with the host myocardium after transplantation. Also, it is 
important to better characterize and understand the biology of BMSCs and their 
subpopulations, in order to find which  of these subpopulations accounts for major beneficial 
effects, ideally these cells should be able to give rise to functional cardiomyocytes together 
with the known properties of conferring anti-apoptotic, and anti-inflammatory effects and 
neoangiogenesis.  
In most cases, acquiring a sufficient number of a specific cell type from the BM may require 
either extremely large quantities of BM from patients, or ex vivo expansion of cells by 
culture, which takes time and decreases the possibility of employing the cells when they 
could exert their beneficial effects, so it is important to find the way of increasing the 
clonogenicity of such cells in a shorter period, with a safe methodology. In addition, 
improving the survival of these cells which will be exposed to a hostile environment by up-
regulating some pathways related with cell survival should be beneficial in increasing the 
clinical effects on long-term.    
Another important subject that needs to be optimized when using BMSCs for treatment is the 
delivery method. Local delivery of BMSCs avoids diffusion of the cells to other tissue and/or 
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organs. Therefore cell delivery procedures also need to be improved. At this moment the 
most prevalent methods for cell delivery are the catheter-based stem cell delivery modalities, 
such as intracoronary infusion and transendocardial injection, which are commonly adopted 
in pre-clinical studies and human trials. Intracoronary infusion is the most common cell 
delivery route in clinical studies. Similar to percutaneous coronary intervention, cells can be 
delivered via a balloon catheter placed in the affected coronary artery with the inflated 
balloon causing temporary occlusion of the proximal section of the coronary artery to prevent 
back flow of the cells. Although considered a safe procedure, cell infusion represents some 
risks. It has been reported that cell infusion by this method is related with an increased 
incidence of coronary events, such as coronary artery restenosis after coronary angioplasty 
(Kang, Kim et al. 2004) and a higher incidence of decreased coronary blood flow (Freyman, 
Polin et al. 2006). 
Using this method of cell delivery it has been observed that a significant quantity of the 
implanted cells could home in to non-targeted organs, which will potentially reduce the 
observation of beneficial effects in the area of interest (Freyman, Polin et al. 2006; Kurpisz, 
Czepczynski et al. 2007). An alternative to this method of delivery is the transendocardial 
injection, which delivers cells to small areas of abnormal heart tissue intramyocardially by 
using an injection catheter guided by a cardiac mapping system. This technique has been 
described as safe, and it has been tested on animal models and on human subjects (Amado, 
Saliaris et al. 2005; Dohmann, Perin et al. 2005). Transendocardial injections may improve 
the efficacy of cell therapy with fewer cells required by preventing the homing of the cells to 
other tissues and organs.  
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6.4 Potential of oxytocin as a therapy for myocardial infarction: effects on embryonic 
and adult stem cells, on isolated ex vivo organs, and preclinical models in rats and pigs. 
Oxytocin-mediated cardiomyogenic differentiation has already been reported in embryonic 
carcinoma cells (Paquin, Danalache et al. 2002). Embryonic carcinoma cells have been a 
good model for developmental studies, but they might not share all the differentiation 
characteristics of ESCs. Also, ESCs OT-mediated cardiomyogenic differentiation has been 
reported previously (Hatami, Valojerdi et al. 2007), ESCs could cause teratoma formation, 
and could be rejected by the host immune system since they are not obtained from the 
patient’s own tissues. As previously discussed, these cells are not good candidates for clinical 
trials. Therefore, it was interesting for us, to verify if OT was a more efficient differentiation 
inducer of stem cells from adult tissues. In this specific case, our objective was to test if OT 
is a better inducer of porcine BMSCs (pBMSCs), than other inducers previously used, such 
as 5-azacytidine. Swine are more suitable animal models than murine models because the 
latter have important differences related to their size and life-span compared to those of 
humans. The porcine model is more adequate, considering its similarities with human 
anatomy, physiology, and life-span (Swindle 1984). 
Recently, it has been suggested that OT could be potentially useful as an alternative therapy 
after MI. Moreover, it has also been reported that OT induces the proliferation of endothelial 
cells (Cattaneo, Chini et al. 2008), inducing neovascularisation and in consequence an 
improved myocardial regeneration after infarction.  
In addition to the beneficial effects of OT on cardiomyogenic differentiation and endothelial 
cell proliferation, a recent report has shown that OT protects the kidney tissue against I/R-
induced oxidative damage (Tugtepe, Sener et al. 2007). Consequently, Ondrejcakova et al. 
reported that OT can attenuate the extent of irreversible myocardial damage in an induced I/R 
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model of MI in rats; this was demonstrated as a reduced size of infarction. Oxytocin also 
decreased or mitigated the post-ischemic cardiac stunning. Apparently the negative 
chronotropic, but not inotropic action of OT appears to be involved in the mediation of its 
protective effects (Ondrejcakova, Ravingerova et al. 2009). 
The beneficial effects of OT administered after MI have been reported in ex vivo preparations 
of isolated Langendorff-perfused rat hearts (Ondrejcakova, Ravingerova et al. 2009), and 
animal models of MI as previously mentioned in the review of literature. In a recent report of 
our group, using the porcine MI model, we observed that endogenous pre-MI OT levels, OT 
dosing and timing of administration post-MI are important criteria in the outcome of the 
infarcted animals treated with OT. These results highlight the importance of better 
characterizing the dosing regimen and the potential signaling pathways activated by OT 
administration.  
 
On the other hand, in vitro cardiomyogenic differentiation of adult stem cells is another very 
interesting feature of OT. To optimize grafting and transdifferentiation of adult stem cells, 
particularly taking account the difference in environment of the target population (old people 
with lower potential of regeneration), the strategy to add factor promoting pre-differentiation 
to BMSCs culture has been proposed (Khan, Mohsin et al. 2009). Moreover, because our 
group has demonstrated that the strategy to use OT administration to increase mobilization, 
the homing and differentiation of endogenous progenitor stem cells in the MI target area has 
some interest in rat (Jankowski, Bissonauth et al. 2010) and swine (Authier, Tanguay et al. 
2010) MI models, it became evident that we must learn more about the potential of OT to act 
as adult stem cell differentiation inducer.  
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6.5 Mechanisms of action of OT-induced cardiomyocyte differentiation (role of 
NO, future implications, propositions of future tests) 
Due to the possible additive effects of OT and stem cells for myocardial regeneration after 
infarction, the experiments presented in this thesis had the objective of exploring the OT- 
mediated cardiomyogenic differentiation of pBMSCs, and the role of the NO-cGMP pathway 
in the differentiation process elicited by OT treatment. It is important to understand and to 
explore the possible mechanisms that induce the differentiation of stem cells to a certain cell 
type and, it has been previously reported that some of the OT effects in different systems are 
mediated through the NO pathway (Thibonnier, Conarty et al. 1999; Danalache, Paquin et al. 
2007). 
An interesting finding was that OT is a better cardiomyogenic differentiation inducer of 
pBMSCs than widely used 5-azacytidine. This was demonstrated by increased cardiac 
specific protein expression. Similar results have been reported with adult stem cells from the 
heart (Matsuura, Nagai et al. 2004; Oyama, Nagai et al. 2007). In the present study, it was 
possible to demonstrate an improvement in cardiomyogenic differentiation of pBMSCs, 
based on an increased cardiac protein expression observed in OT-treated cells, compared with 
control cells and 5-azacytidine-treated cells. It would be interesting to develop culture 
systems that could allow us to test the physiological changes that these cells experience after 
OT differentiation induction, since the objective of cell therapy for myocardial infarction is 
not only to use cells that express cardiac markers, but to use cells that are able to couple and 
act in synchrony with the host cardiomyocytes. 
Moreover, we also found that not only OTR is expressed in pBMSCs, but also NOS 
(endothelial and inducible) are expressed. Both OT and NO systems are expressed and 
functional during embryonic development of the heart and are important for cardiogenesis. 
This has been reported in experiments using ESCs as developmental models (Bloch, 
178 
 
Fleischmann et al. 1999; Paquin, Danalache et al. 2002; Krumenacker, Katsuki et al. 2006; 
Mujoo, Krumenacker et al. 2006; Hatami, Valojerdi et al. 2007). The fact that pBMSCs also 
express both systems could be indicative of the native cardiomyogenic potential of these 
cells, meaning that it is possible that pBMSCs have a cardiomyogenic differentiation 
potential similar to the one of ESCs during early cardiomyogenesis.  
Furthermore, Danalache et al. (2007) already demonstrated that OT cardiomyogenic 
differentiation of embryonic carcinoma cells is mediated by the NO pathway, because they 
observed an up-regulation of eNOS transcripts, and demonstrated that inhibition of NO 
pathway using competitive inhibitors of L-arginine drastically reduced the number of beating 
cell colonies. They also reported that OT was a better differentiation inducer than NO donor 
SNAP (Danalache, Paquin et al. 2007). 
 
It is important to understand the signalling pathways that could be involved during OT 
differentiation, because these pathways could be also exploited in order to improve 
myocardial function after I/R injury. In the present study, we found that induction of 
pBMSCs with OT, elicits up-regulation of NOS, therefore if these cells are used for cell 
therapy in a MI animal model, these cells could be a source of NO production, and it has 
been proved that NO itself promotes the migration and proliferation of endothelial cells, 
which in turns will lead to angiogenesis, improving O2 availability and, in consequence, 
myocardium long-term survival. In fact, as mentioned before, it has been reported that OT 
promotes angiogenesis and this angiogenesis is in part mediated by NO pathway (Cattaneo, 
Chini et al. 2008). 
Furthermore, it has been reported that nitrite anion represents an important storage form of 
NO in blood and tissues. Nitrite is an oxidative breakdown product of NO. Previously, nitrite 
has only been considered as an acute marker of NO flux/formation in biological systems, and 
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an indirect determinant of NOS activity (Gladwin, Raat et al. 2006). At physiological ranges 
of pH and O2 tension, nitrite has been considered to be a highly stable and inert metabolic 
end-product of NO oxidation with limited intrinsic biological activity (Kelm 1999).  
However, nitrite anion can be reduced to NO under certain pathological conditions. Recently, 
it has been found that nitrite anion is cytopretective in a number of animal models of disease 
including myocardial I/R injury. Moreover, during ischaemia, the ability of eNOS to generate 
NO, through the conventional L-arginine pathway is severely reduced because of an 
inadequate delivery of O2 and co-factors (Becker, Kupatt et al. 2000). Recent reports have 
shown that eNOS can reduce nitrite under anoxia, and the magnitude and duration of this 
reduction is relevant for the fast delivery of NO in hypoxic vascular tissues (Vanin, Bevers et 
al. 2007).  
In the results presented in this thesis we observed that OT up-regulates eNOS expression, a 
finding of significance if OT-treated BMSC are transplanted in an MI animal (porcine) 
model, transplanted cells could increase the local production of NO from nitrite contained in 
the blood and tissues, even under low O2 tension conditions, and therefore improve 
angiogenesis and subsequent O2 delivery.  
Even though, OT apparently improves the cardiomyogenic differentiation of embryonic and 
adult stem cells, the mechanism by which OT is improving this differentiation has not been 
clarified yet. We know from the results presented here that a blockage in NO pathway 
decreases the expression of cardiac specific proteins coming from OT-mediated 
cardiomyogenic differentiation. In addition, these results are in accordance with the results 
presented by Danalache et al. (2007) using embryonic carcinoma cells, where they described 
that OT treatment increased the number of beating cell colonies (Danalache, Paquin et al. 
2007). 
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Furthermore, we also observed that there was a significant increase in the total cell count of 
pBMSCs treated with OT, when compared to the cell count of pBMSCs not induced with OT. 
In the case of embryonic carcinoma cells, the authors reported an increased number of 
beating cell colonies (Paquin, Danalache et al. 2002). It has been previously reported that OT 
could induce cell proliferation depending on the subcellular localization of OTR (Guzzi, 
Zanchetta et al. 2002). Therefore, it could be possible that OT induces proliferation of cells 
already committed with cardiac lineage, which will result in an apparently increased 
cardiomyogenic differentiation. The OT-induced cell proliferation could also increase the 
number of cells that could be used for cell therapy, reducing the time of ex vivo expansion 
previously discussed in order to improve the outcomes of BMSCs therapy for MI. On the 
other hand, OT differentiation-induction of embryonic and adult stem cells activates the NO 
pathway, and it has been proposed that NO could be acting as an apoptotic agent of cells not 
committed with cardiac lineage, therefore causing an apparent increased number of ESCs 
derived cardiomyocytes (Kanno, Kim et al. 2004). 
 
6.6 Potential roles of oxytocin in the future therapies: with BMSCs, hypotheses of 
research, as well as limitations  
As mentioned before one of the main problems when inducing cardiomyogenic 
differentiation of embryonic or adult stem cells is to prove that the differentiated cell has not 
only the phenotypic and structural characteristics of a cardiomyocyte, but also that the 
derived cell is functionally like an adult cardiomyocyte. An interesting feature of ESCs is that 
once they are allowed to differentiate by embryoid body aggregation, these cells exhibit 
spontaneous cell beating, this fact allows us to observe a certain degree of functionality. 
Unfortunately, there are reports showing that functionally ESCs, derived cardiomyocytes do 
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not act like adult cardiomyocytes, thus full differentiation into adult cardiomyocytes has not 
been achieved (Dolnikov, Shilkrut et al. 2006; Binah, Dolnikov et al. 2007).  
It will be interesting to verify the functional properties of either OT-induced embryonic or 
adult stem cells, to see if OT is able not only to improve the phenotypic cardiomyogenic 
differentiation of stem cells but also the functional characteristics of the OT-treated derived 
cells.  
Unfortunately, we did not observe spontaneous beating in the OT induced pBMSCs, although 
there are some publications that describe spontaneous beating in BMSCs in vitro (Dolnikov, 
Shilkrut et al. 2006). This could be related to differences in culture conditions and differences 
among species, since spontaneous beating has been reported in murine BMSC (Fukuda 
2002). 
In the future, it will be interesting to test the functional properties of OT induced pBMSCs 
grown in different culture conditions. For example, in order to observe spontaneous beating, 
pBMSCs need to be cultured under conditions that allow them to aggregate and form three-
dimensional structures, because under the conditions described here, adherence to a flat and 
rigid surface and growing in monolayers, it is not possible to observe spontaneous beating. 
Also, it was observed that when pBMSCs are suspended in a solution, on low adherent 
surfaces, they tend to agglomerate; this could compromise the viability of these cells, because 
the cells that are in the inner part of the agglomerate won’t be in contact with the culture 
medium nutrients and O2. Furthermore, another less well-known but essential requirement for 
nearly all cells is the need for a specific physical substrate. Most cell types, including 
cardiaomyocytes (Curtis and Russell 2009) and pBMSCs (personal observation) proliferate 
only when attached to a suitable supporting surface.  
A possible interesting approach for improving cardiomyogenic differentiation and survival of 
pBMSCs is the use of biomaterials and scaffolds for tissue engineering. Tissue engineering is 
intended to mimic the natural tissue structure, by offering the cells a surface to adhere and 
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proliferate in a more “natural” manner. The purpose of using tissue engineering will be to 
recreate a viable cellular environment through the use of biologically acceptable materials.  It 
has been shown that slight changes on the surface provided to the cells to attach affect 
cardiomyocyte viability. This surface should support cardiomyocyte adhesion and at the same 
time allow the cells to exhibit spontaneous beating (Curtis and Russell 2009). Same principle 
could be applied to stem cells subjected to in vitro differentiation. Most of the current 
research has focused on inducing stem cells to become cardiomyocytes by using in vitro 
treatment or in vivo differentiation when transplanted to the host myocardium, but until today 
full differentiation has not been achieved and the survival of the cells is not optimal, therefore 
it could be possible that both technologies, tissue engineering and in vitro inducers, improve 
the cardiomyogenic differentiation potential of stem cells. 
Specifically, it would be interesting to combine tissue engineering and OT treatment for 
inducing the differentiation of BMSCs. In a very recent report, Valarmathi et al. (2010) 
propose a very interesting approach to improve what until now they described as inadequate 
and inconsistent differentiation of BMSCs into cardiomyocytes, as well as the poor survival 
and integration of the BMSCs-derived cardiomyocytes, after implantation into ischemic 
myocardium. The authors developed an in vitro model of three-dimensional (3-D) cardiac 
muscle using a co-culture of rat ventricular embryonic cardiomyocytes (ECMs) and BMSCs. 
They found that when ECMs and BMSCs were seeded sequentially onto a 3-D tubular 
scaffold engineered from topographically aligned type I collagen-fibers and cultured in basal 
medium for 7, 14, 21, or 28 days, the maturation and co-differentiation into a cardiomyocyte 
lineage was observed. They observed expression of transcripts coding for cardiomyocyte 
phenotypic markers and the immunolocalization of cardiomyogenic lineage-associated 
proteins revealed typical expression patterns of cardiomyogenesis. They concluded that the 3-
D co-culture system sustains the ECMs in vitro continuum of differentiation process and 
simultaneously induces the maturation and differentiation of BMSCs into cardiomyocyte-like 
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cells (Valarmathi, Goodwin et al. 2010). The main inconvenient of this study was the use of 
ECMs, because as previously discussed, it will be difficult to know if the BMSCs fused to the 
ECMs, since they did not test this possibility, more over if we think in the possibility of using 
this construct for a clinical application, the use of a cell source that does not belong to the 
own patient adds the possibility of future tissue rejection. Therefore, it would be interesting 
to test if this type of 3-D scaffold could be used in the OT-mediated cardiomyogenic 
differentiation of BMSCs, this scaffold which will provide a structural matrix to which 
BMSCs will attach, to grow and differentiate, and since there is evidence supporting that OT 
improves the number of BMSCs expressing cardiac markers, there is no need to co-culture 
the stem cells with differentiated cells to provide needed microenvironment, e.g ECMs. For 
this purpose it will be necessary to test different concentrations of OT and exposure timings, 
since the 3-D configuration of the cells could affect the concentration at which the cells will 
be exposed, also it will be important to verify the effect of the collagen scaffold on OT-
treated BMSCs. It could be possible that the cells will need repeated exposure to low 
concentrations of OT in an attempt to mimic what it happens during embryogenesis. The 
progressive cell aggregation to which the BMSCs will be exposed together with OT exposure 
could definitively improve the cardiomyogenic differentiation of BMSCs.  
The very encouraging results obtained to date in clinical studies using BMSCs, together with 
the promising results obtained in some pre-clinical studies using OT after MI, could lead to 
the future combination of both technologies. Even though, cautions should be taken if OT is 
planned to be administered after MI, this based on the observations found by our group 
(Authier, Tanguay et al. 2010).  
Furthermore, it is important to monitor the progression of the differentiation process as well 
as the detection of spontenous beating, in a recent report Ohn et al. (2009) described a very 
interesting method of imaging and analysis procedure that yields a dynamic depiction of heart 
development that included, at each developmental stage studied, the shape of the heart in any 
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of its contraction states. This method combines automated high-speed fluorescence and 
brightfield microscopy with high-dimensional image sequence synchronization to reveal the 
dynamics of cardiac morphogenesis with cellular resolution and without perturbing cardiac 
beat. The resulting images are highly suitable for automatic image analysis, specifically, to 
extract quantitative velocity fields and track cell motions both as the heart beats and over the 
course of cardiac development (Ohn, Tsai et al. 2009). This method of imaging and analysis 
could provide a better follow up of the differentiation process of OT-treated BMSCs. The 
ultimate goal of combining these technologies will be to engineer new heart tissue that can be 
implanted into damaged areas. By using tissue engineering and in vitro stem cells 
differentiation technologies, some of the problems related to direct cell transplantation could 
be reduced, for example: when cells are injected directly to the myocardium or delivered 
intravascularly, there is cell migration to other organs (Barbash, Chouraqui et al. 2003); in 
consequence there are a reduced number of cells acting locally in the heart. In contrast, if 
cells are implanted within a matrix or a support material like collagen, it will be possible to 
limit cell migration to the infarcted area rather than to other organs. In addition, it will be 
possible to have a better follow up of the implanted cells. Moreover, it will also be possible to 
have an improved survival of these cells, since the implanted cells will not be in direct 
contact with the hostile environment (inflammatory cytokines) found after MI, without 
mentioning the possible enhanced differentiation achieved. 
Currently, there are many studies documenting the use of different materials to build 
scaffolds and cell sheets for tissue engineering after MI (Ifkovits, Devlin et al. 2009; 
Nakamuta, Danoviz et al. 2009; Singelyn, DeQuach et al. 2009; Seif-Naraghi, Salvatore et al. 
2010; Zakharova, Mastroeni et al. 2010). Extensive research needs to be done in this area and 
stem cells cardiomyogenic differentiation before both technologies could be used together. 
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Finally, it is possible that these scaffolds with engineered tissue could be made with 
biodegradable materials that could be delivered to the MI area by endoscopic surgery, 
similarly to the endoscopic coronary artery bypass. 
    
 
 
 
 
 
 
 
 
 
 
CHAPTER 7. GENERAL CONCLUSIONS 
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7.1 Oxytocin pharmacokinetics and pharmacodynamics 
Oxytocin hemodynamic effects are strongly connected with the pharmacokinetic TMDD 
behavior of this hormone. This emphasizes the need for reassessing the therapeutic index of 
OT in a context of patients affected with cardiovascular pathologies. The TMDD 
pharmacokinetic-pharmacodynamic model proposed here may become a tool for 
understanding the complex balance between OT desired effects and untoward outcomes. 
7. 2 Isolation and characterization of pBMSCs  
 
The pBMSCs differentiation potential was affected by the time in culture and the number of 
passages: cells were affected not only in size and shape, but also their gene expression was 
altered.  
It seemed appropriate to induce cardiomyogenic differentiation during early passages, 
specifically during passage 1, because at this time pBMSCss expressed:  
• Phenotypic profile of surface epitopes described for MSC.  
• Important levels of OTR transcripts.  
• Transcription factors, Oct-4 previously related to pluripotency, and GATA-4 
implicated in cardiac differentiation. 
7.3 Cardiomyogenic differentiation induction of pBMSCs 
 
• Expression of GATA-4, desmin, PLB and cTNI3 transcripts was up-regulated in OT- 
and 5-azacytidine-induced cells when compared to non-induced cells. 
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• Protein expression of cardiomyocyte specific proteins MHC, TNNT2 and cTNI3 
was up-regulated in OT-induced cells; however PLB was also expressed, 
although weaker in non-induced cells. 
• Expression of cardiac specific proteins was more abundant in OT- vs. 5-
azacytidine-treated cells, and PLB expression was up-regulated similarly in both 
induced groups. Although, gene transcripts seemed to be more abundant in 5-
azacytidine-treated cells. Semi-quantitative analysis demonstrated that cTNI3 
protein expression was significantly up-regulated in OT induced cells compared 
to control and 5-azacytidine treated cells. 
In this study, OT induced expression of cardiac specific structural proteins in pBMSCss, as 
previously described for murine ES cells and cardiac stem cells. Oxytocin was a more potent 
inducer of cardiac differentiation of pBMSCs than 5-azacytidine, based on cardiac protein 
expression. 
7.4 Involvement of the NO-sGC pathway in the OT mediated cardiomyogenic 
differentiation of pBMSCs 
• pBMSCs express endothelial and inducible nitric oxide synthase isoforms. 
 OT induction:  
• Up-regulates transcript expression of eNOS and iNOS, it also increases expression on 
NOS protein. 
• Increases abundance of cardiac specific proteins cMHC, TNNT2 and cTNI3. 
Specifically in OT-induced pBMSCs, inhibiting NO production with L-NAME, a competitive 
inhibitor of NOS, and inhibiting sGC using ODQ, significantly affected the expression of 
cardiac specific markers transcripts and proteins. 
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• The exposure of pBMSCs to NOS and/or sGC inhibitors reduced the abundance of 
cardiac specific markers to levels similar to those found in control cells. 
• Endogenously produced NO under OT stimulation, with the consequent activation of 
sGC-dependent pathway(s) seem to be important in OT-mediated specific 
cardiomyogenic differentiation of pBMSCs, since only cardiac specific protein 
expression was affected. 
These results suggest that OT induction with the subsequent activation of NO pathway directs 
pBMSCs to a preferential cardiomyogenic phenotype. 
• OT increases total cell count of pBMSCs and this increase seem to be also dependent 
of the NO-sGC pathway, since inhibition of NO pathway with L-NAME  and ODQ 
gave the similar cell counts of those registered in control cells. 
• Apparently, OT, through NO-sGC pathway, increases proliferation of pBMSCs.
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